var title_f26_61_27600="Foot and toe bones PI";
var content_f26_61_27600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Foot and toe bones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the foot and toe bones. The foot bones include the tarsals and metatarsals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27600=[""].join("\n");
var outline_f26_61_27600=null;
var title_f26_61_27601="Fetal alcohol syndrome PI";
var content_f26_61_27601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Baby with fetal alcohol syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27601=[""].join("\n");
var outline_f26_61_27601=null;
var title_f26_61_27602="Pacemaker photo PI";
var content_f26_61_27602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medtronic Adapta&reg; Pacemaker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Medtronic, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27602=[""].join("\n");
var outline_f26_61_27602=null;
var title_f26_61_27603="Phytophotodermatitis 1";
var content_f26_61_27603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phytophotodermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous linear streaks that subsequently became hyperpigmented occurred on the trunk of this 14-year-old male who was exposed to the sun after squeezing limes during a Carribean vacation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27603=[""].join("\n");
var outline_f26_61_27603=null;
var title_f26_61_27604="Neomycin, polymyxin B, and gramicidin: Patient drug information";
var content_f26_61_27604=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Neomycin, polymyxin B, and gramicidin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/58/34723?source=see_link\">",
"     see \"Neomycin, polymyxin B, and gramicidin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg; Ophthalmic Solution",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg;;",
"     </li>",
"     <li>",
"      Optimyxin Plus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to neomycin, polymyxin B, gramicidin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11805 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27604=[""].join("\n");
var outline_f26_61_27604=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177336\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177337\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014007\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014006\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014011\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014012\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014014\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014009\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014010\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014015\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014016\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/58/34723?source=related_link\">",
"      Neomycin, polymyxin B, and gramicidin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_61_27605="Simpson uterine sound";
var content_f26_61_27605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malleable callibrated Simpson uterine sound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27605=[""].join("\n");
var outline_f26_61_27605=null;
var title_f26_61_27606="Principles of polar body biopsy";
var content_f26_61_27606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 601px\">",
"   <div class=\"ttl\">",
"    Principles of polar body biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 581px; height: 489px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHpAkUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACisjU/E+g6UzLqmt6XZMuci4u44yMdc7iKzoviH4LlkCReL/DrueirqcBJ/8AHqAOooqtYahZajF5un3dvdR/34JVcfmDVmgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKhvLqCytZrq8nit7aFS8ksrBVRR1JJ4Arj11/XPFGR4RtUsdLPH9s6lE2JB6wQZDOPR3Kr3AYUAdpI6RozyMqIoyWY4AHua5mf4geFYp3gj1y0up04aKyJunU+hWIMQfaoIvh/pFxIJ/ETXPiO6B3b9VfzY1P+zAAIk/BAfc11dvBDbQrDbRRwxKMKkahVA9gKAOYHj7RiNy23iJl/vL4d1Ag+4IgwRQnxC8K7lW51iGxLHA/tBHtM/wDf0LXV010WRGR1DKwwQRkEUAMtriG7gSa1mjmhcZWSNgyt9CKlrk7z4f6BJPJc6ZbyaJfucm60iQ2rsfVgvySf8DVhVaTUPE/hfLavAfEekA83ljCEvIV9ZIB8soHcx4PohoA7WiqWj6rY61p0N/pV1Fd2coyksTZBxwR7EHgg8g9au0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVfUL6102zlu9QuYLW1iG6SadwiIPUseBWH4o8T/ANmXUOlaTaHU/EFyheGyR9iomcGWZ8ERxg9+STwoY8VU0zwaLi8h1XxfcjW9WQh40dcWlo3/AEwhOQD/ALbZc+oHFADF8ZXerceEdAvNTiP3b67b7FaH3DODI490jYe9Siw8aXuGu9c0nTUI/wBVY2DTOP8AtrI+D/37FdbRQByg8May3MnjrxAGPaO2sAo+gNsT+tJ/YXii3GbPxg07DoNR02GUH6+V5R/Ij8K6yigDj31bxdpRzqegWmrWw6zaPc7Zfr5E2B+UjH2rV8PeKdI195YbC6IvYQDNZXEbQ3EOf78TgMB74wexNbdYviTwzpXiKKP+0rc/aIebe7hcxXFu396OVcMp+hwe+RQBtUVwy61qng+eO38WzC90N2EcGuBQrQk8Kt0oGFyeBKuF/vBOCe5ByMjpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVW1PULTS7Ga91K5htbSFd0k0zhFUepJqn4k12z8P6b9rvfMcs4igghXdLcSn7sca/xMf8AEnABNYOkeGbvVdQh1zxr5c99G3mWemI2620/0OOkk3rIeh+4FHUAamveIPEoH/CLWCadprj5dV1aJgZB/eitsq5HcGQp7BhUqeA7O7O/xJqWq69KfvLd3Jjg+nkRbYyP95WPua7CigDK0vw3oekoqaXo2m2SL0FvapGB+QFaU0UcyFJo0kQ9VYZH5U+igDnNQ8DeF9Ql8640LT1ue1xDCIZl+kiYYfgaoN4Z1zSPn8MeIriSNf8Alw1om7ib2E2fOX6lnH+zXZUUAcppfjFBqMOleJbGXQ9WmO2FJnD290fSGYfKx/2Ttf8A2cV1dU9X0yx1nTp7DVbWG7s5l2yQyruVh/j6HqK5CK6vfAdwkGr3Ut94UkYJBfzsXm09icBJ3PLxE8CU8rwHJzuoA7uigHIyOlFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVS1nVLLRdLudR1S4S3s7dd0kjduwAA5JJIAA5JIA5NXa4TT0HjbxOdUm+fw7o1w0VhER8t3doSr3B7FYzlE/2g7dlIAH2Oh3Xi27i1fxdbvFp8bCSw0OXG2PHKzXA6PL3CHKp7tyO4oooAKKKKACiiigAooooA4/XPDd1YalLr/g/y4NUc7ryxJ2QamB2fskuPuyjnoGyvTb8Na7Z+IdNF5YmRSrtDPBKu2W3lX70ci/wsPT6EZBBOrXD+MIW8L6qfGOno32ZVEet28ak+dbjpcAD/AJaRdc9Sm4c4XAB3FFNikSWNJInV43AZWU5DA9CD6U6gAooooAKKKKACiiigAooooAKKKKACuc8Za/NpMNrZaVCl1r2pOYbG3cnYCBlpZMciNByx78KOWFdBNLHBDJLM6xxIpZ3Y4Cgckk+lcf8AD+CTV5rvxhfqwn1VQtjG4wbexBzGMdi/+sb3ZR/CKANjwr4ei0G0lLTPeandsJb6+lA8y5kxjJ/uqOioOFHA99uiigAooooAKKKKACiiigBk8MdxDJDPGksMilHR1DKykYIIPUGuH06SXwNrNro91I0nhi/kEOmTSNlrGY9LZ2PWNv8AlmT0I2Hqldwk0TyyRJIjSR43oGBK56ZHbNU9e0m013R7vTNQQva3MZjfacMvoynswOCD2IBoAv0VzHgHVLu802403WZA+taRN9ivHxjzsAGOYDsJEKt6Alh2rp6ACiiigAooooAKKKKACiiigAqG9uoLKznu7uVIbaCNpZZHOFRFGSxPYAAmpq4vxsv9v67pPhQYa1m/4mGpjsbaNhtiP/XSTaCO6pIKAG+D7KfX9SHjDWYmV5UKaRaSD/jztm/jI7SyjDN3C7V7NntqK838TeOdY034j2+kWVhZPoUC2i6hczmRJFe5mMUYjb7nB2kg8kHjoaAPSKKp6xfx6XpF9qEwzFaQPO4zjIRSx/lXD/Bnx7dePNIvLm+j0xJoWjYf2fcNKoSRdyq+4Aq4wcj+VAHolFFFABRRXk2j/GBb/wCN198P5NK2JFvWK9WbJZkj3sGTHA+8OCeg/AA9ZqO4giubeWC4jSWGVSkkbrlXUjBBB6giuf8AiN4oTwX4J1bxDJb/AGkWMQcQ79m9iwVRnBxyw5xUfw18XQ+OPCFprkNuLZpWkjkgEolCOjlSA68MOMgjqCKAKHhd5PCuvL4TvJGfTZ0aXRJpGLMI1GXtWJ6mMcqTyU45KEnt65/xzokuuaBJFYusWqWzrd6fM3SO4j5Qn2PKt6qzDvVzwtrMXiHw9YarAjRrdRB2jb70T9GQ+6sCp9waANSiiigAooooAKKKKACiiigAooooAKKKKACiiigDl/iHqFzbaHFYaXKYtV1eddOtJFGTEzgl5R/uRrI//AK3dH0610fSrPTtPjEVpaRLDEg/hVRgfyrm5gNS+KkCE5i0XTDNt7ebcyFFP1CQSD6Se9dfQBw/j/x3J4S1TTrddIe+t50MtxKlwqNCgdEG1CMucuDjIwFJ9q7ivA/2hbVX8UWdy9/NbyxaPM9sscW7BWaMyHqCScxjHIIDAjBr3mKWOaFJonV4nUOrqcgg8gg+lAHn3wy+JqeONSu7X+ypLBVjae1kabf58SymJiRtG1gwGV5wGXJBOK9Erwb4JA3vjaw1C3k0uW1Tw86brM4kG+eJl80bz83yOM7VPy854x7zQAUUUUAed+OfiQfDHjnRfDyafDOL2NZpZZLgxsFMmzEaBTvYAMxyVGBjOSM+huwRGZjhVGSa+dvj9diw+LPh6aWW6S3fRrkPFEPlnVH8xkY5HGF3Hryq8dx9A6jNFDpl1PLIiQpCztIxwoUKSST6YoA4r4beP5fF19dWt3p8FjILK21K3WK684tbz79m/wCVQr4UEgZ4cc5zXeuqurK6hlYYIIyCK+f/ANmq2urXxDqkV5BF5iaFpO6VHZ2GYiyo5IGGCkfKOgxyetfQNAHG/DwnSZNV8Jysx/seRWsy3VrKXJh/74KyRf8AbIetdlXI68v9n/ELwzqKnal9HcaTN6MSnnxE/TyZAP8ArofWuuoAKKKKACiiigAooooAKKKKACiiigDj/iYWvdL0/wAPxMyvr14ljIVOCLcBpJ/pmKN1z6uK69FVFVUUKqjAAGABXKXQN58U9PQ8x6dpM02P9uaVFU/gsMg/4Ea6ygDyH9pS9lsvDnh8pZarqMEurIk1lpty8Es6+TK2MoCxwVDY9VFdv8MNRuNX+HXhrUL2RpLm50+GWR2OWYlByT3PqfWuE/anttWHwzOq6Dd3NrdaXcCaRrckMYXVonGRzjEmT7A1t/AnWbC4+GGm2sd7aSPo8C2ly8UoKDYuVfJ/hZMNk4xkg4IIAByfiCEj44JqkL6iLy21OzsS7SSeQsEtvkxqM7Dk+YSMZB2nvXudfO/hjXD46+JQW2ttls+srrMNyk/zG1ih8pN8eMhWMUbKTx+865yK+iKACiiigDxr492sGoarpFpfPItmul6lcMyhD5bL5ADgN/GAxCkfMC3HrXrelO0umWcjsWZ4UYsTnJKjmvMPj2kOnx6J4h1ASDSbMz2V/LFF5jwwzqoDgYP8caKTjgPxzit/wp440o/DRddvbtRDptuEvDjDBkAAwpwfnG1kBAyHX1oA8w+DGp2cvxq8QWkc8UmqefrBuwlv5bqgu4hEJH/5aH75H90HFfRNfOH7POiNc/E/xJ4hNqsMkMUsN3MjlkmubiUTsg7ZiAKEjg8fU/R9AHHawDo/xG0XUUJW31mJ9KuR2MqK00DH6ATrn/bUV2Ncn8UB5XhN79eH026tr8H0EU6M/wCaBwfYmusoAKKKKACiiigAooooAKKKKACuQ8EL9u1zxVrj8/aL42EB9IbUeWV/7/G4P/Aq6+uT+FADfDrQrgDH2y3+3H3MzGUn8S+aAOsr5U+Ottd2f7R3hzUGnW30spp9xcvJMI42SO6OQ2ThiNu7bycDIHFfVdeRftHeEdT1rwlLrPhiRo9a062nidFVWNxaSriaLkdccjvwQOSKAO6+JEix/D3xO0kqwqNMuR5jMFC5iYA5Necfs0NHLZeIJYtOisEZ7TyY4pFdfJNsjRcr0JVgxBJO5mJ5NeUX3xR1PXvBvhzw9q2iXmoaPdZgtbiLKya1NCVWKFwGzEN5QuQzE7eMZr6O+Eng5fBPhCOwdIlvrmV7y8EJJjEz4yqZJO1QFUZ6hc9TQB2dFFFABXzH4Y1G1tv2pNSsbq3jgvW1WVklKAM6NaSbQzE55yCuB3Of4a+nK8E+PXhA2XirSPG2nQ+VumgttRvYo98tmFcGK5UegO1X7lAF4BJoA6r9pqZYfgj4kJkEbkQBCWwS3nxnA9+P0pv7Ntyb34aR3XylZbuZgyliG5GSCxJPzbs89c14r8TfFXiL4q65pvguTR2tXBmSI2dz5tvdXSOEM5YLjyU2ydzgk5ORivqTwZoMHhfwppOiW2wx2NukJZE2B2A+Z8dtzZb8aANmuQ8GL/ZviTxXoo4iS7TU7df7sdypLfnNHcH8a6+uTl/cfFa1xx9t0WbPv5E8WPy+0H86AOsooooAKKKKACiiigAooooAKKKKACiiigAooooA5Pwp++8YeNpyOY723tAfZbSGTH0zOfzNdZXKeEsx+LPHELdX1GC5H+61lbp/OI11dAHnPxs8O6rqnh6LVvCq7vEWlN5kEROFuoSV823fkZVgoOM8lR06159pl747u/gso0zS47Xw0bbbFJ9q36oundW8tCNhYRZVMsCQAcZr0T4z+LIfDuhQWTXz6fJqZkV7uMZe3t403zSIO77cKv8AtOp7V5r/AMIn42u/hZcXGh6/eWPhk2rSWXhqSKMXLWeMiJrvG5Sy5O3BwCFz3AB237PPgUeEvC9xf3MUsd/q0pmCTKqtDb7mMUe1SVQ4YsVB4Lkdq9Xrzn4OeJ7TVbK70W21VdWXS1ja3vASWltn3eWHJHMiFWRiOu1WPLED0agAooooA89+M3h641HQItb0WzsrnX9D8y5tVuow6yRshWWLnj5l5Ge6rXmWqP8AEqT4LWk+q2+h/wBhLbwzXFrC0jXrWgYMEOSEb5NgZcgsoYbgTmu8+O3ihdMstI8PLeRWkutyyLLJI7p/o8S75FygJXfxHu4wHJ7VxV34I8UyfBm3ubvU57q1iij1CTwsAyW5tgA5tRLkznC9AXIyAuMYoA9Q+Efha58N+Hri41fe2u6tcNf35eQyFHbhY9xJJCKAvUjOcHFdxXnfwV1i+vPDaadqy3H2m1hhnhe4ffI9tKCY9zZO4qVdN+fmCBupIr0SgDlPiN+707R7oD5rfWtPwe48y4SE/pKfwzXV1ynxIy+kaXbr96bWtNx/wC7ilP6RmuroAKKKKACiiigAooooAKKKKACiiigDlNPwfirr+eSui6dt9sz32cfkPyFdXXJyn7L8VrcsMDUNGdVPvBMpx9cXBP4H0rrKAK+pR2s2nXUWorE1i8TrOs2NhjIIYNnjGM5zXzF4M8MfCW7stV/4S+6KRxTumkyatevaF9PyfKaEBl8xM7/mwT64yBXtnxhN1P4XttKso4pH1a/gspFlkEatCSXlUsf70cbr77sDmqPws8O2VzpGo65qNpYzz63MzbFgURJbp+7jjVccKVXcR6uc0AY37Nlxod74Zv59Hv7q+uo5/ssj3agSR20ZYWqAD+DyznPdmcnnIHsFeEeC9DsvAniaG3tJ/LktNdm0oxFhmWzuolmgXnk7H24H/XQ4G417vQAUUUUAY/jD+xz4W1UeJjCNFNs4u/OOF8vHPvn0xznGOa+GhBpGoaZq1qNT12zCXmDc3Mcnk2luCwt0umUtlwyhACBtJOM819R/tEaull4fsbW4sRqFluk1K8tGcIs8NsA2xiQflMrw5GDkAitP4W+CtLt/hVbaffWFqx1q2FzqKrCFEjyruIIx/CCFH+7mgC98GpdNl8Exf2bc3N3cpK8eoz3b755LtQBIztkhs/LggkbduDjFdzXzv+zboz+D9f1bTJLp3FxdXdkVeUN5ptZAsUqpgFAVMynOcmPt0r6IoA5T4tY/4VZ4wJ/h0e7YH0IhYg/XOK6uuT+KZ8zwTeWY5fUJYLBR6maZIv5OT+FdZQAUUUUAFFFFABRRRQAUUUUAFcp8Jj/xbDwmh+9FpdtC3+8kaqf1U11dcl8NT9n0vVNJYnzNL1S6tiD1CNIZoh/36mjoA62vCv2nfGN9plrpnhrSdPa+a+V729jWUpvtYiC0Z24O1zwcEEgFRndXdeNfij4f8HeLNE8Pav8Aaze6qV8t4kUxwhn2K0hLAgFs8gHoa8q+Ol9qP/C6PD+k20kK2V3a2Ut6ropDxpevgcqT/F0BGaAKXjT4VXPh7whH4svZru6mgmbUNW0a2naO3iRz1tguNjwqRgng7M8YAr2v4WeILjW/D7wajI8mpadILaeR12NMpRXjlZezMjKWA4DBgOBW94rEB8L6wLzy/sv2ObzfM+7s2Hdn2xmvMvgPqMt/rXihZNTl1BoINOik8y2WDypBE4ZVA6gAJye+aAPYaK4T4cfFHw/8QdQ1iz0EXay6Y4Dm4RVEyksA8eGOVyvfB5HFd3QAV87fGnxdcar8UtN8HaVdHdZCKZbULmG7vnb93FO3ICKuHwQQee4Fe32nivw7eau+lWevaTcaojMjWcV5G8ysudwKA7gRg5GOMV4L4X07TpP2mdTvmeV9SGrSpsaRSgjFk+DszuDbgeTxjp3oAzPEfgPUPhLfW3iifxFcX6pbTMl3KCv2a8G6fYqBtvlT4kjK+r564r6O8G69D4o8KaTrlunlx39tHceXu3bCwBK574OR+FcR+0xHDJ8FPEIuciMG3ywXcU/0iPLAd8DPcVR+AGvWVt8Iv7U1W6s9N02O+uArykW9vChlwoXecKpLcAnq2KAPXq5S+O/4q6KF/wCWOi3+7/gc9nj/ANFtW5o2s6ZrlobrRdSstRtgxQzWk6zJuHUblJGeelYOjN9v+JHiK6BzFp9ra6avtKd88n/jssFAHW0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcihGnfFWVW4TWdKVk9DJbSEN+JW5T8E9jXNfEj4wWfgjxtpOgS6a15HcLHLfXaz7VsI3lEauw2nPPOCV7etdN8SIJoNMs9fso3ku9CuBfeWgy0sO0pOgHcmJnIH95Vri9U+DmmeLn8W6vqWuXN5L4ljjazmt2kiitYlUeSCiybZwMI3zDBxkBSc0AYX7UMIe3klZ4UWPRrhT9odRE264t/lIKk7jtypXaQyrk4JFe82yBbWJAoChANo6AY6V438Svh54n1nS9A06wvResumPpF9eiUW2VYxZlkjYPvUhGJUENu2kEc17Qo2qAOgGKAPnD9n3Wbi4+I/8AYrW32e10rRru2hKB1WZFv8IdpAXK/MNy5zk5OQQO98JfGGz8RfFDUvCMemtDBA08VrqJn3JdyQ7fMRV2jGASchjwM96p+Bfh94o0XxTq9zeapZpYw2d3ZaTLGGd8TzibzJIyQoKsMEKRu9sAmHSPgVaaLaeE5dL127TWtDvTdveTeZLHchiTKnkGXbHvG0Fl5wOcnmgD2Wud8U+M9F8K5bXZL63gVFke5XTrmWCMFto3SpGUXnsWB5HqK6KvJfif8IH8c65e3765FDFc2Is1gu7D7V9lIYN5kB8xRGxxgnB4J5GeADmPjtqdiniu0mfU3habQJjZeUA8dwXlUMCdpG0xkt1GcDk4xX0AQGBDAEHgg968n8WfCW41u+8OPHq0CW+m6X/ZM6yWxLvGdod0O7CsVUgZyBnPPSvWaAPnD9mPVtYvfFmp2msK8cNjotnFZoR/y75JTnJJ6tj6np0HtOk+OdB1TXV0aC4u4NVeE3CWt9YXFm8kYOCyiZF3D6Z6Guc+H/w3vfDMmoPf66l08tkNPtntLJbRoYgWIdiCd8nK8nptFY3gH4LN4U8W6Prkmt213Lp8E8DeXpvky3fmFjvml81i7jdjOOgAwOpAO08TsL7xx4S0tefIe41aUf7McflKD/wO4Uj/AHD6GuurjPAzf23reueKSc21062GnnsbaAsC4/35WlIPdQhrs6ACiiigAooooAKKKKACiiigAooooA474jv/AGamieIs7Y9Iv0e5P/TtKDDIT7L5iyH/AK5159+0fJceJdQ8NfD/AE2C7uZNSla/vo7MxiUW8QOMeYyoMtnqRyn4H2rULODULC5sryMS2tzE0MsbdGRgQwP1BNcz8PL+4S1uvDuqyvJq2iMsDyP1uICP3E/vuUYP+2jjtQB5V4A1281bwN4E07ULwadrmheIjpF15yhyrxW1wqqwzzldq5zy2cGvVfhLK8/w38PzSkM8lsHLAYySSc1ueIdD0zxHpUum65ZQ31jKQXhlGVJByD+BFXraCK1t4re2iSKCJBHHGihVRQMAADoAKAPnHxTqFla/tMyW8rwPc3UulxR2zRszMysHMoPRdqgjnnn8awvjNdaz4m+Ieua/4dtL2e28BLD5MtuY/KW4VxLM0m5wxAUMpCBj8ozgdfp+bRNKn1aLVJtMsZNTiG2O7eBDMg54DkbgOT37mtCgDO8Oavba/oGnavYsGtr63S4j5zgMoOD7jOD7ivMvjp42vvDd7penaVqN1pd5dW1zMly8tvFakouQrNLBKWfIwqJtJ3YzyMevUUAfLXj/AMaXOpfDLwPrur6TZatqOp6ZqMbrIqLGJAIz5u1gQx/dA7Bye2MV9JeFznw1pHJP+iQ8n/cFS6to+m6zDHFq+nWd/FG/mIl1AsoVum4BgcHnrV4DAwOlAHgXgi+s7j4uHT7aGX7fYa3qpuWfAJicSOpCn5toMuNxABJ4JFZ1r8VtbuPihpFnYalN/Zd1rkumXGm6g9u06KMYby44EeJRk7S0jltpz0JP0DFpWnQ6pPqcNhaR6jOgjlu1hUSyKMYDPjJAwOCewqXUb2203T7m+vplgtLaNppZX6IijJJ+gFAHLeJG/tTx54b0dDmOy8zWLoDsFUxQqfq8jMP+uJrsa5L4e2lzNBfeI9TheHUNbkWcQyDDW9soIgiI7EKSzDs8j11tABRRRQAUUUUAFFFFABRRRQAVxsp/sH4mJK+FsfEVuIc9lvIASv4vEW/78CuyrF8YaGPEOgz2STG2u1Kz2lyBk286ENHIB3wwGR3GR3oA8l8ZfBjV/GGr+N9U1TWYre51JI4NKit9rRpFFhkEzPEXXLqpPlkY55bpW7q/w78Qa9rPhjUNV1TTYzb2trDrEaQmVrhoJDJ+7kIBCuzHIIGMA813PgzXjr2lM11ELbVbSQ2uoWv/ADwnUDcB6qQQynurKe9b1AFbUrKHUtOurG7XfbXMTwyr6qwII/I15D4Y+F/ijw54W8cRwa7ZXniHxAiQwzSK8UcKorRh2YBm3lGzgDAYAdOa9nooA8Y8EfCLUvBPi7wvquj6tHdWttpz6dqkNztjJQ/OPJ8uIbv3hLfvCWwB8x7ez0UUAeFn4X+NL3xzous63q9lfppusvfCeS/uCTbHG2JLfZ5UZGOoPzZ5PHPQ6P8ACc6f8Yb/AMbtqscsdxK0y2v2XEiMYjHjzd33cMTjb2X0r1OigDlfin4Xfxp8P9a8PwzJBNeQgRyPnaHVg65x2yozXD6J8PvF+j/BgeHNI1aw0zxA9wZ2e1LxwojPlo1cAsuR/EBwTgDFexUUAeU/Dbwvd/DdPG+ueJbi0isb2YagBFeTXbRIiMWDySqrO3PXqfbpXX/DnT7qz8Mpc6nF5WqanLJqN5Gesckp3CM/7i7I/wDgFZ2ut/wlviqLw/Ad2kaVLHdas4HyySjDw22e/O2Rx6BAfvmu4oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAAjIwelcN4Wf/AIRPXm8J3RK6bcF7jRJW+6E+89pn1jySo7x8D7hruayvE2hWfiLSnsb8SKNyyxTRNtlglU5SSNv4WU8g/gcgkUAatFcj4f8AEN1a6nH4d8WFItYIP2W7VdkGpIP4o+yyActF1HUZXkddQAUUUUAFFFFABRRRQAVxvjq+uNQuIfCWizPFqOoxl7q4iPNlZ5w8meztyie+W6Iau+J/EzWN3Ho+iQLqHiO5TdFa5OyBM486dh9yMfmxGFyelnwp4ej0K3uHlna91S9k86+vpFAa4kxjoPuooGFQcKPU5JANXT7O306xtrKyhSC1t41hiiQYCIowAPYAVPRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK+MtGvZLi01/w8qnXdOVgsLNsW9gPL27ntnAKsfuuAehYHqqKAMzw5rln4g0tL6wZ9pJjlikXbJBIvDRyKeVdTwQf5YNadcp4g8O3sWqtr/hSaK21gqFubaYkW2oIOiy4BKuBwsgBI6EMOKseG/FtlrF0+nXEcum67Cm+fTLvCzKP7y9pE/wBtCR64PFAHR0UUUAFFFFABRRVLWdVsNE06a/1e8gs7OIZeaZwqj0HuT0A6ntQBdrgpnPj/AFlIYPm8I6dMHmlB+XU7hDxGvrDGwyx6MwAHCtlZF1Xx4fLeK60bwm339+YrzUl/u46wwnvn94w4+Qde3tbeG0tore1ijht4UEcccahVRQMAADgADtQBLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJ+JtEvbfVl8SeGVU6tHGIrqzZtkeowjJCMeiyLklHPTJB4PGv4b16w8Rab9s02RiquYpopF2SwSj70ciHlXHcH+RBrVrmPEHhX7VqX9taFeHSdfChWuFXfFcqOiTx5AkUdjkMv8LDkEA6eiuMg8bHSnS18cWX9h3Gdovd/mWEx9VnwNmf7sgU+metdhFIk0SSwuskbgMrqchge4NAD6KKKACiisvX/EGk+HrZZ9a1C3s43O1BI/zSN/dRert7KCaANSuT8R6/dXOpP4d8LNHJrRUG6uWG6LTY26PIO7kfcj6nqcKCaqPd+JPFv7rTILjw3ojDD3tygF9MP+mURyIh/tSfN6IOtdL4f0TT/D+nLY6VAIYAxdiWLvI55Z3c5Z3J5LEkmgBvhrQ7Tw9pEWn2AdkUl5JZW3STyMcvJI38TsSST6mtSiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM/XtG0/X9NksNXtY7q1cg7W4KsOjKRyrA8hgQQehrmVHijwplQsvinRV+78ypqEC+hzhJwPXKv/AL5rtqKAMHQvF2h65cNbWN+gv0/1ljcKYLmP/eicBx35xit6szXNA0jXoFh1vTLLUI1OVFzCsm0+q5HB9xWMPA1lb/8AIK1XX9NHZINSkkQfRJS6j6AAUAdZRXnN1peuQeMtK0aPxv4hFpdafeXTkw2BdWiktlUBjbdMTvnOTwOeudo+CIZ+NT17xHfp3R9RaAH6iDy80AaniDxPovh5U/tnUra1kf8A1cLNullPokYyzn2UE1gvqHifxP8Au9GtZPDmlsfm1C/iBu3X/plbnhM/3peR/cNb2heGND0FpH0fSbKzlk/1k0cQEkn+8/3m/EmtigDI8N+HdO8O2skWnRN5k7+bcXMzmSa4k7vI55Y/XoOBgcVr0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWV4g8P6X4htkg1izjuFjbfE+SskLf3o3XDI3upBrVooA41dJ8WaLxous2+s2g+7a60CkoHoLmME4/343PvUo8Vara/Lq/hDWIiOstk8V3EfptcSfmgrraKAOPm+ImiW8kEV3beILeaeQxRRvoN8TI4Vm2riEhjtVmwCeFJ7GpP+E0Ew/4l3hzxLeMei/2ebbP43BjA/GneMv8AkY/An/Yak/8ATdeV1VAHHvceNdVO22sdK0CA/wDLa7lN5OP+2SbUB9/MYexqxpPguxttQi1PVri61zWI+UvNQYN5J/6ZRqBHF9VUH1JrqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbIiSxtHIqujAqysMgg9QRXKP4A0WGVptEN7oMzEsTpVy0EZPqYeYmPuUNdbRQByf9h+KbcYs/F6zAdDqOlxyn8fKaLP5D8Ky9Hn8barqOu2ja74fgXS71bQvHosu6XNvDNuGbohf9dtxg/dz3wPQK5Xwb/wAjH47/AOw1H/6brOgBh8Latecat4v1aSM9YbGOG0Q/8CVTIPwcVf0LwhoWh3LXWn6fGL5hhrydmnuWHoZpCzkcnqa3qKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjPjP/ySXxh/2C7j/wBFmvmfV/COuaX8OPh9qF7q8c/h0XmnzadZrnzI5LhRJN5mRjCsrbME8O3SvsuigD55Pj3xpcfEHVLSXW9H0VbHWlto9Iv5Ar3doTtUxxC3aWRn+8HWUAY5UDmsnwz431q0sdJt2vrXQNDvvEeo2+oazb2VtCtuECmNTmPylLkkF3Uk468GvpyigD5kvPih4zi8H6Fqt7q1nb2265M4imtbTUNQhRtsU0MdwjIwPXCJlivHUVZuPGGtnX/Ft1ot7pulXx0PTJoLrXYLa1mDSBN3nS7FBfBOFPyBuigcV9JUUAec/BDxXc+LPD19cXkmqTS2920DTXj20sbEAZ8mW3jRJEBz82D9fTkPgB/wjH/CwviL/YX9jeb9uH2T7H5W77Lhd3l7f+We/bnHy5x3r3WigAooooA5XUv+Sp+Hv+wLqf8A6PsK6quV1L/kqfh7/sC6n/6PsK6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV8Zf8jH4E/7DUn/AKbryuqrlfGX/Ix+BP8AsNSf+m68rqqAPIv2rf8AkiGtf9dbb/0cledal4S17wx8U/hl/bmqx6lBFeS2WlRxk5jtI1BTzMgfvDvCkjIwi819RUUAfNXhXx/401mYy6xrmi20jNewXvh25Km5jwjFAkAt96hQMlpJXRgecHiqOg+P9etPDHhe3uNYt/DGkSeHrm+ivrexto47q8WVwtuFaMxrwAdiKGOeDyK+o6KAPmnW/ih4vso/D97rV6tpBcafC1xpejzWi6mJ3bG829wjsykYIVAMbuTwadd+LtfsJfHUmiahoWlTReJRExuTaWEs0AjLMiSSJsaU4A3SByBmvpSigDhPhz4htfFHwyTVtaN42nzRzfaH1tIF3wgtuL7ESMx7c87QCOuetcf+yt/Yv/CIaz/ZX9nfbP7Un8/7Ns8zyt7eTu287cbtueMZx3r2uigAooooAKKKKACiiigAooooAKKKKACiiigArlfBv/Ix+O/+w1H/AOm6zrqq5Xwb/wAjH47/AOw1H/6brOgDqqKKKAPEP2pdNTWdO8DaZNI8cd74jtrZnT7yhwykj35riobDxb4V+NC6hrVzDr3itvDN1cxx24YxuYwyRRqCASTsBPHLM2PWvqSigD5Y/wCE78Val4C1m81HxHoGpxy6JJNNpkixXNxa3CuM74fsyLGvO3ZKXzjIZq0Na+IvifTodQiXVk0Z7DR9Nn0WwSzhK6vJIieYApQlgCSu2Lbt/A19L0UAeAyfEPxHbfE+w0/WL8PZ3tzbW8Om6FcWcsts5UGRbqGRGmAySGZWUKFPciuT03x7r+keANNvrPVNH0+0XUNQa+trZrGwu5kRwF8hJIzGxGSThCzHAzk19VUUAcBq+oadq3wUnv8AxErLZ3Gl+ZINbSJG3lfkMgwqBt+3GAOcYA4rO/Zq/sz/AIU9oX9lfYt+w/bPs23Pn9/M2/x7dmc842+1eoUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByupf8lT8Pf8AYF1P/wBH2FdVXK6l/wAlT8Pf9gXU/wD0fYV1VABRRXLXfjfTRdy2ejwX2u3sLbJItLi81Y2/uvKxWJW9mcGgDqaK5Qa94kYb18G3AT+6+oW4kx9AxXP/AAL8aaPHVlZuqeJLDUvDxZgok1CJTBk8D9/GzxDrxuYH2oA62ikRldVZGDKwyCDkEV4P8S7jWr3413Gi6YfEN3G3hVri3s9L1VrJY7nz2VZ2/exqQMgH7x5HynHAB7zRXzHryeOB4vt9BvtYuZ9TtfBJu7jZrdxYRR3Cyuvn5hBEjqCBhgA2MkjArRm1a51/Svg1eprOvr/a8osr9lv57U3KopBLLE4GSwJ3D5iMZJoA+i6KKKACiiigAooooAKKKKACiiigAooooAKKKKAOV8Zf8jH4E/7DUn/puvK6quV8Zf8AIx+BP+w1J/6bryuqoAKKhu7mCytpbm8nit7eJS0ksrhEQDqSTwBXLp43jv8AB8N6JrGtRHpcwRJBAR6rJMyBx7puFAHXUVyZ8QeI4hum8GXcid1tr+3d/wAnZB+tWNJ8ZaVf6hHp05udN1SQEpZajC0EkmOuwn5ZMf7BagDpKKK+afDS+MvEes+Im0K619r2x8Zzw/2hNqx+xW9mjAtAbdpfm4PAERGCPmGMUAfS1FfKE2v+IrKfXvEM2raoNP0zxzJZySprFw8n2cOP9GSzb9yyfMDnORyNuBXqnhxJv+Gh/Etm2o6tJZWunw3cNrJqVw8CSykhyIy5XHPC4wvGAMCgD1uiiigAooooAKKKKACiiigAooooAKKKKACuV8G/8jH47/7DUf8A6brOuqrlfBv/ACMfjv8A7DUf/pus6AOqooooAKKhu7mCytpbm8nit7eJS0ksrhEQDqSTwBXLp43jv8Hw3omsa1EelzBEkEBHqskzIHHum4UAddRXJnxB4jiG6bwZdyJ3W2v7d3/J2QfrVjSfGWlX+oR6dObnTdUkBKWWowtBJJjrsJ+WTH+wWoA6SiivnHxIfFWvfEr4m6V4dm8RT31p/Zw0x7bV2trXT2eIM7PGZVDK2CcBH6HgZyQD6Oor5X8c3/i1fEHxQePWr4NoMGmS/aItYuLZbUmJTK0Nuv7uTeVb5XKgZ4yTXfS3cmp/GrwTJBqWtpp2qaMdSktTfzxRvIoUoWhVwg4xlQNpOcg5NAHtVFFFABRRRQAUUUUAFFFc1pHjjQNW1NNPsrq4NxJJNDEZbKeGOZ4iwkWOR0COVKtkKT90+lAHS0VXlnkS9t4VtJ5I5VcvcKU2REYwGBYNlsnG1SODnHGbFABRRRQAUUUUAFFFFAHJahIh+J/h6QOpQaLqZLZ44nsM811gIYAggg8givlrxx8Lby9/aP0+yga4HhrWA+p3MSyERBVZTcRkf7brGT7yL6cfQHxDvLm18MvbabI0N/qM0WnW8icGJpnCGQe6KWf/AIDQBkSm58f6jcQRTyW/g22doJXhYpJqkqkh1VxyIFIKkjlyCM7R83XEWHh/RJDBbxWmnWMLOIoIwqxooJIVRx0B4FS6Vp9rpWm2un6fCsNpaxLDFGvRVUYApmt2J1PRb+wD+Wbq3kg34zt3KVzj8aAMbwR4vt/Fvh19Xt7G9s40ODBcqvmYKLIp+ViCGR1I571W+G3jjSPiV4Xl1XSre4S0857WWG7Rd24KpIIBIIIcd+9eQ+DPidpvg7wzr/hvxDcQQeIdOgjijhRHCvMIVgEWW7holJbhSHBHQ11X7Kugz6B8NLiOWRZoLnU557adVKrNFhEWRQedrGMkE9QQaAOjvrKX4eynUtGVm8I5LX+mqC32EHrPbjsg6vGOMZZQCCG7KGx02bUE1mG1s5L54BCt8samRoSdwQSdSmecZxnmrrqrqyuoZWGCCMgiuR+HYOmpq/htiTHo135Vrk5/0WRRLEv0QM0Y9oqANTWvCXhzXbtbrW/D+kalcqgjWa8so5nCgkhQzKTjJJx7mm6p4P8ADOqyQSap4d0a9kgiWGFrmxikMcYzhFLKcKMnAHHNbtFABRRRQAUUUUAFFMmkSGJ5ZDtjRSzHrgDk1geGfGmheJZUi0i5uGkktxdxLcWc9sZoTgCSPzUXenzL8y5HI9RQB0VFVxcSG/a3NpOIhEJBckp5bMSRsA3b9wAB5XGCMEnIFigAooooAKKKKACiiigDk/GDq3iPwNtYNt1uUHBzg/2decVv6rqtlpWkXOp31wkVjbxmWSXOQFHpjqewA5J4r5w/aN+Hmqan8TvDN14fmubeLxDOtndmFyoSVEI81gO/kFx9I2Hfn2LVNNtpde8LeErSIJo+nQf2hLCPulINkdvGR3G9t/1hFAC6RoN14nuY9b8aW/7oP5un6NKMx2i/wvMvR58c85CdF5yx7K9u7awtZLm+uIba2jGXlmcIijpyTwKnrz74421veeC7eC9hWa1fVLFJUcAqVa4RfmB4xzj8aAO31HUbLTNPlvtRvLe0sogGkuJ5AkaAnAJYnA5I/Oota0jTte017LVrSC9s5MEpIuRnswPYjsRyOxrw34k6msX7MHhu6tIYrox2+n4tbiLzFmMagujJ3ACMSP8AYJ7V7D8O4Li2+H/hmC9V1uotLtUlVzlg4iUMD75zQBk6PeX/AIW1yDQtdupL3S71imlajMcyBwCTbTt3fAJR/wCIAg/MMt1enaZYab9p/s6ytbT7TM1xP5ESx+bK33pGwPmY4GSeTVLxfoi+IfDt5p3mGGeRd1vOPvQTKd0ci+6uFb8KPB+rtr/hbS9Ukj8ma6t0eWL/AJ5yYw6fgwI/CgCGLwb4Yi1b+1IvDmipqfmmf7WtjEJvMJyX37d24kk5zmpLbwp4dtdZbV7XQdJh1ZneRr2OzjWcs2dzGQDdk5OTnnJraooAKKKKACiiigAoqlreq2eh6Reapqk3kWNpE000u1m2IBknCgk/gKqaB4k0zXpLqPTpLgT2u3z4Lq1ltpYw2SpMcqq2Dg4OMHB9KANiiq8E8ktzcxPaTwpEyhJnKFZgVBJTDFgATg7gpyDjIwTYoAKKKKACiiigBrusaFnYKo6knAFcr4PdV8R+OdzBd2txAZOMn+zrPiui1WwttV0y70++jEtpdwvBNGejIwKsPyJr5t/Zy+HmqaZ8TvE114gmubiLw9O1naGZyweV0A81Qe/kBB9JFHbgA+nKp6xqVpo+l3Wo6lMsFnbRmWWQ9lHt3PoByTxVyuP8UINZ8Y6DoTjdZQK+r3ano/lMqwoR3Bkff9YRQBW0jQbrxPcx6340t/3QfzdP0aUZjtF/heZejz455yE6Lzli74p+N5/BOn2E1npY1O4upJR5Rn8kLHFBJNI2dpydsZwMck9a7evNvjzYSz+EIdQhhEi6dO0lywQs0dtJBLBM4A5O1ZS5AzwnQ0AXfiZ8Qk8F6fpF3FYrfR30jFi9wIVjhSMyO+SDk7Rwvcmut1vSNO17TpLHV7SG8tJOTHKuRnswPUEdiMEdq+Z/G3iyz+L+ieE9P8NRsLv/AI954WXBSaZfKaNRgllSMSys4wAqryC3H1LFGkUSRxqFjQBVUdAB0FAHF6PeX/hbXINC126kvdLvWKaVqMxzIHAJNtO3d8AlH/iAIPzDLdXbaZYWt/d31tZWsN7ebPtNxHEqyT7Rhd7AZbA4Gegql4v0RfEPh2807zDDPIu63nH3oJlO6ORfdXCt+FHg/V21/wALaXqkkfkzXVujyxf885MYdPwYEfhQBDf+DfDGo6m2o6h4b0W61BmVmup7GJ5SVAAJcrnIAAHPYVJc+FPDt1rK6vdaDpM2rK6SLeyWcbThlxtYSEbsjAwc8YFbVFABRRRQAUUUUAFFFFABXkujfDu+/wCEWu21ae/m1CGXVZbDTHkg+zwPPJcBHUqoJZklz87tt3nheg9arnPEviuLRNQt9Ph0vU9Vv5YJLo29gkZaOFCAzsZHQdWAABLE9AaAPPtb+Ht4mj6XFo2jwpdf8I9qNresrxq8l1LbxIgdicuSUI3ZIAA5AxWdrPwlQW+u/wBleG7NJW8NQR2BRo1K6mpm3SKd3yy/6n96cZ/vda7q4+J+jJF9qtLXUb7S47e3urrULeNPJtI5gChk3Orn5SGIRWKjk4qW6+IlrFb6heQaHrt3pVl9oD6hbwxNC7QEiUKDIH4KuMlQpKkAk4yAcU/hHxFcfE2y1uXRjDLBqwke9tY7GKOS08ply8g/0mRzkBlJCccA4BpNQ8NHwf8AC6z1r7DBbeLNMu0uoyWDPcv5zotuXUkkOkzIFBwDJnHWup8U/EY2d7b23h7TLjVmF/aWtw8XlbCJ0aQJGWlT95tCHn5QHX14Ln4t+HbXxPFoVyJor1riKzkDTW2YZ5NuIzH5vmNgsAWRGQHPzcHAB0vgbQ28PeGLOxndZb3DT3kw/wCW1xIxeV/xdmx7YHat6isnxF4j0rw7BHJq12sLTNshhVTJNO392ONQWc+ygmgDWorkV1zxPqfOjeG0src9J9ZuvJYj1EMYdvwYoaetp45cbm1vw1Af7g0eeXH/AAL7Uv8AKgDqtqlwxUbgCAccgHr/ACFcr41/5Dngjdnyv7abf/4BXW3/AMe201p/HFllpLPw/qyDqsE0tnJ/wEMJFJ9iy/Wue8Z+KIL/AEpbaWzvdJ8R2c8V/ZWN/GEN3JC4cxQyKTHIzqHTCsT82cCgD0q6nitbaW4uHWOCJDJI7dFUDJJ/CsPwb4x0HxppMmp+GdQW+so5TC8gjeMq4AJBV1B6Edu9c38Vf7W8W/CqaDwHGt7LraRxLMsqRrHbScvISxGRsyuBk/N0rlfh78PfEXgfxN4i023FvL4c1XS4zFd2SC3SC6jXywPKeR3yy/MWGQTj6AA5WSfxR4+0jxlrWh3VlHol9bqb62NtG8ssOwlYom5/erAVYl/+WjbRgDNewfCvxbba/wCAI9RllULYb7e4mMRhVljAKyhDyqvGUkA7Bq479mXR9Tsfh1qi6vbalBPc3WEj1GMxy7VtoY+hx8uUYKfQCuY8MeHfG8vwB1jRLHSLiDW9VvIrNlnAtjFbi3ghkch2BIxEy8ZLZyBg0Ae4+C/GGg+NdLk1HwxqC31nHKYHcRvGVcAEgq4B6MO3eqelf8lP8SbM7P7L07d6b/MvM/8AjuyuG+FHgbXPh1451e3KWk/hS/sYZftVqgt44LiIbMGJ5XcFlBZmBIJx06Dtfh2TqSav4kYER6zd+ba5GP8ARY1EUTfRwrSD2loA6+iiigAooooAKKKKAK+pRPNp11FGNzvE6qM4ySDivIo/hpqKfDCyhupr+/8AEcWj2unpbXE0CpZqGhaWKMxqq9YwNzMzEIPmPf2WuR8SePLHQdQvbaXT9Tu4tPgS61C5tY0aKyiYnDPudWPCsxCBiAMkUAcb44+Hk9ze6vb6Bo0C6ZdafYQBImjiEkiX5lmzyDu2HcWPUnqTUE/wxFjq2s3mh+H7S2kj17TbnS3gMcZhtl+z/afL5HlqSJ9y8bvQ8V2snxC0yPVjbNZ6h/Z63o05tV2x/ZRcEcR537+uF3bNu44zUMPxHs5LG31GTRdcg0a5MJg1GSGMQyRyyKiS8SFlXLqfmUNtOcEA4APPNL8D+Jf+Egu9Ql0P7Fc3VjqUF41uljBbTSSgeUE8rEsgJGd0xJB5wuTWn4r8OT+GfDvhKXwzFb6f4puCulSd2na4hCSM7DJdozGkuSTxDjpiulv/AIh3B8Vabp2iaJe6jaS3d3ZTyx+SC7wKpYxF5lGFYsDkfwMAOmZNG+K/hvWPFsXh+ykd7maaW3ilE0DK7xhiw8tZDKo+RsF0UHHB5GQDsdC0q10PRbHS9PTy7SzhSCJf9lRjn37k+tXqK5zW/GGl6Vf/ANnR/aNR1fbu/s/T4vOmA7FwOIwezOVB9aAOjorkheeNL/5rbSdI0mEng3101xNj3jiAQfhIad9j8cABv7d8NMf7n9izr+G77UfzxQB1TKrFSwBKnIJHQ4x/U1ytj/yVXW9+f+QLYeX/AN/7zf8A+yfpTDqni/TRu1HQLHVIAMs+k3e2b8IZgo/KQn2rBn8W6TJ430fVLe4eB9r6TqVndRtDPbeaytBI8bAEL5ieWG5UmYYJ60AemVjeMY9Kl8L6kniFgml+STOxJBUDkFcc7gQCuOc4xzWH8T/Fk3hi10mHT5kXVNSvFtbWBrE3RnYg/KB50KqclfmZ8e3OR50fH58XfB+31jxXaw2sUGvQWt+LdiItsU6MGxuY4yFyAW5746AHj/gqyuJ5tDj8T6rraeF7We5a7tZ/NjTZvdJkVGQAlTgzbWOElfA4fH2yoAUBcBccY6Yrw7xXpEl9+z34RtdKujaySpp4+1Fs7BOojkY565Ergg9dxqbVPiJquieC/B0WmTW8+v3+if2g1tJp5m8xEgVy7ObiFYwAGz98nsOMEA9srlPhj/yK8u3Pl/2pqfl/7n26fb/47isrQfiA+ofCCy8X3Noi3t1bZis4iT51wWMaRpnn53wAO2eveuo8H6Q2geFtL0uSTzprW3RJZf8AnpJjLv8AixJ/GgDYooooAKKKKACiiigDl/ijpV5rnw68R6XpcPn313YywwxblXe5UgDLEAfia53xD8Pnmls5/tF/rd5canaPfXN5LEji2i8zCgRrGoUeYxwoySxzmvSq5C58e2FvrM1m1hqTWcF7Hp0+prGn2aK4k27YyS+/q6LuCFQWAJ60AcZqvw6kuvEM8CaFaHw62vWV0LZfKWH7NHYtE37vI+UPgbcc+hFVNO+HOoaI1je6DoVlb6pBrOpsHZ0C/YXjuRbxsQcmLJg/dj7vXAINdj/wtHRY1Nze2uo2WlPHcSW2pTxp5F0IAWk8sK5fO1WYblXcFOM1etvG8ZvrC21PQtb0k3s4t4ZL2OIRlmjZ1yySNjIRhjqDgEDIyAeU6V8PvEMeneIIodEnsV1DTraNoMWFqj3CXG59iWxChQpOGcl8cZ6Cuk8deF4oPFOi6H4ajt7K18Q28ljqlvCNmbWKQTPNx/Ed8sZY8k3ANbOl/EmTU/E1rDZ6NePoE+nNfC8PkqVQTMnnHM2fKKruGFLEMDjqBc8EfFHw/wCMtZbTdJaTzzbm7jLTQSCSIMqk4jkdkPzL8sgRuenBwAdzHGkUaRxIqRoAqqowFA6ACnUVzmt+MNL0q/8A7Oj+0ajq+3d/Z+nxedMB2LgcRg9mcqD60AdHSKqqWKgAsckgdTjH9BXJi88aX/zW2k6RpMJPBvrpribHvHEAg/CQ077H44ADf274aY/3P7FnX8N32o/nigDq65Sx/wCSq63vz/yBbDy/+/8Aeb//AGT9KYdU8X6aN2o6BY6pABln0m72zfhDMFH5SE+1YM/i3SZPG+j6pb3DwPtfSdSs7qNoZ7bzWVoJHjYAhfMTyw3KkzDBPWgD0yvPvjjrN/pfgW4t9GmWHUNQJtlmJ/1EflvJLJjrxHFJjHfB7Uz40aPrWuaXo9ro+kWmqWgvle+SSC1mmjiAILQrc/ut/JGW9frXks3wz8cf8KcsNFisJf7VtNYuXit3uomKWksEkYwyyKoXL8gHjJO0jggD9K8L3Xwri8O6/BLb3Ooz2j3NySoVjHFEhktVIXLJ5KgrnkSQ5zhyB7r4v8b+HPBdra3fibVUs7e9l8uBijyBjjPGxTgY5yeOevSuF/aC8F674l8G6PaeFbGK6v7SbYymYRlI2iZCyliAcHb1544rN+J3w38SfEPxyY7w2dvoWnaQ9vaXV3EJlnupRiSRY0lVkIGMMwIBQcNQB7iCGAKkEHkEd65X4Y/8ivLtz5f9qan5f+59un2/+O4rF8L6trfhb4OWU3iywePX7G2Fotr5qStczA+XAqsjEEudg65yTn1rrfB+kNoHhbS9Lkk86a1t0SWX/npJjLv+LEn8aANiiiigAooooAKKKKACiiigArm/EvhOLW9Qgv4dU1PSr+KCS1NxYPGrSQuQWRg6OOqgggBgehFdJRQBwlx8L9FeIWtpdalY6XJb29rdafbyJ5N3HCAEEm5C/wB0BSVZSwGDmtHTfB8ek300+n6nqRsmknuF0iSWMWnmSlmc8R78FmY7SxUFiQvSuqooA878MfDS3034f6XoM93Na31tcJftd2LhjHcg5GwyqwKqMIAyn5VGRWtbeCEtNWkvrTX9cgSe4ju7q1jkiWK6mQKC7/u9y7ti7lRlVvTBxXXVk+K9bi8O+H7vUpY2maJQsUCH5p5WIWONfdnZVHuaAMzxR4gu49Qi0Hw3FDca/PH5pM2fJs4c486XHJ5yFQcsQegDMLHhrwpZ6LNJfSyS6jrc67bjU7rDTSd9q9o0z0RcKPTPNHgrQZNF02STUJEuNbvn+06jcr0kmI+6ueQiDCKOyqO+a6GgAorxL9pT4o6z8Ol8PR6EkAa+eWSWSaLzARFsxHjIwGL4J6gdOa9f0K+OqaJp9+U8s3VvHPs/u7lDY/WgC9VTVtNstX0+ax1S0gvLOYYkhnQOrD3BrxrwZ8TdV1j44X/hqe/tprJZL6A2MdqUNoIJNsbmUkl2cBiR0HGPSvcKAPMbO2f4SRyhXnufATOZDvLSzaQzHk92eAk5J5ZCSTkEkej2F7a6jZw3dhcw3VrMu6OaFw6OPUMOCKlmjSaJ4pkWSJ1KsjDIYHqCO4ryTwz4KsPD/ijUfDthdahorsp1DTbnT59glgLAPG8bBo3aJio3MhOx48knNAHrtNlkSKN5JXVI0BZmY4CgdST6Vyw0HxIo2L4yuCn959PtzJj6hQuf+A/hTR4Fsrx1fxJf6l4hKsGEeoSqIMjkfuI1SI9ONyk+9AGZfXsvxClOm6MzL4RyVv8AUlJX7cB1gtz3Q9HkHGMqpJJK99DGkMSRQoscSKFVFGAoHQAdhSoqoqqihVUYAAwAKWgAooooAKKKKACiiigArkPEvgOx16/vbiXUNTtItQgS11C2tZUWK9iUnCvuQsOGZSUKkg4Jrr6KAONl+HumSasblrzUP7PN6NROk74/shuAOJMbN/UBtu/buGcVUuPAL2fhLVdH0zU72+t5dNk06y0/U51+y2yEYUZjjDkLwAWLMAMAjrXe0UAcbbeArW20fw3aWepX9lc6GpEN3bmMvIXXEpcSI6neSWPGc9CKsaH4Mi0TUUmsdZ1ldPjnmuI9LMsf2ZHl3Fv4PMK5diFLlQeQOBXVVyfjy/u5PsHh3R52g1TWGZDOn3rW2QAzTD3AKqp/vyJ2BoAqXupaj4u1G50vw5dNY6PayGC/1aP/AFjyD70FtkYyOjSfwnhcsCV6XQND03w/YfY9ItI7aEsXfGS0jnq7scs7HuzEk+tT6TptppGmW2n6bAlvZ20YjiiToqj+f171boAz7/W9K0/ULOwv9Tsra+vDttreadUkmPoik5bqOlaFfOf7Q0esf8LBsrjSYJ2it9Pt5J50t45EhC3TPlmYFkzsIGzBJwCccH6LbO04644oAz9J1vStYe6TSdSsr57WTyrhbadZDC/PyttJ2ng8H0rO8beDND8aaYbLX7JZgAfKnQ7JoCe6OOVPT2PcEV4X+zLr1jqnjOS206K5tprXw/Hb6hFIECtcx3By6lfvZ8xuTzyRX0tQB5gbqysDZ+FfirFp2pQu+NM1TUIEeC9KjhZA4KpcAHvw/VecqOxuvB/h258P3Ghto1jFpFw/mS2tvEIUZ8ht3yYw2VByOeKf4y8NWHi3w5d6PqsYaCdflfaC0TjlXXPGQcH9DwSK4rwHoMk+jtFp+s6roOp6dM1lf2VrKs1ssqAcpHOr7EdSkihNuFce9AHc6p4b0fVfDh0DULCGbRzGkP2U5ChExtAxyMbRj6VQ8XWHhG30mC58WWGjNYWICwNfW8cgi7BYwwJycAALycDFQnw/4jlG2bxndxp3a2sLdH/N1cfpVjSfBulWGoR6jOLnUtUjBCXuozNPJHnrsB+WPP8AsBaAMTwtosmq31lqN1pcej6BppLaLo6xCLaxBBuJYwMK2GIRP4QxJ+Y4Xv6KKACiiigAooooAKKKKACuPuvAOn3GtS3rX+prZz3seozaYsifZpbmPbtkYFN/VEbaHCkqCRXYUUAcF/wq3RZVa3vbrUrzSkjuIrbTp5U8i0E4Kv5ZVA+drMo3M20McYqPxR4Au9V8IX2inXL/AFKS9ltgbjU5lDWsccisWi8qNf3gAJBPJONzYr0GigDmbvwbYy6nYXlrc3ditrZ/2e1tB5Zintsg+U4dGOOOqlW5PNHhTwkPDbQpDrmtXtnb2/2W2s7uWNooI8gjG1FZiAoAZyxAyM8mumrk/Hl/dyfYPDujztBqmsMyGdPvWtsgBmmHuAVVT/fkTsDQBUvdS1HxdqNzpfhy6ax0e1kMF/q0f+seQfegtsjGR0aT+E8LlgSvS6Boem+H7D7HpFpHbQli74yWkc9XdjlnY92Ykn1qfSdNtNI0y20/TYEt7O2jEcUSdFUfz+verdAGHr3i7w/4f1DT7HW9XtLK7v22W0Uz7TIen4DPGTgZ4rcr5z/aU1OKx8UR2st8to17pEaRJ5Jd7iRL6J1RT0XoSSew4zX0ZQBz/hzxn4d8S6hqFjoWrW17d2DbLmOMnKHJHccjIIyMim+NvBmh+NNMNlr9kswAPlTodk0BPdHHKnp7HuCK8S/Z3ju08Z6Y9zey3NvJ4YPkRsiqISLiMuowASu5uCSTnfX0fQBwGj+JLjwnd2vh7x1ex75T5Wm6zIdkd8AOEkPRJwOoPD9V5yo7+sTxl4asPFvhy70fVYw0E6/K+0FonHKuueMg4P6HgkVxXgPQZJ9HaLT9Z1XQdT06ZrK/srWVZrZZUA5SOdX2I6lJFCbcK496APUKoa3rGnaFp0l9rF5DZ2icGSVsAnsoHUsewGSe1YR8P+I5Rtm8Z3cad2trC3R/zdXH6VY0nwbpVhqEeozi51LVIwQl7qMzTyR567Afljz/ALAWgDN0ezv/ABTrkGu67ayWWl2TF9K06YYkLkEG5nXs+CQifwgkn5jhe2oooAKKKKACiiigAooooAKKKKACiiigAooooAK5DxGP7T8d+GtKIBt7RZtXnGerR7YoQf8AgUrP9YhXX1yliA/xV1st1h0WwCe2+e83f+i1/KgDq6KKKAPAv2otHTU9U8Gi70u41G0nN7p6JbuqNHczRr5L7mwuAUJ5IHBPavWvhzeRXvgHw/PFIHX7DCjnPR1QK6n3DKwPuDS/EPwvB4y8Hanodw4iNzH+6mxkwyg7kcfRgDxXi3hDwr4q8RfDTxBHpfia38O2dzPcQHT4lNykckbFJmFw771EjqzHsNxPOTQBzvwahstW/aL1PXtKuftBuJ9QuXjTDpHbM2IpCwPDMxPyHkAqe5x9W14t+yv4FtvC/wAPotXMkU+o62q3EkkZDCOMfcjBBOcZJPucdq9poAK5H4hj7FHouvR4Eml6jD5h9YJmEEoPsBIH+sYrrq5T4sgf8Kv8WP8AxRaXczL7MkbMp/MCgDq6KKKACiiigAooooAKKKKACiiigAooooAKKKKACuQ8ND+0vG/ifVpMFLVotItjnoqIJZCPrJLtP/XIV19cp8NQDoeoyn78utaoWPrtvZkH/jqLQB1dFFFAHzr+1Vo+upf6HrWjXa2+nzD+zr55pdkERJbynkx2/eSDd2OO5Feiah8RYbnwLHc6Wqr4mvmGnwaXLkSxXzfKUdSMhUJLsSMbFz0Iq38btd8P6F8ONVk8VxNcWFyn2dLZDh5pSCUVT2IK7t3bbntXyjpWu+J/Fulw3+p6VaxPqM8WjJ4pKmO4Mo2eXG0gYYB2bWl2k4Y8nG2gD2/9mbwdZ6Rea/q9jbstoMaZbXLOW+1+XI5lmGVBwWKL042Edq96rlfhhquk6t4J06TQbU2Vpbq1obRmDNbyRko6MQTkgg/Nn5shu9dVQAVyLD+y/ihGUwINc05t/wD13tmXafq0czfhEK66uU8YAL4p8DSj751WaEn/AGTY3TH9Y1/KgDq6KKKACiiigAooooAKKKKACiiigAooooAKKKKACuQ8ND+0vG/ifVpMFLVotItjnoqIJZCPrJLtP/XIV19cp8NQDoeoyn78utaoWPrtvZkH/jqLQB1dFFFAHgv7VHhiO90zTNeln+zWlvItte3IhMrW8ZcOkqgejgof+uo9K1j8ZLDV/B8lto17aDxlMz2UduH3IkoJDXIb7pgVQZN+cYGCc5FdZ8ZfFmleEfAt3ca1bwXcV4RYx2s5/dzPICMPwTsA3FsAnAOBmvkeXwVqKaTBfaXbiTwldiPSW13VJf3VsTMTJNAp2vFBuJGWB6tzlqAPfP2aPCM2kza/q8upXGq2LlNO0q8mDKJLaIksUVmYqhkJwM4+UkcGvdK5D4X6/Yaz4ajt7C3trOTTdtpNaWzBoosIChjYcNGyFWVh1B55BA6+gArkWH9l/FCMpgQa5pzb/wDrvbMu0/Vo5m/CIV11cp4wAXxT4GlH3zqs0JP+ybG6Y/rGv5UAdXRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFclcH7F8VLN3OE1TSZIQcfx28oYL9Ss7kf7prra5f4hWN3No8GpaVE02qaPcLqFvCv3pgoKyRD3eNpFHbJHpQB1FFVNI1G11fS7TUdOmWezuolmhkXoysMg//WrkPiZ49Pgz7KltbWV/dzxSyize4mSd1Rc5RIoJSRjOWbaox164AKHxz8RS6V4bsdKsJJ477XL+LTVkgYq8aN80hBUEglAVBAJBYHtXnvw2+DttrnwnDHWNW0w6vAZIIrC8kSARkEI0sedsrMu0uSBngALjJ5L9pbxG/jPwh8Nda0iC4t21D7VLHDks8bgRg429SDnBxnvxX0z8PRGPAXhryQoi/s222hRgY8pcYoA8U/Zd1C80KSfwlqE8DR77lVt13eZa3VuyLMjZJ4feGXGB8rHAJNfRVfKXw9jZf2stZkF3GY3v75fsoc71YRk7yvTBHGefSvVB8Yol8dafoJ062urK91CTTo9QsLqaVUkXoH3wJGTyMqkjlffjIB6zXI/FM+b4On09T+81SeDTkHXPnSqjfkhdj7Ka66uMeQ+IviJFHF82m+GwXlfs99KhVUH/AFzidifeZe4NAHZ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcl4DP2a/wDFWlscPa6tJMo9UnVZww9t0jj6qa62uM8Ryf8ACO+NdN15jt03UUTSb9u0b7ybaQ+293jJ9ZV7A0AdnRRXzF8bPHfiCP4kXlx4ZvtUj0zwhHbyXlvaJO0N3K8gZ0mZBsVRHkfvD/CwHJ4AHftc67c2niPwtpqQW01vJbXL7ZofNG59qZ2kjoARnqAzEc4r3aXwfpb/AA//AOESeBF0sWQs9qgDaAuA4P8AeB+bPXPPWvC/2g/EthHrmiXS2iXsWu6JKthdu202wfaw2AA7iwwMdfn619MOu5GXpkYoA+Yv2QtQitb670m21BbsX+nnUbmBQR9lnjnMJzknJkQxv26dOlfT1fI/7IukTaL428QXVzPbNbxafLHcFCc27JOoxJkDaSEdgPQZrU+G3xE1y4+K1hrmq3+rN4a8U3lzY2lpcRzi2tgCotzGzARszFSpCHI5zycUAfUlcjrh+2fEbwxZoc/Y4LvUZP8AZ+VYEz9fOkx/uGusd1jRnkYKiglmY4AHqa5DwAX1i51TxXKpEWqskVgGBBFlFu8puf77PJJ/uuuelAHY0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcl4DP2a/8AFWlscPa6tJMo9UnVZww9t0jj6qa62uM8Ryf8I74103XmO3TdRRNJv27RvvJtpD7b3eMn1lXsDQB2dZ9/relaffWdlf6nY2t7eNttoJ50SSc5Awik5Y5I6etaFfMHxY8K+MPGvjXxR4h0zR7hF8NxwxaO87SQySPE/mvJBH5ZExJDKPmUHK4LdAAWv2s9asYb6w0fVIWmNzp8v2IiJXWKZ5Y1LkE5BCo2COfmNfQA0DTf+EZ/4R9rSI6SbX7GbcKApj27cYHTivnP482994q1Pwpcjwnqlze6npCxQjypIzp1000bEyKV4xypzjAYmvqGgD5j/ZUsL/QvEVxayXNtNp+qaYbpBE6s8bQTBQj4zztuAc+mOwr6cr5e/Z58H674Y+IviW+uraeYQ6ZNB5JR4ws3nrtiVmUKQRESpUkbSpOOlbPwqu/GsnxK0WW+tfEVno91ZXAvrO8jv5ILaRS2wGW6dwzkBTuTapzjk5oA+iK5HXD9s+I3hizQ5+xwXeoyf7PyrAmfr50mP9w11jusaM8jBUUEszHAA9TXIeAC+sXOqeK5VIi1VkisAwIIsot3lNz/AH2eST/ddc9KAOxooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDgp3b4fapc3TBj4OvZGmm2qW/sydjlnwP+WDkkn+4xJ+6xK6/iLwb4c8XXFlqOqWpuZooWjgube6lhJikHzLuiZdyMD0OQQT610rKGUqwBUjBB6EVxbeF9S8OyPN4GuoIrViWfRb0t9kJJyfJcZaAn0AZP9gHmgDC8c/BXw94m8N6FotpJcaVa6K0gtBExl2pIPmU7zknIBBJ4Ir0XRNOh0fRrDTLQsbeyt47aPecnaihRk+uBXPDxsll8niTRdY0iQdZPszXUB9xLCGAH+/sPtT1+I/grHz+LNChb+5PfxxMP+AsQf0oA53RvhBpWk/Fi78dwajevd3DSubV9vlh5BhjkDOOTgH+lbFt8LfB9tq1vqUGlOlzb3jX8IF5P5UU7fedYt+xScDOFwcD0FWG+Ifh6XI0ue61eTsmmWct1n/gSKVX6sQPeoZW8W+Ij5cUQ8Laa33ppGSe/ceiqu6KL/eJkP+yDzQBP4q8RXAvP+Ef8MeXP4jmQMWZd0VhEf+W034Z2p1c47biNjwzolt4e0aDT7RpJFQs8k0pzJPIxLPI57szEkn3o8O6Dp/h6xa20yAoruZJZXcySzyHq8jsSzsfUmtSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKq6tp9rq2mXWn6jCs9ndRtDLE3RlYYIq1RQBxPh3V7rQNQh8M+KbhpJmbZpepSfdvowOEdugnUcEcbwNwz8wXpYtC0iGPUI4tLsEj1Fma9VbdALosCGMgx85IJB3ZzmpNZ0qx1rTZrDVbWK6tJRh45BkeoI7gg8gjkHkVzEdl4p8MnZpso8SaQPu295MI72EeizH5ZR6CTa3q7UAdRaaZYWdvbW9pY2sEFqu2COKFVWIeiADCjgdKuVyQ8f6PAdusxalosoOCuo2UkaD6SgGJv+Auad/wsfwSR8vi7QGb+4uoRF/ptDZz7YoA6Se0tri3nt57eGWC4UpNG6BlkUjBDA8EEcHNUpPDuiy6daafJo+nPYWbrJbWzWqGKB1ztZFxhSMnBHTJrF/4TyxuwF8P6dq+tyt937JZukR/7bS7Iv/Hifaq8mha94oJHiq5j07SW66TpsrFph6T3GASPVECjsWYUAV9Uuj4/vJNG0qRj4Yhcpqt6mQt2QebWJv4lPIkccY+QHJbb3iIsaKkahUUYVVGAB6Co7O1gsrWG1s4Ire2hUJHFEoVUUdAAOAKmoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqurafa6tpl1p+owrPZ3UbQyxN0ZWGCKtUUAcT4d1e60DUIfDPim4aSZm2aXqUn3b6MDhHboJ1HBHG8DcM/MF7aqWs6VY61ps1hqtrFdWkow8cgyPUEdwQeQRyDyK5iOy8U+GTs02UeJNIH3be8mEd7CPRZj8so9BJtb1dqAO0orkh4/0eA7dZi1LRZQcFdRspI0H0lAMTf8AAXNO/wCFj+CSPl8XaAzf3F1CIv8ATaGzn2xQB1dFcj/wnljdgL4f07V9blb7v2SzdIj/ANtpdkX/AI8T7VXk0LXvFBI8VXMenaS3XSdNlYtMPSe4wCR6ogUdizCgCvql0fH95Jo2lSMfDELlNVvUyFuyDzaxN/Ep5EjjjHyA5Lbe8RFjRUjUKijCqowAPQVHZ2sFlaw2tnBFb20KhI4olCqijoABwBU1ABRRRQAUUUUAFFFFABRRRQAUUUUAFc1q3imWz1+bSLDw/q+rXMFrFdytZtbKkaSvKqAmaaMkkwv0B7etdLXK6b/yVPxD/wBgXTP/AEff0AH/AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVT7jx54dt9ek0ea9lW+iuY7OT/RJjFHNIqtGjS7PLUsGXGW5JwOeKl07xpoOo61/ZVnevJdmSSJCbeVYpXj/ANYkcpURyMuDkKxIwfQ0AV/+Eo1f/oRPEn/f/Tv/AJKo/wCEo1f/AKETxJ/3/wBO/wDkqrfiPxhonhydYNVupUmMRuCkFrLcNHEDgyOI1bYmeNzYHvVS4+IHhuA3Ye9nYWszW0pjsp3AmWTyzECqENIWPCDLMOQCOaAD/hKNX/6ETxJ/3/07/wCSqP8AhKNX/wChE8Sf9/8ATv8A5Kps3xD8NRWMF0by5dZnmjWGKwuJJ1aLHmh4VjMibMjO5RjIz1FSr440GbUBYW17I9w+1FkWzmeBXaMSKjShdgYqQ2wsGwRxzQAz/hKNX/6ETxJ/3/07/wCSqP8AhKNX/wChE8Sf9/8ATv8A5KrPh+Jnhu0sLJtS1jz5ZbGHUHuLbTblYRBJkLMw2v5SEqfvt8vc1p33jvw9Zaz/AGXPeTm6+0w2jNFZzyxJNKVEcbyqhjVjuXhmB5BNADP+Eo1f/oRPEn/f/Tv/AJKo/wCEo1f/AKETxJ/3/wBO/wDkqtTxB4h03w/HbNqcswe5k8qCG3t5LiWVsEkLHGrO2ACTgcd6z4fHfhqawu72PVIza2tiupSuY3GLdt4DgEZbmNwQMkEYIBwKAI/+Eo1f/oRPEn/f/Tv/AJKo/wCEo1f/AKETxJ/3/wBO/wDkqp5vGugw6qmny3U63DSxwFvsk3lJK4BSN5dmxHO5fkZg3I45FWfD3ifSvEW86NPNcxoMmX7NKkeckFQ7KFLAjlQcjjI5FAGf/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lV1VFAHK/8ACUav/wBCJ4k/7/6d/wDJVH/CUav/ANCJ4k/7/wCnf/JVdVRQByv/AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVXVUUAcr/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lV1VFAHK/8ACUav/wBCJ4k/7/6d/wDJVQ3HjO6s2tm1Pwh4gsbaa6gtPtEslkyRvNKsSFglwzY3OucKa7CuV+Jf/IuWf/Ya0n/0429AHVUUUUAc/wCIfEjaRqthptto2pate3kM1wsdk0C7I4miVixmljHWZAACT19Kq/8ACUav/wBCJ4k/7/6d/wDJVGpf8lT8Pf8AYF1P/wBH2FO1rx74d0TVptN1K9miuoVjkm22c0iQpIcI0kioURSeMsQB3xQA3/hKNX/6ETxJ/wB/9O/+SqP+Eo1f/oRPEn/f/Tv/AJKqw3jTQV1/+xjev9t88Wufs8vkiYruERm2+WJNvOzdu9qs+IvE2leHvIXU5phLOGMUNvbS3ErhQCzCOJWbaMjJxgZGetAGd/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlUf8LA8M/6URqLFLRd9xILaYxwr5Sygu+3au5HXbk/MTtGWBFIPiB4cNk9x9qu1KXCWpt20+4W58113qogMfmnKgsMLyAT2NAC/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVJ/wALC8NFrVVvbhzcRpKNljcMIldyimYhP3OWVh+828g+lVU+IOh2NhZNqWptdz3f2p4TY6XcnekEpSTEah2GzIBJODgsMDoAW/8AhKNX/wChE8Sf9/8ATv8A5Ko/4SjV/wDoRPEn/f8A07/5KpmofEbwvYpHJLqMssT28V2ZbWznuI44pP8AVu7RowQN23EZrb1/XNP0CyW61SZoonlWGNY4nlkkkY4VERAWZj6KCaAMf/hKNX/6ETxJ/wB/9O/+SqP+Eo1f/oRPEn/f/Tv/AJKq1pfjLQdUltorS/BkuI5pUWWJ4jiFgsobeo2shYZRsMM5xjmqZ+IfhkQWs4vp2t7iGO4Ey2U7RxRyf6tpWCYiDdR5hXI56UAO/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqtDSfE+lavqNzY6bPNPPbSSxTlbaURxvG+x0aQrsDZ6DOSORkc1tUAcr/AMJRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lV1VFAHK/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVdVRQByv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVXVUUAcVq3ji90jSr3UtQ8E+JIbKzhe4nk82wbZGilmOBdEnAB4AJrta5X4sf8ks8Zf8AYFvf/RD11VABRRRQAUUUUAcVpPji91fSrLUtP8E+JJrK8hS4gk82wXfG6hlODdAjII4IBq3/AMJRq/8A0IniT/v/AKd/8lVT+H2p2ejfBnwrqGp3CW1nb6HZtJK/QDyEH1JJIAA5JIAq0PiH4cPlqbm9WeR5Y0tm025W4Z41jZ1EJj35CyxnG3JDZGcHAA7/AISjV/8AoRPEn/f/AE7/AOSqP+Eo1f8A6ETxJ/3/ANO/+SqfbePfDdxqEtnHqJEkfnDzJLeWOFzECZQkrKEcoAdwViRg56GoE+Ivht4BKtzfEs6Rxw/2ZdCaYurMpji8vfICqOdygjCk5oAk/wCEo1f/AKETxJ/3/wBO/wDkqj/hKNX/AOhE8Sf9/wDTv/kqq0nj/Q7Y3N9c6xF/ZiW1rMI1sJ/NTz5XjRmPOdzLt2hAVKnd1GLI8f8Ahw6eLsXdyQbo2It/sNx9p88LuMf2fZ5u7b82NvTnpzQAf8JRq/8A0IniT/v/AKd/8lUf8JRq/wD0IniT/v8A6d/8lVraHr2m63oi6vp1wW08mQebLG0O0xuyPuVwCuGRgcgdKxrT4i+GLq3lnj1CVIo1ikLTWc8W6OV/LSRd6DdGWIHmLlR1JAoAf/wlGr/9CJ4k/wC/+nf/ACVR/wAJRq//AEIniT/v/p3/AMlVZ1Hxjoen3N1bz3Ur3NtMltJBBayzyGVo/MCKiKS52EMQoOBycVBB498O3ElnHbXs0812hkhihs5nkKiQxtlAhZdrAhgQCuDnAFADf+Eo1f8A6ETxJ/3/ANO/+SqP+Eo1f/oRPEn/AH/07/5KrqqKAOV/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kquqooA5W38XXH9r6ZYal4Y1vTP7Rma3gnuXtHj8xYpJcHyp3YZWJ+duM11Vcr4y/5GPwJ/2GpP/TdeV1VABRRRQAUUUUAFFFFABXK6b/yVPxD/ANgXTP8A0ff11Vcrpv8AyVPxD/2BdM/9H39AFTUPAn2v+2v+Jjs/tLWrPV/9Rny/I+z/ALv73O77P97jG7occ19H8A3NjqemfaNZW40XSry4vrGzFpslWSUSDEku8h1UTSYARTyMk4qHV/iM2n+NI9Fi0+3vLR7yKxN1BNOxhlkUYWT/AEfyVO44I84tjB254rz3RrrxLfw+Fpb95mTV7q9urwp4kvI/MSIOVA2Rjygu5sJHgNsTcfQA9Y8QeGNUufEcmteHtbh0u8nsVsJzPZfagUV2dHQb12uDI/J3Kc8qcVUl8CSDSZoLXVRFfDW5dbtbhrbekUjyM2xk3DeuHZThlJzkYrntN+MEt3YSajL4W1OPTJLQXNpOIp1DlmRY45GkhSNS+8YKPIvB56Zv6n4j8bxeLPDlgdF0q1F09yJYf7ULxTqsSsCJPs+9dpLcbRkjuDmgCvqfwuu7+1Yza1YyX9xdz3t1PLphI82RUQNDtmV4tqRoB87A4ywJxi1B8N7yPxLa6o+vq3k7PMlW0Md3chYtmyaZZAsinAJ3RluAN3AxSh+Lpee8uW8N6kdBt1u3a/jhuDtW3WQszZhEIVjGQNsrHJUEDnGl4U1jXdR+Isq61axafDJocNzFZwXzXKDdM/zNlEAkxwcBhwPmNAFe0+Fv2fwzqWkf2xu+2eHLfw/5v2XGzylmHnY385837uRjb1OeMvWPCfiI+Ko9P0uOb/hH5NbtNZuJ54YQu6IxM4SQT+ZgmIfKYeufmx16LVvH1xZajqTQ6Ok2h6XfwadfXpu9kqSyCM5SHYd6r50eSXU8nAOOaK/FE29rBqmqaN9n0C8hvJ7O5iuvNnkW3jeU+ZFsATckbkYdumDgmgDqPFXh+71S/wBK1LSNRisNU05pPLee2NxE6SKFdWQOh7KQQwxjuDiuYk+FNu8HhuI6rLjTndr/APcjGoq863LIwz8i+coYDnAJXoSav/8ACZa1YRafd+IvDttYaZdz28JuodS84QiYMFLgxrgh/LVucfvAQzYNYdh4+17UfFem3Frp9pH4cuNJuNRaOa6KyNClwqi4AEJJYxEMse4A7+WGASAX5fhhB/wmlxrkL6KyXN/Ffyfa9FjuLuNl25WK4LfIp2DqrFckqQenX+DtD/4Rvw5Z6V9o+0/Z9/73Zs3bnZumTj72OvauZ+H/AMQLzxZqKRS+HL6wsp7T7XBePFcBCMrhHaSCNd5DZGxpFIB56Zm/tKV/HfiS6vL1oNN8P2EQSFp2igLyK0kksuOCAqoASDtG4gc0AdzRXldh8WXntdW+1aZaWt3aQ21xb+ZPdLDdpM7IuwvarKx+RsbInDcYPXEWseMrrWPhzf8Aia3iu9J1Hw/f5lt1klVJfLZd6MsiRsyPG54dFIJBxkCgD1miiigAooooAKKKKACuV+Jf/IuWf/Ya0n/0429dVXK/Ev8A5Fyz/wCw1pP/AKcbegDqqKKKAOV1L/kqfh7/ALAup/8Ao+wqn4k8Cf21/wAJd/xMfJ/t+zt7T/UbvI8rf833huzv6cYx3q5qX/JU/D3/AGBdT/8AR9hVPxJ47/sX/hLv+Jd539gWdvd/6/b5/m7/AJfunbjZ15zntQBDJ4CuX1gn+2EGgnVl1o2P2T999oBD487fjy/MAfGzPbditXxL4cvr7XLHWtD1SHTtUtbaaz3XFobmJ4pSjEFA6EMGjQghvUEHNYb/ABBv0164gbQof7Ig1qPRHvBffvTLIE2uIvLxtzIoOXBGcjPSsLW/irePBrlpp+n2xZdOv7ix1C3nneFmt1yfme3RCcHP7tpACuCR1oA6hvATT6N4msrzVpJZ9auIro3KwKhhljhhRW25Ib5oA+OBzj3rN1P4c6jqq39zqes6bdapezQNK0mkn7N5UKOERY/O3q2ZHbesoOTjpxXGQavq/h3Ure61mK6m07StBj1aeKPxFeTO8kkjqHwyDzS2xR5b4RcnGe/X2XxL1OcLbzeFLm31G4u4bOyExuLe3neRJHOZJ7eNxsWFy2I26rjOeACJvhZfNJpTHxIrSWSRx/azZsLxQshcrHOsoIQglQsgkAHTqc7fh7wD/Y95pc/9ped9ht9Qt9vkbd/2q4WbP3jjbt245znPHSshPF/ii18a3kes6ZY2mlWejC/u7Zb7zWiCzTqZYyIQZCyxrhSUwMZwciobD4r3k9o00/hS+h89bcWJZbiOOaSaVIo4nkmgjVWzIpJTzFwGIJxyAYGrfD3xHpWlL4a8ONNdWN9ZWNpfXkltAsYMAEZdWNwHTKKCVEUnbBBJI9V8YaBLrsGmvZ3q2V/pt6l9azSQ+dGHCOhDpuUspSRxwwPOQeKxfh3f6teeI/G8euBIprfUIES2iu3uIYFNnA2I2ZU4JJYjaOWPXqaKfEx4lg1DUtHFv4eu5rqC1vEuvMmZoElcl4dgChhBJtw7HgZAzwAR6v8AC5tU8OfYp9clj1WW/mvrnUILcJ5gmVo5okTd8itG20fMSCA3JFHiL4VWmpeI7jVLP+w0W5ihikj1HRY75ovKG0GBmYeXlQAQQw4BxSSfEy9svs0OseHkt77ULeC402C3v/OE/mzRwhJGMaiNg00ZON4wTgnGKvan48vPDjL/AMJfosOnRvb3MsU1tffaUlkhUOI1zGhy6liuQDlGGOhIB0fhXQv7At9Ri+0faPteoXN/nZs2ebIX2dTnGcZ7+grbrymHx54h02+8V33iDS7VNJ0uztrl7aK7LzwO8O4xqPJHmZfgksMYyAeldP4D8WX/AIkm1CHUtAu9Ka2EbJK8VwsUwfdwpnghYsu3kBSPmHJoA6+ivMofE76XoXj3xfqV3M6WV1cWltbPKRDGtufLRQudoZ5Mkt1O4DgCsTRviVLafDPxNPqHiHTNW1vR5RapqMTxCCZ5wpgclPkwGk2t6eUxPrQB7RRXj1t4mvNc+EOv31t4hjvNb8NTXEn9o2MqrFdNb5lQsIyEZJIyoZeVyW7ivWrC5F5Y210qlVnjWQKeoDAHH60AT0UUUAcr8WP+SWeMv+wLe/8Aoh66quV+LH/JLPGX/YFvf/RD11VABRRRQAUUUUAed+GNBXxL8CvC2mG5a1d9I06WKdVDGOSNIpEbafvAMi5HccVrWPhjVn8RaZrOu63b3tzYi6VI7ex+zx7JliAUAyORtMROSWJLnoABWP4c11vDXwE8N6ulr9se20SwIg8zy95aONcbsHH3vSnS/EDUre6m0u60C3XX/wC0ILCC3j1AtbyGWFpg7TGIMoVI5MjYTlcDORQA2H4c3atbWsmuo+kWE91dafb/AGBfMilmWVQZHLlZFTzpMLsXORuLY5yoPhJex2Ets2taXJC0sci2baS5s4yiuu9IvtG6OQ7+WjkQYUDbjOdSP4hardX2n6Xp/h22k1maa9t7iGbUjHDA9t5eSJBExdWEqkHYD0BA5xmv8To/sY1y00W5lnl0exu1t31BlTM900Pl7MFAysSfMxlhgHAAwAX4/hhKI0+0a/PcyiLTI2lnhLu5s7p58kl8/Pv2852gZy1N8TeEdT07VLjxD4fe4vNWk1X7dFDHaxSLGrWi27q6yXEIYYjByHUgkcEA1i+LfFHiHWtR03w6mnRWF/Hra2l7Hba3NAkyGye4QLcRxCRVP8WFBygHIYkb9p8Q7hEs7ibRBHol5Nc2lhdG+Mk0kkCSN+8jKfIHEMmG3ueBuAzQBpeA/DF1a/DQaF4j/wCPm7F2bsRkAj7RNLIwyMgECTHBIz0JqnY/DyadZ08UatFqqHSG0WFYbP7OEgYgsz/O26Q7E5G0DbwBmq0Hj/xDeDw2LHwtYvJr1m97bJNq5TYiRxu28iBsEmTAxnPBO3JCxaH8UZ72wtr3U9Hs9Ltb/R5tXsZZtRLKVjKApNiL93kypgrv4PTPy0ANm+E0c/hvSrO71G11HVbO9lv57vU9OW5hvJZFKv5sBYcbSoGGBXYvNb/g/wAEjw9qNteC5syYrF7MwWWnpaQ5adpdyopIUDO3HJOMliSa429+Jmu6lYImkaZDZanBrOn20qTyTRxTQXDcYM1srgHG0ny+Adyk4wd6y8a/2frV3FqWnG2jOrx6be3P9pSTxQTPZxyqUDqNsZZvL4CjOGxliAAejUV5Pd/Fu6EVkNO8MXd5dXNj/aYgQXMhNs0jrCR5VvJh3EZba+xRkDceTXqVnP8AarOC48qWLzY1k8uVdrpkZww7EdxQBNRRRQByvjL/AJGPwJ/2GpP/AE3XldVXK+Mv+Rj8Cf8AYak/9N15XVUAFFFFABRRRQAUUUUAFcrpv/JU/EP/AGBdM/8AR9/XVVyum/8AJU/EP/YF0z/0ff0AU5vDnhC58bGNop31uN01hoI7m58lJAdqTNGreUrnaQMjcwU9QDW5Y+F9HsRpgtbPYNN837J+8c+X5n3+p5zk9c47Yrgr+PUHf4vWeltOviKaJJ7HyXKSmM2SpEYyMEfvElAI/izWZrt/r/iG+1VtJj8V2dg6aJAjG3ubRwTeP9pZAwBGIyN7Y6DnIwaAO9t/h14XginhTTna2lhkt/s0t3NJDHG5yyxxM5SMEgH5AvQVj6xo/gjQryysr9tUS+LtfRzR3l9NcRhVWNpJJ0YukQUqpLsEx9K5TW4dfsJdQ0aNPETaSusN9m1B31K6kgh+ywuF/wBHlSaZGkaVQWfapByeAKzV8O65q+hPe6zb+IJdV/4QueAkyXMTSXGXVY2RWAZyCDtYEk4JyeaAPSfDvhnwhrCtrOmWF4be4eZxFc/aoYGMqkSOttKQnzq7fME5DHB5NauieE9A8LTz6jZRzQyC2EMk91fTThIUyQuZXYKq89MAV5R4l0nxHYS2djZ6h4jsNJj0mFrN7a2v9RlF2S/mKxjnUhh+7wJt0WOMLgg6V/Z6jqkuu2Ot/wDCYSa3cPPFa/ZfPisGtjbt5e7afIGSeefM38ZxQB6HceD/AA5q2rRa49r588jxXQeO6kEEzoB5crRq3lyMBjazKSMDB4FUb3wx4P8ADZm1e9tPKikc222WWaaGM3Uioyxwkske93UHYo6nPGa8uubfWU0nQLfTLjxXpujJphWTdYarczpfgKGUqk0coULjZndDndxU3iC21q+jlt9bh8V32rjUNJaxMVvcpZm2VrZ5ZJEjJhDhxOWDlmU7ccAGgDsPG/hbwvofg280tpr6yt9beDTmYpdapK6JuYQxR5dl+QSBdowpOcHAFdPqOk+GbnWtDS6eO31SGFlsII7x7aSSEbWZPLVlMkY2ruRgV45FUviT/wAhDwP/ANjBF/6Tz1xHjDTfFF94s1TxZYaGkqaLdW62BkmkS6aGAMbgQwCI+YJRNKg+cbtq4BwMgHoHh/w74V8Na9Ha6U6waobVhDZyajLK0dvvBbyoXchE3Kv3FA4ArOtLbRvEfjTXza3ErK9iun63pl3YTRCdSZBE6mQL281cqGDAjkYBrj9Q0/xO/jG48bRaGrR2urJFEfNlF41hGGgdFt/KO5WMkkw+cZ+UgcDPceHP+SreNf8Arz03+VxQBJH8NfC6Cf8A0O8eWZYVaeXUrmSZfKYtFtkaQuhUscFSCOnSq+s+CtKsvDM1la3Emn6J9r/tPVQ5luZLpUw7AyO5Ybiilj8xIBGPmJrir+51K88deJIdLuvEsms22vWcdmkT3JsIbfybZphLj9wAVMpKt82SNoycmC3i8Rzh4Wj8TyatJa6mmtpdic2bAxuIRbhv3RO/y9nk87d27mgD2+yuob6yt7u1ffbzxrLG+CNysMg4PI4Pepq+ftTk8VQ6ho6WFprtlLY/2VFHHDBfyx3UR8rz2bbILaIKC6sroznaT8vDD0z4fafffada1DWJ9Wa5/tS9ito7q4lES2/nEpsjJ2kYA2tgkDgEDigDqNN1Wz1OS+Sxm81rK4NrcDay7JQqsV5Azw6nIyOau14lDZalb+NNXOnReJINWn8TRTx4S5TT3stsImdzjyGyqyDkl9wXGKo2TeNV0snSR4mPigaXfHVft/nG1N1j919n8z91nf8Ac8r5dv3qAPbk1WzfWptJWbOoQ26XTxbW4idnVWzjHJjcYznj3FXa8EFpcx6h4m1rw6fFFnHY6NZXUdzrbXcTTzQTTyyQs1xzsZDtZfuDcSB0Neo/Dc6hdeHf7W1drgXWrzNfrbzOW+yxPjyogCSFxGEyBj5ixxk0AWU8a+GpYI57bW7C7ge5Sz820lE6JM5wiOyZCZOANxAyQOpFVviX/wAi5Z/9hrSf/Tjb15xdylvhD8QopbS/tri81S9Nkl3aS2zyyTzf6MUEiqSSzIRjofQ16L8Rgw8MWIkIL/2xpG4juf7Qt6AOsooooA5XUv8Akqfh7/sC6n/6PsKpeLPDfg/XfEkVjrkM0uq6hakNBBcXEazQxHIMyxMEIUv8pk7nCnNXdS/5Kn4e/wCwLqf/AKPsKxnnls/iZ4ub7O1zfy6FbS6fCG2tMkbXG+NG7HeyZ9N6mgDd1rSPDWlaXf6jqsSwWUd6us3ErSSYE8e3bJgHPGxPlHBx0OeeX0TRPAGo6m9hYWOrNcNazRNbzpqCR2sM4IeMrJhLfeASE+Q4wVHINefLp/iTVdC8RWc6eIp7O50+0lS3eHUo/LuBcfPGj3MjyOQvUrtUgA7eM10OteG9b0u58dXnhoa4lybmwigka5upzLbCKATsitIPNcKHG4Nv4IVgaAPU7jwroly1wbiwjlFxYLpkqyMzK9spYiMgnHVm5689ayLbwP4TdLzTolmnmR4JJd+qXEtxbsgYwlZDIZIsBm27SvU46mvPtOj1mCG1TUtQ8XX3hk38huGtrDULW5T9yvlhQ0kl40W8MSc/eIH3arS6bqtjP4nu9Ch8XJrV5p1rLpst59qk3qsRWUSgMIfOCg4VyG3EbcE5oA9WtfAvh+0ntJoLW5WS2jeIE30581HdnZZsv++BZ2bEm7ljWRofgvwVqOmX0WnW1xc2Qd9OdJby6YQGCbmOIO/7oJJGCDHtGVBB6VwlguuwwxCfUPFt54dbUYftwg07Uba5ii8iXiIyyy3TKZfJ37CMfw8E13vwZtJbTwldLLa6harJqt/NFHqCyLOYnuZGRn8z5iSpByck5zk0AW/honhl9NvL7wgl+1teziaa5vBdbrh9oXeGuPmcYAG4Ejj1zVuz8DeHbTVn1GHTv37NK4R55HhRpf8AWskLMY0L5O4qoJyc9TXmWnyX/wDwpnwJbWMF+IZlHn3lmL2RrYBHwTHZukrhicY3BQcE9BjJ1e48ZXPgnRoJofEdvqcem3LreRwai00k4kdY4miglUK+1UYPOXHP8XOQD0Oy8OeBYNbvPCy2N4b64tF/d3X2x1+zxMjAQTSEqqo0iHETDa2OARxpal8PtMu7fSbONn/s+z1NdVnjumku5bmVVIXMsrsw52k5zkLt4BNUInuJPiV4Le9DC6bw9etKHXa28yWe7I7HOeK5j4kXN7N448RWNndeJzfpolrJpNvpT3IiW7aS4AeTy/3aglUBMvykA5zjgA9K1HwhompaleX17aSSTXlv9luk+0SiG4jwVAkiDbHIDHBKkjsRxVfwHpvh+3sZb/wy11NBdHyGmubq4nY+S7psBmYsqq28ADA6kda4K5/4SUeKZRL/AMJEdf8A7Xtfsxh8/wDsv7BiPzt2P3P3fOzu/ebtuOMVzGqQeJbbwjaafZ2Wu6fPHDqVxDcWsOoOzzNdzFIvLt5EVSRtcPNuXDDAbkUAew23gy1TUdUa5l+06XeX0WqJZOrDybpCpLhg3zKWRG2EYDAnnOA6bS/DWseMp5pIfO17TEtpJfmlUIP3phJGQj43SkdcZ7cVjeB7LVrzxPrF9r02sqsBtGtIpJpYoCWs4xKQgIV/nLZBBAbJwG5rlPHllqK+NfFlxpsPiWPVrixsk0eXT0uVtpLhfN/1roPKKqWXIlOME8ZoA9C8VeDbbXLXU4YJzZNq3kw6nIoZzcW6ZzGBuCoWUlS+CcHBB4xuTanY2uq2OkvKEvLqKWW3hCHDJFsDnIGBjzE4JHXjoa8qu/8AhJP+EukEP/CQ/wBvf20vln9//Zf9nbRnOP3H3M9f3nmY7Vj+GtH1DW9b0FLoeMLXV30K+g1XULz7UiW15J5H+oZiI1+ZXI8rCkBeuOAD3usC68Y+HbaLVHOsWcx0sFr6K2kE8tsAcEvHHllwc5yOMHPQ1zfwhvtZ8Q2d34h12SVDKEsYLZZSYf3GVlmVQduXl8zBxnaqVH4fu4Lbxf8AEm61W2u7fTGeGVp7uylihkijtlSQq7qFcAqw4JyORkHNAG18U5Em+E/i+SJ1eN9EvGV1OQwMD4IPcV1teTpBdW37LtzDfh1uE8KTAq5+ZR9lbaD7gYH4V6xQAUUUUAFFFFAHCeCLLTtQ+CXhi31pVbTTodk8+9ygCrCjZLAggDbnr2qUWng/xXdsBHLLd6nBBqob/SLeUpGdkUyN8rRsM4G0q2D6GuauIpJv2X9OSON5B/wjlm0iIMlohDGZBjvlA3FTeM9Gm13xNc6jpsmrJbr4ZkazudMnlhDzby0YDRkbj0IQ5B4yDQB2+leEdD0mSwksLLy5bET+RIZpHbMxBlZizEuzFQSzZPHWs6w8GeEbnT1isLWGe0iijsB5V1I4VbecyLHkP1SUNnvkEHpivN9QHjK68Rxy3+oa5Y4isJLJbTTLudX/AHcZmV/KmSBW8zzAwnQ4UjB6AU00rWdJ0aew0keJLOUa/dNqjmLULlfsjy3DRPCEkQuCWiLGBw/OWzyCAe0P4W0Z9a/tZrPOofaVvPN81/8AWrCYA2M4/wBWxXGMd8Z5qnb+A/DlvqUt9Fp7CeQzMFNzKYo2lBErRxFtkbNk5ZFBOTzya4bwvpeuX+peHbPUtS8Sz6T9j1EzTMlzp5cieAwq+ZGlUhd+0u4kKg54LA5ehS63BHbS6nb+Nbm7Swu28RQ5uwkkox5a2hBChi/CfZyBsPzGgD1618OaVaSaO9va7G0i3a0sj5jnyomVFK8n5uI05bJ4+tZzeA/DT6bZ2D6YrWdpYvpsEbTSHZbuULJndk8xodx+YbeCK8usrvU/D/gt/FMV14kmv7HUI7q60rUHvkjMEv7oWsZuwDIV3K27nLjjAYCl8XQ61oGjynxLqHiaRIfD8lxFc6bPdBF1JnkeUyPC3yooMYQSHywoIoA9LT4e+G1tr6E2t3Ib6SGWeaXULmSdnhOYnErSF1ZT0IYGp7rwN4eu9E1PSbuxe4sdTaN7xZrmV3mZERFYuWL7gIk5BySMnJJJ811B/Ej3krA+KG1dl046K1sZzZlPLj84z7f3Wd/m7/O527dvNWU1PxHHd6ZpjQeJzd22uanNdTJazNG1qUumgAkYeXIvzQ7V3EAqoOCBQB6LrPg3Q9Ynt5ru1ljmggNqj2l1Nat5P/PJjEy7k/2Tke1TW3iHw7b6nHoFvrOlLqUQES6eLuPz1wuQvl53dMHp0riPgx/a6XWpw6mNbniW3gxeaibuNZZMuGxDc5KP0LeWxj5AHTJZpnhHVNX8S+JDfXC2eip4lh1KOFrFhPcNFBbFXSYvgRlkwcIT8rDdyQADuNP8YeGdRnnh0/xFo13NAjSSxwX0TtGq/eZgG4A7k9KSHxf4euUsZLPV7O7gvbk2kE9q/nRNNt3eWZEyqsR0DEZ6DmvH/AdrqNnc+CnKeJbm501rgXdrf6O8VvYwNG+8xSeShdyRGAN0hOTgd6v24kX4DWNhNaXlrqjalFDbQXVrJby+eb4SRlVdQeAQ24cYB54OAD0Xxl/yMfgT/sNSf+m68rqq5Xxl/wAjH4E/7DUn/puvK6qgAooooAKKKKACiiigArgLvxHofh/4p63/AG9rOm6Z5+jad5X226SHzNs99u27iM4yM46ZFd/RQBxreOvh61+t6fFPhQ3qxmJbg6hb+YEJyVDbs4zzirH/AAsfwP8A9Dl4b/8ABpB/8VXVUUAcr/wsfwP/ANDl4b/8GkH/AMVR/wALH8D/APQ5eG//AAaQf/FV1VFAHK/8LH8D/wDQ5eG//BpB/wDFUf8ACx/A/wD0OXhv/wAGkH/xVdVRQByv/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VXVUUAcLrXi34aa7aLa634g8Hajaq4kEN3e20yBgCA21mIzgnn3NXk+IngZEVE8YeGVRRgAanAAB/31XWUUAcr/AMLH8D/9Dl4b/wDBpB/8VWdpfiv4ZaRNdzaVr3gyxlu38y4e2vLWJpmyTucqRuPJ5PqfWu7ooA4638efD+2luJbfxV4VikuH8yZ01G3UyvtC7mIbk7VUZPYAdqn/AOFj+B/+hy8N/wDg0g/+KrqqKAOV/wCFj+B/+hy8N/8Ag0g/+Ko/4WP4H/6HLw3/AODSD/4quqooA5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iq6qigDjr7x38PtQtJbS/8AFXhS5tZl2yQzajbujj0KlsEfWph8RvA4GB4y8NAf9hSD/wCKrq6KAONu/HPw9vHt3u/FHhSd7eQTQmXULdjE4BAZctwcE8jnmsfxv418K6vpenWOleJtEvr2XWdK8u3tr+KWR8X9uThVYk4AJ+gr0qigAooooA4XxZrelaD8SfDd1rmp2Om2z6TqUay3lwkKM5msSFBYgZwCcexqebxz8PZ7y2u5/FHhSS6tt3kTPqFuXi3DDbWLZXI4OOtdnRQByv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXVUUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQBwmi+K/hloUMsOia94M06GV/MkS0vLWFXbGNxCkZPvWj/AMLH8D/9Dl4b/wDBpB/8VXVUUAcJD4r+GUOtTaxDr3gyPVp08uW9W8tRPIuANrSZ3EYVeCf4R6VaTx58P0vJbxPFXhVbuVFjkmGo24d0UkqpbdkgFmIHbcfWuxooA5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iq6qigDlf8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+KrqqKAOV/wCFj+B/+hy8N/8Ag0g/+KpD8RvA7AhvGPhog8EHVIOf/Hq6uigDjrHx38P7C0htLHxV4VtrWFQkUMOo26IijoFUNgD2FJqHjn4e6lZyWmoeKPCl3ayY3wz6hbyI2DkZUtg8gH8K7KigDy/4m+PvB158NvFlrZ+LPD89zPpN3HFFFqMLvI7QuAqgNkkkgACvUKKKACiiigAooooA8v8Ahn498HWnw18KWl74r8PwXEOkWkUsM2owqyMIUDKylsgg5BBresPHXw+0+zitLDxT4UtbWIbY4YNRt0RB6BQ2AK7KigDlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKrqqKAOV/4WP4H/6HLw3/AODSD/4qj/hY/gf/AKHLw3/4NIP/AIquqooA4288dfD69SNL3xT4UuEjkWZFl1G3cK6nKsMtwQRkHqDVLV/Enws1m5t7jWNZ8E39xb/6mW6urWVouc/KWJI5APFd/XK+Df8AkY/Hf/Yaj/8ATdZ0AH/Cx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQByv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXVV53dfGDwxZeMdd8N6g13aXej27XM08yKIZAEDlUYMSW2nOCBnBxQBtf8LH8D/9Dl4b/wDBpB/8VVa48c/D25uLa4uPFHhSWe2YvBJJqFuzRMRglSWypIJHHY03wl8TPDfiLwdH4ma6Gj6W87W4fVpI7c71OMZ3lee3Na0fivTJ9X0yxs54LtdRge4guYLu3ZGRepC+Zvce6KwHcigDmdY8WeHNe8W+B7XQ9f0jUrlNWlkaKzvI5nVBp94CxCsTjJAz7ivRax9M8T6BqrXS6Xrml3rWoLXAt7uOQwgdS+0naOD1rMufiB4bFkLrTNW03VoxcRWz/YtRtT5bSE7dxeVV52nABLHBwDigDq6Kxx4n0A60NHGuaWdXJKix+1x+fkDJHl53ZwCelY/jPx1D4V1nR9Nn0XVr6bVpPJtXs/s+xpeSUPmSoQQBnJGORznIAB2FFcfpvjqG/wDH194TXRdWivrOPzpriT7P5AiOdj5EpYhscDbkZGQOcdhQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvg3/kY/Hf/Yaj/wDTdZ11Vcr4N/5GPx3/ANhqP/03WdAHVUUUUAFeUWvwltL/AOIXi7W/FdrYahp2o3VleafEJJPMhkgjZSXGAMEt93LAjqK9L1bU7HR7CS91W8gs7SP7807hFHtk9/audXxhc33Og+Gdb1CE/duJY0s4j/3+ZXI9whH6ZAPKdM+CfiCw0TwuDf2Mt/ouoXdy1tFfXNrFPHOR0njUSRuAOoUjnHTIN8fBe9e805bX+zNF02LTdRsZIbS6uLhoWuQwUo0oy+N2WJKZOcAV6S3iPX7cb7vwZqDxjqbO8t5WA/3WdM/hk1e0PxZpOs3b2VvPJBqUa73sbuJre4VfXY4BK/7QyPegDyWy+EGtTxafHrsWiy2+maA+iR29reSx/btx+/JJ5WYuPmwA/wA3NMb4TeM7jw4dJutbtZLCDU7K6sLK5vHuRaQQ7t6ifyUZicgKpUABRz3PvdFAHkXh34e+ItG+IratpN5Fo2gXF3PeahYRalJeJeO+cMInhQRE55IduigdM1r/ABM8MeIte8U+EtQ0SHSXttDujeOLy9kheViCpQBYXAGMHdnuRjjJ9GooA850Twx4itPjFrPie6h0kaTqFqlmFjvZGnRY8lXKGEKS3GV3fLk8tjn0aiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuZ1PxzoGmahcWd1c3JltnWO4eGxnmigZgCqySohRDhlOGYcEetdNQAUUUUAFFVNY1CLSdIvtRuFdoLOB7iRYwCxVFLEDJAzgetSWF0l9Y213EGEc8SyqG6gMMjPvzQBPRRRQAVyvg3/AJGPx3/2Go//AE3Wdb+sW9xd6VeW9ldPZ3UsLpDcIATC5B2uAeDg4ODxXzn+z54j8d+JviX4itteuY7e00+4M+qpFbqpmuhElsiE4+UYg3YXGSh7HFAH0vWV4m1u28PaRJfXSySkMsUMEI3SXErHakaDuzEgD8zgAmtWuPkQa38Sgko3Wfh+1WZFPRrqfcA2PVIkOP8AruaADw74YuLi8h17xiYb3Xh80EK/Nb6cD/BCD/F6ykbm9hgDsKKKAGo6PuCMrbTtbBzg+hrL8R+HtN8RWiQapb72ibfBOhKTW79njcfMjD1B/SvHP2Zr+21DXPHE9qZfNkuVlu9xcq87XF0d4zwCY/Kzt44HeveaAOQ8L6rqNhqzeGvE8yz34RprC/ChBfwKQDkDgTJkblHBBDDgkL19cp8S7SR/DMmqWSk6norf2naFeGZowS8efSRN8Z9nravNasLPw/Nrd1P5emQ2xvJJtpbbEF3lsAEn5ecAE0AaNFcVZfFHwjdwzSpqc0SRWDap/pNjcQGS1UZMsYeMGRcDPyZqbRfiP4Y1q4MGnXl3JcGy/tGOGTTrmJ57f/npErxgyg9tgYntmgDr6K4iL4p+EpfD95rkd5fnSbOXyZ7n+yrvbG3OQf3WcDaQT0UkA4LDPVaLqdtrOl2+o2HnG1uF3xmaCSBiM4zsdVYA9RkcjBHBFAF2iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8n8T6N4gGvapceFNI1rTNSuJ0kS+g1KBtOnYBV82eB33A7RghI8sAOc4IyF8Ba4fHV9qNxBqrX7anPcWuqwy2KQx27hhGjuU+1EKrBfKzsO0EEcY9AufHthb6zNZtYak1nBex6dPqaxp9miuJNu2Mkvv6ui7ghUFgCetUv+Fo6LGpub211Gy0p47iS21KeNPIuhAC0nlhXL52qzDcq7gpxmgDiLbwVejw9ZWy+BDb3Fv8AZf7XBvYD/bYRj5i8PiTJ/ebptpP3T1NX9G+H093f6ONZ8PW8egR6jf3SaTO0UkdlDJGgjjKKxQ5dXfau5V347V21t43jN9YW2p6Frekm9nFvDJexxCMs0bOuWSRsZCMMdQcAgZGcbS/iTJqfia1hs9GvH0CfTmvheHyVKoJmTzjmbPlFV3DCliGBx1AAOJu/AWt/2BBaan4XOu7NBk06ygknt3GnXHmykSfvXAGUaEB03MPLxxT77wV4muPF2j3zaHsmsb7TWjvbVLFF+yxiITCWVv8ASWcYkG1SFKjHzdD3/gj4o+H/ABlrLabpLSeebc3cZaaCQSRBlUnEcjsh+ZflkCNz04OO7oA8U1fwqnhvwFqXiO6sLe38T6Zq11qVlO+15JFa8keOAONxCyq4TYMcycgHNek+ANFm0PwxbQXxV9TuGe8v5F/juZWLyY9gx2j/AGVAroq5fUfGunw6hLpukwXeuapCdsttpyBxCfSWRiI4z7MwOOxoA6is3StD07Sb3VLuwtlhuNTnFzdOP+WjhFTPtwo/Ek9SaxBN44vcNHZ6BpMZ6CeaW8k/EKI1B9gzfWnNaeOUG5db8NTn+4dHniz/AMC+1N/KgDq65Twh/wAjR453Z8z+1IcZ/ufYbXH/AI9vpja54n0znWfDUd7bjrPot15zD3MMio34KXNY2heJtJn+Ib3GnXiyWutW6W0kbqY5Le9g3MI5EYBkd4nJAYD/AFB/EA9Hryb48a5qOlwWNquq6joeh3Ntctdanp9k08scqBDFHlQdgbLknj7v3gM16zSMoZSrAFSMEHkEUAeSfs7x+HtM+GB1a01G3d5v32qzyYhW1kjjUGJgfuLGqgZJ55bPzV6RofiLRdfWVtC1jTtTWEgSGyuUmCE9M7ScdK8M+GVrcl/Hnh/wVqgs7gw+TFNtzHaXSTXMSgjHy5hii5GeFBHbPVfCv4d+IPDfjrUfEGvXNpL9s02G0fbqFxeSvMhXdIzyopwdpIA4XOAMDNAHrNz5f2aXz/8AU7Dvz/dxz+led2unX+sfs52+m2sRm1O88LJbxxlgpeVrQKBkkAZJ6k4rd+Jd3InhmTS7JiNT1pv7MtAvLK0gIeTHpGm+Q+yV01nbxWdpBbW67YYUWNF9FAwB+QoA8YtvhTdL8NDJeyX+oeLE8Kvo9ra3EsAjtGaDBijKKqn5jt3uzHH8XeqPw28GeJdB8SeHNTGhalZxaZoBsdSS91CK6e8lVcrFa5mcRLvGQMxr7CveqKAPnuw8K+LYvgd4q8MSeFr8atqF5M8CfarTaVlcuGLedgBdoB75YYDDJHtng5bmPwrpUV/ZTWN1DbJDJbzNGzIVG3qjMpBxkYJ4Izg5A2KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4+68A6fca1Letf6mtnPex6jNpiyJ9mluY9u2RgU39URtocKSoJFUv+FW6LKrW97daleaUkdxFbadPKnkWgnBV/LKoHztZlG5m2hjjFd7RQB594o8AXeq+EL7RTrl/qUl7LbA3GpzKGtY45FYtF5Ua/vAASCeScbmxW3d+DbGXU7C8tbm7sVtbP8As9raDyzFPbZB8pw6MccdVKtyea6aigDmfCnhIeG2hSHXNavbO3t/sttZ3csbRQR5BGNqKzEBQAzliBkZ5NdKzBVLMQFAySegFLXFeMi/iLW7Xwhbsy2ssX2zV3QkEWu7Cw5HQysGB/2Ek7kUAV0mvfiBIWs7maw8HBivnwOY7jU8HB2MOY4M/wAQIZ+xC4LdlpOm2WkafDY6XaQWdnCMRwwIEVR7AVZhjSGJIoUWOJFCqijAUDoAOwp1ABRXnf7QN9Jp3wo1iePz9pe2jlWBisjxvcRq6KR0LKSv41U/Z3u4rrwHciyu5LrTYNTuorJ3DjbBvyiAOSwAyR8xJ460Aen1yXjrwFpHi9Ip7lXs9Ytir2eqWvyXFu6nKkN/EAedrZH0PNdbRQBxfh3xc8GqReGvGL21l4k25gZTth1FAceZCT/F/ej+8p9RgntK5L4l+DrXxl4da1kgtnv7ZvtFi9wm5FlHQN/sN91h6HjkAjI8JaTJqmgWmpeHPEWu6THIpWTT7iRLxLeVSVeI+crOCjhlIDgccdqAOl8M+EtJ8N3+sXmlQulxq1x9puWdy2W5IC5+6oLNgD1NWfEfiHTfDtok+qXGxpW2QQIC81w/ZI0HzOx9AP0rJbw5r9wCl34z1BIz1FnZ28TEf7zI+PwwavaH4T0nRrt723gkn1KRdj313K1xcMvpvckhf9kYHtQBneF9K1G/1ZvEvieFYL8o0NhYBg4sIGIJyRwZnwNzDgABRwCW6+iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkPh2DeprevSAGTVNRm8s56QQsYIgPYiMv9ZDXX1ynwmA/4Vf4Tf8Ail0u2mb3Z41Zj+ZNAHV0UUUAcN8cdCn8SfCfxJplpzO9uJkUdWMTrJtHudmPxrz79ljxX4fudH1Tw9o3n28dvL9ut47yVWlaKQAPnHXbIGXPcMh7171XzJHafCOD4q+Kl8RXNuLVCJbUXLGO3EzO/wBpEbJjcQ4UYJODkLwOAD6borhvg/cXN14Zu52mu59Je+mOkSXhYzNZcBCxYbiN2/aW5KbSSa7mgArkfDo/szx34k0sYFvdpDq8I9GfdFMo/wCBQo595TXXVyl8AnxV0Qr1m0W/D++yez2/+jG/OgDq6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkfhYfK8HQaex/eaXPPpzjpjyZWRfzQIw9mFddXGJIfDvxEljl+XTfEgDxP2S+iTayHt+8iRSPeFu5FAHZ1zXxH8W2/gfwZqOv3UP2gWqjy7cPsM0jMFVAcHGSfQ4GTjiulriviV4EHjttCt7zUpLbS7C9F7cW0SMGuiowqiRXUx4y3IyeRjBGaAOXvfia2ufAjXfFNlbtpWpRRzWUkEkuWs7jf5Q3NgdN6v0H0rn/wBmbRdH1vTrnxWumRwhEj0mzgllNx5SRKpeQMwGDI53EADGPc1X+K3gP/hBfhf8SL3SdRnn07VJbS8SznDyyW8wnj3uZndjJuPJ3DPA5POd39ky9m1D4WS3NzzNJqdwzsIxGHJ2nIAwO/agD2iiiigArkrc/bfipeOhyml6THCTj+O4lLFfqFgQn/eFdFq+o2ukaXd6jqMywWdrE000jdFVRkn/AOtWF8PbK7i0efU9WiaHVNYuG1C4hb70IYKscR90jWNT7gnvQB1FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVl+JtEtvEOjT6fdtJGrlXjmiOJIJFIZJEPZlYAg+1alFAHJ+FfEVwbz/hH/E/lweI4ULBlXbFfxD/ltD+GNydUOe20nrKy/EWg6f4hsVttTgLqjiSKVHMcsEg6PG6kMjD1BrAibxb4dPlyxDxTpq/dmjZIL9B6MrbYpf8AeBjP+yTzQB1Oqafaarp9xYalbx3NncIY5YZBlXU9QRUWhaNp2gaZFp2i2UFlYxZKQQrtVckk8e5JNYK/EPw9FgapPdaRJ3TU7OW1x/wJ1Ct9VJHvTm+I/grHyeLNCmb+5Bfxysf+AqSf0oA6umzSJDE8szrHEilmdjgKB1JPYVyZ8bJe/J4b0XWNXkPST7M1rAPcyzBQR/ubz7VAvhfUvEUiTeObqCW1Uhk0WyLfZAQcjznOGnI9CFT/AGCeaAK8Dt8QdUtrpQw8HWUizQ7lK/2nOpyr4P8AywQgEf32AP3VBbvaRVCqFUAKBgAdAKWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArj7fxndXjXLaZ4Q8QX1tDdT2n2iKSyVJHhlaJyoe4VsbkbGVFdhXHeAbqGx8Iand3T7LeDVtYlkfBO1V1C5JOByeB2oAn/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSqsah400DT7Y3F5f+XCLJNQ3eTIf3DMFV8Be5YDHX2plr420W7sby6tW1GYWcqwzwppd0biNmUMuYfL8zBBBDbcY70ARf8JRq/wD0IniT/v8A6d/8lUf8JRq//QieJP8Av/p3/wAlVz2u/EmN9a8P2fh6Vmtr6O5uLid9Hu7pkWGRI2i8qMKyPuZgxf7m0bh8wy3wT8TIb7wvaat4jmZJr2P7THa2ejXm63h2qSW4cyINwHngLGTkDpQB0f8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVReePvD1vP5CXktzLsRs2tpNPGC6741aSNGVWZSCqkgnIwDkVQ8OfErSdV8K6TrFzBqNrNfxK62aafczSligZvLVYt0qLuGZEUr055oAv/wDCUav/ANCJ4k/7/wCnf/JVH/CUav8A9CJ4k/7/AOnf/JVYfjn4paTpHhK/v9CuRf6gunG/tkS0nnjCkHY0xRf3SkqR85XofQ122vazYaDp5vdVnMMAdYxtjaR3djhVVFBZmJPAUE0AYv8AwlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVSS/ELw1HYwXX224cTPLGsEdjcSXAaL/WBoFQyLtyN25RjIz1FPufHvhuCS0X+0WmFzDFco9tbyzosUhxG8jIpEasehcgHB9KAG/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVQa58RND07wwdYtZnvfNtbq5tYEhlDTG3UmRT8hMeCNpLAYJ554oT4i6Cul2t5dtqFuZoPtDxHTLpnhjHWR1EW5I85xIwCnBweDQBP8A8JRq/wD0IniT/v8A6d/8lUf8JRq//QieJP8Av/p3/wAlVa8ZeIf7D8J3Gq2SR3czCOOzTd8k0srrHEMj+Es65I7ZrH8YeN5fCDaHbX1pHqFxcASahNbsYUtYFeOOS42ncdoaVPlznGeeKAL3/CUav/0IniT/AL/6d/8AJVWvD3iRtX1W/wBNudG1LSb2zhhuGjvWgbfHK0qqVMMsg6wuCCQenrUdxrd3ZePLTR7tIDp+o2kktnKikSLNEV8xH5IIKuGUgDG1gc8VDpv/ACVPxD/2BdM/9H39AHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcX4Jsk1LwTq9jMzLHc6prMLFeoDX9yCR+ddpXC+FbuWw+H2vXluoaa31DW5UBGcst9ckfqKAMo/DPUrq0kh1XxFbzn+zIdLhMOnGIIkcqSBmBlbcx24PQc5AHSr3iz4dPr1/qF0mpQILu7tbpra5szPbyCGN08uZBIvmId+7GQMqM5rEg1a58LeCfCVh4aaOfWNUtG1CXfZrcG5OxJJ53ZriBE+aQEsznrgCuF8Qajqfi6x13xUx0qCW38FwX0KS2TTSWrSpc7zBJ5g8tyU+/tJwEGPlJIB6l4M+Go8NXNhMNShlFrFqEXlQWQgj/0qeOX5VDEIqeXtCjgg9sYrOvPhDDJYeHY0udIurrStKTSWfVdHS9ikRcYkWMuPLcHJzuIwcEHFYtt4h8QeFJZ/D3hvQ9Ga20aGCW6Ntaw2cE3nZbcPMu1MXy4G/bLuYMeOlWfHHivxLfeDvGN7pmpaPplpZvqNhHCVlF8Gt45P3kciyAbzsLBdnyoQ2TjBAOt0XwVqOh3sq6TrdtBpV1LDPeWv9nLud0hSJhEyuFiRliT5djY52kdsKX4Ty3Gj+HLO+1HRtQfw/G9rZC/0Xz4Ht2RF2yxNN80g8tSHVk6fd5NReIPGPjHTNRg0TS7aw1XUotKGqTXKWyRRSKXdVXbLeIUA2Dc4aT7wO0d8zxN4k1fxGtlLJJpVnpdp4o0m0NmFMtxJJ50EhYSiQIBl+AEbKrnPPABs6n8K76XRdT0zStfsdPttW09LG9RNIXb8m/DQokiLGMOQVIbp1B5ruPGGgya9Y2i2t4LK+srqO9tZ2i81FkTIwyZG5SGYEAg85BGK534o6dZarrfgOy1Sztr2zl1lxJBcxLJG+LK5IyrAg8gH8Kzbnx9qyePLWytIobrQJtVOkvMbMQmOUIxZVlNwWkKsvOIAuCRuyOQC1a/DzU7DUW1rTvENvF4kne5N1dS6d5lvIs3lZCw+aCm3yItp3noc7s1Jonw+vvDUkI8MeIFtIGtbe1uxc2IuHl8kt+8jbeoRmDMDlXHIwBipPhdp1lpWt+PLLS7O2srOLWUEcFtEscaZsrYnCqABySfxrkNNXxDf6/qt5px11Baa3ercX0+qFrM2qBx5KW5lb5s7cERrjGd3YgHRaX8PjPrPjy4vkltLXV1lsrGPej+TFLGDPKgH3fMlJbBOflBOM4qvqnwrn1S6sr/Ur3w9fajBYLprNe6ALiExIxZGSN5iUkG5stuKnIyvArl/h8+rxDwj/bd3qAtvEWgSD93r91dyTy+THL57iTabc7Q2PJJwz4z0zZ8KG6uNN+DE0+q61JJqHmSXhbVLk/aSLWSYeYN/zDeqnByMDbjaSKAPSPGvh651HwK2m6WYjqFp9nuLQMojR5beRJEUgcKGMYHAwAfas3Vfh/ZeLL+/1TxI+pI1/Yx2S2UV5Jb/AGaLDF438mTbLlnJOcjgDnvL4BjXTvFHjPRrQBdOtryK5giA4haeIPIi+g35fH+2a7igDhtO0DVz4p8Otqcnn2mgaa0X28hUN9cyBULBAzFQqoSc9S4xkCr+m/8AJU/EP/YF0z/0ff11Vcrpv/JU/EP/AGBdM/8AR9/QB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXKfDZQ3hu9VgCp1nVgQRkEf2hcV1dcq3gLRPOuJIpNbt/PmkuHjttcvoY/Mkcu5CJMFXLMxwABkmgB9h4G0G30S00i8sYNVsLKRns49Rgjn+zAnISPK8BRwOpwAMmtSPw/o0drLbR6RpyW0tutnJEtsgR4F3bYiMYKDc2F6DceOTWR/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0AamqeGtC1a7t7rVdF0y9ubYAQzXNrHI8QByNrMCV554ol8M6DNqsmpy6Jpj6lKhjku2tIzK6ldpUvjJBXjGenFZf/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/QBbk8F+FpLK2s5PDWiNaWzM8EDWERSJickqu3Cknk4qa48LeH7jVItSuNC0qXUYihjuns42lTYQUw5GRtIGOeMDFZ3/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/QBc8VeG08QnTJP7RvtOutNuTdW9xZ+UWDmN4yCJEdSNsjdvSpz4Z0E6udWOiaWdULBzefZI/OLAYB343ZA75rM/4QPSP+fzxJ/wCFHqP/AMfo/wCED0j/AJ/PEn/hR6j/APH6ALnhXw2nh46nJ/aN9qN1qVyLq4uLzygxcRpGABGiKBtjXt61rQWVrBHNHBbQRJM7SSqkYUSM33mYDqT3J61zv/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/QBbsPBfhbT0uUsPDWiWqXURgnWGwiQSxnqj4X5lPoeKWLwb4YhNiYvDmiobB/MtCtjEPs7bt26P5fkO7nIxzzVP8A4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfoA1PDug22hpe+RLPcT3t093c3E5UySSNgc7QBgKqqABwFH1rWrlf+ED0j/n88Sf+FHqP/wAfo/4QPSP+fzxJ/wCFHqP/AMfoA6quV03/AJKn4h/7Aumf+j7+j/hA9I/5/PEn/hR6j/8AH60NA8MaboN3d3Vh9ue5ukjjllvL+e7dkjLlFDTOxABkc4GPvGgDaooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the absence of crossing-over, analysis of the first polar body (PBI) enables one to deduce the genetic status of the oocyte and, hence, whether the zygote could be affected. If PBI is heterozygous, crossing-over has occurred between homologous chromosomes and PBI analysis is noninformative. However, PB2 analysis enables deduction of the maternal contribution to the zygote. Polar body analysis provides no information about paternal genotype and has the theoretical disadvantage of inefficiency in autosomal recessive disorders. If segregation of a mutant paternal autosomal dominant gene is sought, blastomere analysis rather than polar body analysis is necessary.",
"    <div class=\"footnotes\">",
"     A: normal allele; a: mutant allele.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Simpson JL, Elias S. Genetics in Obstetrics and Gynecology, 3rd ed, WB Saunders, Philadelphia 2003. p.416. Copyright &copy; 2003 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27606=[""].join("\n");
var outline_f26_61_27606=null;
var title_f26_61_27607="Basilar artery thrombosis";
var content_f26_61_27607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Basilar artery thrombosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 474px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Postmortem photograph of the ventral surface of the brainstem showing a dilated, thrombosed basilar artery. The thrombus extends into the anterior inferior cerebellar artery on the right. The two vertebral arteries that join to form the basilar are seen at the bottom of the photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27607=[""].join("\n");
var outline_f26_61_27607=null;
var title_f26_61_27608="Naproxen: Pediatric drug information";
var content_f26_61_27608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naproxen: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"    see \"Naproxen: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"    see \"Naproxen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aleve&reg; [OTC];",
"     </li>",
"     <li>",
"      All Day Relief [OTC];",
"     </li>",
"     <li>",
"      Anaprox&reg;;",
"     </li>",
"     <li>",
"      Anaprox&reg; DS;",
"     </li>",
"     <li>",
"      EC-Naprosyn&reg;;",
"     </li>",
"     <li>",
"      Mediproxen [OTC];",
"     </li>",
"     <li>",
"      Midol&reg; Extended Relief [OTC];",
"     </li>",
"     <li>",
"      Naprelan&reg;;",
"     </li>",
"     <li>",
"      Naprosyn&reg;;",
"     </li>",
"     <li>",
"      Pamprin&reg; Maximum Strength All Day Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anaprox&reg;;",
"     </li>",
"     <li>",
"      Anaprox&reg; DS;",
"     </li>",
"     <li>",
"      Apo-Napro-Na DS&reg;;",
"     </li>",
"     <li>",
"      Apo-Napro-Na&reg;;",
"     </li>",
"     <li>",
"      Apo-Naproxen EC&reg;;",
"     </li>",
"     <li>",
"      Apo-Naproxen SR&reg;;",
"     </li>",
"     <li>",
"      Apo-Naproxen&reg;;",
"     </li>",
"     <li>",
"      Mylan-Naproxen EC;",
"     </li>",
"     <li>",
"      Naprelan&trade;;",
"     </li>",
"     <li>",
"      Naprosyn&reg;;",
"     </li>",
"     <li>",
"      Naprosyn&reg; E;",
"     </li>",
"     <li>",
"      Naprosyn&reg; SR;",
"     </li>",
"     <li>",
"      Naproxen Sodium DS;",
"     </li>",
"     <li>",
"      Naproxen-NA;",
"     </li>",
"     <li>",
"      Naproxen-NA DF;",
"     </li>",
"     <li>",
"      PMS-Naproxen;",
"     </li>",
"     <li>",
"      PMS-Naproxen EC;",
"     </li>",
"     <li>",
"      PRO-Naproxen EC;",
"     </li>",
"     <li>",
"      Riva-Naproxen;",
"     </li>",
"     <li>",
"      Riva-Naproxen Sodium;",
"     </li>",
"     <li>",
"      Riva-Naproxen Sodium DS;",
"     </li>",
"     <li>",
"      Teva-Naproxen;",
"     </li>",
"     <li>",
"      Teva-Naproxen EC;",
"     </li>",
"     <li>",
"      Teva-Naproxen Sodium;",
"     </li>",
"     <li>",
"      Teva-Naproxen Sodium DS;",
"     </li>",
"     <li>",
"      Teva-Naproxen SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipyretic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"      see \"Naproxen: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed as naproxen base; 200 mg naproxen base is equivalent to 220 mg naproxen sodium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analgesia: 5-7 mg/kg/dose every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inflammatory disease, including JIA: Usual: 10-15 mg/kg/day in 2 divided doses; range: 7-20 mg/kg/day; maximum dose: 1000 mg/day. Manufacturer's recommendation for JIA: 10 mg/kg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 and Adults &le;65 years: OTC labeling for pain and fever: 200 mg every 8-12 hours; if needed may take 400 mg for the initial dose; maximum dose: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis: 500-1000 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute gout: Initial: 750 mg, followed by 250 mg every 8 hours until attack subsides.",
"     <b>",
"      Note:",
"     </b>",
"     Delayed release tablet is not recommended due to delayed absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild to moderate pain, dysmenorrhea, acute tendonitis, or bursitis: Initial: 500 mg, then 500 mg every 12 hours or 250 mg every 6-8 hours as needed; maximum dose: 1250 mg/day initially, then 1000 mg/day thereafter.",
"     <b>",
"      Note:",
"     </b>",
"     Delayed release tablet is not recommended for treatment of acute pain, due to delayed absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Moderate to severe and severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Not recommended for use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as sodium: 220 mg [equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aleve&reg;: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     All Day Relief: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Midol&reg; Extended Relief: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pamprin&reg; Maximum Strength All Day Relief: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid gel, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aleve&reg;: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package, oral, as sodium [strength expressed as base, dose-pack/each package contains]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprelan&reg;: Day 1-3: Tablet, controlled release: 750 mg (6s) [contains sodium 75 mg] and Day 4-10: Tablet, controlled release: 500 mg (14s) [contains sodium 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aleve&reg;: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 125 mg/5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprosyn&reg;: 125 mg/5 mL (473 mL) [contains sodium 39 mg (1.5 mEq)/5 mL; orange-pineapple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 375 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprosyn&reg;: 250 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprosyn&reg;: 375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprosyn&reg;: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 220 mg [equivalent to naproxen base 200 mg], 275 mg [equivalent to naproxen base 250 mg], 550 mg [equivalent to naproxen base 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aleve&reg;: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anaprox&reg;: 275 mg [contains sodium 25 mg; equivalent to naproxen base 250 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anaprox&reg; DS: 550 mg [scored; contains sodium 50 mg; equivalent to naproxen base 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mediproxen: 220 mg [contains sodium 20 mg; equivalent to naproxen base 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral, as sodium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprelan&reg;: 375 mg [contains sodium 37.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprelan&reg;: 500 mg [contains sodium 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naprelan&reg;: 750 mg [contains sodium 75 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral: 375 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EC-Naprosyn&reg;: 375 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Caplet, suspension, tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088657.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088657.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food, milk, or antacids to decrease GI adverse effects. Shake suspension well before use. Do not chew, crush, or break delayed or controlled release tablet, swallow whole. Separate administration of naproxen and antacids, sucralfate, or cholestyramine by 2 hours.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets and suspension at room temperature [15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)]; avoid exposure of suspension to excessive heat &gt;40&deg;C (104&deg;F); dispense naproxen tablets and suspension in light-resistant, well-closed containers",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of inflammatory disease and rheumatoid disorders [including rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis, ankylosing spondylitis]; acute gout; mild to moderate pain; primary dysmenorrhea; fever; tendonitis, bursitis.",
"     <b>",
"      Note:",
"     </b>",
"     Due to delayed absorption, the delayed-release tablets are",
"     <b>",
"      not",
"     </b>",
"     recommended for initial treatment of pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Naproxen may be confused with Natacyn&reg;, Nebcin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Anaprox&reg; may be confused with Anaspaz&reg;, Avapro&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Naprelan&reg; may be confused with Naprosyn&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Naprosyn&reg; may be confused with Natacyn&reg;, Nebcin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flogen [Mexico] may be confused with Flovent brand name for fluticasone [U.S., Canada]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flogen [Mexico] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F199912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, palpitations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache, lightheadedness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Ecchymosis, pruritus, purpura, rash, skin eruption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, indigestion, nausea, stomatitis, ulcers, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Abnormal renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding time increased, ecchymosis, hemolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: LFTs increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing disturbances, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, alopecia, anaphylactic/anaphylactoid reaction, angioneurotic edema, arrhythmia, aseptic meningitis, asthma, blurred vision, cognitive dysfunction, colitis, coma, confusion, CHF, conjunctivitis, cystitis, depression, dream abnormalities, dysuria, eosinophilia, eosinophilic pneumonitis, erythema multiforme, exfoliative dermatitis, glossitis, granulocytopenia, hallucinations, hematemesis, hepatitis, hyper-/hypoglycemia, hyper-/hypotension, infection, interstitial nephritis, melena, jaundice, leukopenia, liver failure, lymphadenopathy, menstrual disorders, malaise, MI, muscle weakness, myalgia, oliguria, pancreatitis, pancytopenia, paresthesia, photosensitivity, pneumonia, polyuria, proteinuria, pyrexia, rectal bleeding, renal failure, renal papillary necrosis, respiratory depression, sepsis, Stevens-Johnson syndrome, tachycardia, seizure, syncope, thrombocytopenia, toxic epidermal necrolysis ulcerative stomatitis, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naproxen or any component; history of asthma, urticaria, or allergic-type reaction to aspirin, or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with decreased hepatic function; closely monitor patients with abnormal LFTs; severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur. Use with caution in patients with asthma. Safety and efficacy have not been established in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     OTC labeling: Prior to self-medication, patients should contact healthcare provider if they have had recurring stomach pain or upset, heartburn, ulcers, bleeding problems, asthma, allergy to aspirin or any other pain reliever or fever reducer, high blood pressure, heart or kidney disease, other serious medical problems, or are currently taking a diuretic, steroid, anticoagulant, aspirin, other NSAID, or any other drug. Recommended dosages and duration should not be exceeded, due to an increased risk of GI bleeding, MI, and stroke. Stop use and consult a healthcare provider if symptoms get worse, newly appear, or continue; if an allergic reaction occurs; if the patient feels faint, vomits blood, or has bloody or black stools; if the patient has difficulty swallowing or heartburn; if fever worsens or lasts &gt;3 days; or if pain worsens or lasts &gt;10 days in adults or &gt;3 days in children. Consuming &ge;3 alcoholic beverages/day or taking this medication longer than recommended may increase the risk of GI bleeding. Not for OTC use in children &lt;12 years of age without consulting with physician.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, heart failure, or fluid retention; be aware of sodium content of sodium naproxen products in patients with sodium restriction. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     NSAIDs may increase the risk of gastrointestinal irritation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, salt depletion, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. Naproxen is not recommended for use in patients with moderate to severe or severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the &ldquo;aspirin triad&rdquo; who receive NSAIDs. Avoid use of NSAIDs in late pregnancy as they may cause premature closure of the ductus arteriosus. NSAIDs can cause serious skin reactions including exfoliative dermatitis, Stevens-Johnson Syndrome, and toxic epidermal necrolysis; these events may occur without warning; discontinue use at risk appearance of rash or other sign of hypersensitivity. Pseudoporphyria (ie, increased skin fragility and blistering with scarring in sun-exposed skin) has been reported in naproxen-treated children with JIA (reported incidence, 12%); discontinue therapy if this occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F199900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4426399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Delayed-release tablets: Food delays the time to peak concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7696306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies naproxen as pregnancy category C. Naproxen crosses the placenta and can be detected in fetal tissue and the serum of newborn infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including naproxen. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at (877) 311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelets, BUN, serum creatinine, liver enzymes, occult blood loss, periodic ophthalmologic exams, hemoglobin, hematocrit, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Almost 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; &sim;1% distributed into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 0.16 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively metabolized in the liver to 6-0-desmethyl naproxen; parent drug and desmethyl metabolite undergo further metabolism to their respective acylglucuronide conjugated metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: Children: Range: 8-17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 8-14 years: 8-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 12-17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets, naproxen: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets, naproxen sodium: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets, delayed-release (empty stomach): 4-6 hours; range 2-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets, delayed-release (with food): 12 hours; range: 4-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 95% excreted in urine (&lt;1% as unchanged drug; &lt;1% as 6-0-desmethyl naproxen; 66% to 92% as their conjugates); &le;3% excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"      see \"Naproxen: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Naproxen is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency; do not take longer than 3 days for fever (adults and children), 10 days for pain (adults), or 3 days for pain (children) without consulting healthcare professional. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of naproxen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Naproxen may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Children with JIA: Protect skin from sun; use sunscreen, wide-brimmed hats, etc.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician if changes in vision occur, if pain worsens or lasts &gt;10 days in adults or &gt;3 days in children, if fever worsens or lasts &gt;3 days, if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; or palpitations. Report weight gain or edema to physician.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     OTC (pediatrics): Do not administer to children for &gt;3 days unless recommended by physician or other healthcare professional; notify physician if child's condition does not improve or if worsens within 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a multicenter, retrospective chart review, 19 children, 4-14 years of age (mean: 9.1 &plusmn; 2.9) with rheumatic fever (but without carditis, chorea, or rashes), were treated solely with naproxen (10-20 mg/kg/day divided in 2 doses) until ESR normalized (between 4-8 weeks); fever and arthritis resolved within a median of 1 day of starting therapy; no patient had side effects, or developed carditis over the following 6 months; comparative studies with aspirin that include patients with mild carditis are needed to confirm these findings (Uziel, 2000)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to its effects on platelet function, naproxen should be withheld for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/61/27608/abstract-text/2216644 /pubmed\" id=\"2216644 \" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang BA and Finlayson LA, &ldquo;Naproxen-Induced Pseudoporphyria in Patients With Juvenile Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 124(4):639-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/61/27608/abstract-text/8151484/pubmed\" id=\"8151484\" target=\"_blank\">",
"        8151484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uziel Y, Hashkes PJ, Kassem E, et al, &ldquo;The Use of Naproxen in the Treatment of Children With Rheumatic Fever,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2000, 137(2):269-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/61/27608/abstract-text/10931426 /pubmed\" id=\"10931426 \" target=\"_blank\">",
"        10931426",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells TG, Mortensen ME, Dietrich A, et al, &ldquo;Comparison of the Pharmacokinetics of Naproxen Tablets and Suspension in Children,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1994, 34(1):30-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/61/27608/abstract-text/8132849/pubmed\" id=\"8132849\" target=\"_blank\">",
"        8132849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12630 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-201.211.0.116-1DF3930827-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27608=[""].join("\n");
var outline_f26_61_27608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709165\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199854\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199855\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054290\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054283\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199830\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199815\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874744\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054294\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054286\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054293\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199915\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199912\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054297\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054282\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054281\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199900\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199824\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426399\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199826\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7696306\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054289\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054280\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054296\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054288\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054298\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12630\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12630|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=related_link\">",
"      Naproxen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=related_link\">",
"      Naproxen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_61_27609="Treatment of resistant depression in adults";
var content_f26_61_27609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of resistant depression in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/61/27609/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/61/27609/contributors\">",
"     Wayne Katon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/61/27609/contributors\">",
"     Paul Ciechanowski, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/61/27609/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/61/27609/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/61/27609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/61/27609/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/61/27609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only 40 percent of patients in primary care respond to the first choice of antidepressant medication [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Approximately 20 percent stop the medication due to side effects, and 30 percent have no response.",
"   </p>",
"   <p>",
"    Augmentation of treatment regimens and other treatment strategies are discussed here. Initial treatment for depression, specific medications used to treat depression, changing antidepressant medications, the indications for treating unipolar major depression with ECT and its efficacy, and the prognosis of depression are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"       \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"       \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"       \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=see_link\">",
"       \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=see_link\">",
"       \"Unipolar depression in adults: Prognosis and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF TREATMENT RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial severity of depression and chronicity of a depressive episode are associated with a higher risk of treatment resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with higher initial severity and chronicity are also more likely to meet criteria for psychiatric comorbidities such as panic disorder, posttraumatic stress disorder, and dysthymia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who appear to be treatment resistant, adherence to antidepressant medication should be carefully evaluated with nonjudgmental questions such as: \"Many of my patients forget to take their medication on a regular basis. How often does that happen to you?\" Patients with comorbid anxiety disorders such as panic disorder or post-traumatic stress disorder (PTSD) may be especially prone to side effects of medications, leading to nonadherence.",
"   </p>",
"   <p>",
"    Other important factors that can limit antidepressant response are chronic social stressors such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marital discord, which may need to be addressed with psychotherapy.",
"     </li>",
"     <li>",
"      Patients with severe childhood adversity such as experiences of abuse or neglect, which may need to be addressed with adjunctive psychotherapy to help improve adherence to medication, cope with chronic emotional pain, and improve interpersonal functioning.",
"     </li>",
"     <li>",
"      Alcohol",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      substance abuse, which may impede recovery with medication and necessitate referral for substance abuse treatment.",
"     </li>",
"     <li>",
"      Chronic physical pain, which can impede depression recovery due to effects on sleep, physical activity, social interactions and physiologic stress [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the more common causes of patients failing to respond to usual treatments for major depression is undiagnosed bipolar disorder. This includes bipolar I disorder, in which the patient has episodes of major depression and mania, and bipolar II disorder, in which the patient has episodes of major depression and hypomania. Compared with mania, hypomania is shorter in duration and the symptoms are less intense, and thus making it more difficult to diagnose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with bipolar II may have been previously diagnosed with attention deficit hyperactivity disorder and may complain of distractibility, insomnia, flight of ideas, irritability, social anxiety, or bursts of goal-directed activity or speech. In addition, the prevalence of substance abuse is high in patients with bipolar II disorder. Careful questioning for hypomanic symptoms is essential; input from family and friends can be important in developing an accurate history of symptoms. Features that are particularly helpful in suggesting bipolar rather than unipolar depression include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A family history of bipolar disorder",
"     </li>",
"     <li>",
"      More than one family member with suicidality or substance abuse",
"     </li>",
"     <li>",
"      Sudden onset of depression",
"     </li>",
"     <li>",
"      Onset at an earlier age (ie, adolescence rather than the third decade of life that is the modal decade for the onset of unipolar depression),",
"     </li>",
"     <li>",
"      Rapid resolution of depressive symptoms after a few days of an antidepressant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients may have subthreshold bipolar disorder, defined as episodes of major depression and mood elevated symptoms that do not rise to the threshold of hypomania. A 10-year prospective family study of a community sample found that among 488 people identified with major depression, 59 percent had pure unipolar major depressive disorder and 41 percent had subthreshold bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared to individuals with pure major depressive disorder, those with subthreshold bipolar depression had a significantly increased family history of mania, and higher rates of nicotine and alcohol use disorders, panic disorder, and legal difficulties. Interrater reliability (agreement) between clinicians in diagnosing subthreshold bipolar disorder may be relatively low because of overlap with other psychiatric disorders. There is little evidence to indicate how clinicians should treat patients with subthreshold bipolar disorder. In this context, we suggest the use of adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Lithium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with bipolar disorder often experience substantial side effects with typical antidepressant medication regimens, and have more rapid cycles of mood swings with SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/7\">",
"     7",
"    </a>",
"    ]. Therapy for bipolar II should include mood stabilizers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PSYCHOTHERAPEUTIC STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis has shown that evidence-based psychotherapies and antidepressant medications are equally effective for patients with mild to moderate major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes for patients with severe recurrent and treatment resistant depression, however, are significantly improved with treatment combining pharmacotherapy and psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/9\">",
"     9",
"    </a>",
"    ]. An increment in treatment efficacy with combination treatment was demonstrated in a trial that randomly assigned 681 patients with chronic major depression for two or more years to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    (maximal dose 600 mg per day), cognitive behavioral analysis therapy (CBAS), or a combination of both [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/10\">",
"     10",
"    </a>",
"    ]. The overall rate of response was 48 percent for patients who received at least one treatment session with CBAS alone, or who received nefazodone alone, compared to 73 percent in the combined treatment group. Differences were more striking for patients who completed the 12 week study: response rates for nefazodone, psychotherapy, and combined treatment were 55, 52, and 85 percent, respectively, and withdrawal rates were the same for all three groups. Because of its potential adverse effect on the liver, however, nefazodone has been withdrawn from most world markets.",
"   </p>",
"   <p>",
"    In another study, cognitive behavioral therapy (CBT) was not as effective as pharmacotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ), particularly for depression with greater chronicity, in a group of men sequentially assigned to either treatment strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from the STAR*D trial arms (see below) indicate that, for patients who did not respond to an initial trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    pharmacotherapy, outcome was the same for patients who elected CBT as either a switch or augmentation strategy, compared to patients who switched or augmented with medication [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/12\">",
"     12",
"    </a>",
"    ]. Response was more rapid for patients choosing augmentation with a second medication than with CBT; patients who elected to switch medications experienced more side effects than those who switched to CBT. However, fewer patients than expected chose to participate in the CBT arms of the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials suggest that for euthymic patients with a history of at least three unipolar major depressive episodes, mindfulness-based cognitive therapy may possibly delay or prevent recurrence of major depression as effectively as medication [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Trials that evaluated the therapy in patients with only two prior episodes found that it was not beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8584?source=see_link\">",
"     \"Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of pharmacologic strategies, with varying levels of supportive evidence, have been used in patients with treatment resistant depression (",
"    <a class=\"graphic graphic_table graphicRef51851 \" href=\"UTD.htm?19/12/19660\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The STAR*D trial, conducted in 18 primary care and 23 outpatient psychiatry practices, is a large study of sequential treatment strategies in a highly representative sample of outpatients with nonpsychotic major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The randomized trial was designed to compare long term outcomes of various treatments, and to determine patient characteristics that might predict better response to one treatment over another.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients were initially treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      as monotherapy. Patients who failed to remit were encouraged to move through a cascade of subsequent treatments, identified as levels.",
"     </li>",
"     <li>",
"      Patients in Level 2 were offered the option of switching treatment (to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      SR,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      , or to cognitive behavioral therapy) or of augmenting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      with bupropion,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      , or CBT.",
"     </li>",
"     <li>",
"      Patients who didn't remit were then offered Level 3 treatment: switch to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      , or augmentation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , triiodothyronine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Level 4 treatment was a switch to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"       tranylcypromine",
"      </a>",
"      or combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been suggested that primary care physicians might best refer patients to psychopharmacology specialists for patients requiring treatment beyond Level 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from the STAR-D trial are still being published, but several interim findings are discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Overall findings include the recognition that patients at any level who experienced clinical remission had a better long-term prognosis than patients with partial response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/18\">",
"     18",
"    </a>",
"    ], but that there was reluctance on the part of clinicians and patients to push treatment towards full remission [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/17\">",
"     17",
"    </a>",
"    ]. Longer drug exposure times than had been initially thought were required to achieve remission; a modest improvement at six weeks may require a dose increase or further time (up to twelve weeks) at the same dose, for a full response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Switching medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail a trial of one antidepressant can often respond to a second, whether of the same class or different class.",
"   </p>",
"   <p>",
"    The STAR*D trial randomly assigned 727 patients who either did not achieve remission or could not tolerate a 14 week trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    to substitute one of three antidepressants: sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/19\">",
"     19",
"    </a>",
"    ]. After treatment with one of these medications for up to 14 weeks, remission was achieved in 25 percent of patients, and response in another 25 percent; there was no difference in tolerance or response rates between the three medication groups. Thus, patients who did not initially tolerate one SSRI (citalopram) were able to tolerate and respond to a second SSRI (eg, sertraline) to the same extent as other antidepressants were tolerated.",
"   </p>",
"   <p>",
"    A meta-analysis of four randomized trials that included the STAR*D trial above (n=1496), however, found that remission rates were higher when patients who had not responded to an initial SSRI were switched to a non-SSRI compared to a switch to another SSRI (RR 1.29) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/21\">",
"     21",
"    </a>",
"    ]. The difference in remission rates was only modest, however; the number needed to be treated with a non-SSRI, rather than a second SSRI, is 21 to obtain one additional remission.",
"   </p>",
"   <p>",
"    After two negative SSRI trials it is preferable to choose an agent that works by modulating different neurotransmitters (",
"    <a class=\"graphic graphic_table graphicRef53818 \" href=\"UTD.htm?24/43/25278\">",
"     table 2",
"    </a>",
"    ). Some evidence suggests that agents with dual action on both serotonin and norepinephrine may be more effective in patients with more severe depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These dual agent medications include first generation tricyclic antidepressants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients needing a switch to a third medication at Level 3 in the STAR*D trial, based on nonresponse, had a lower remission rate to treatment, and there was no difference between response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other options for antidepressants include agents that have primary action on non-serotonergic neurotransmission, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    which raises levels of dopamine and noradrenaline through reuptake inhibition of these neurotransmitters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Care should be taken when switching from one antidepressant to another, as many of these drugs have overlapping side effect profiles",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug interactions. In addition, the underlying depression should not be left untreated during the switch, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Augmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychopharmacologists frequently use augmentation strategies in which one medication with a different mechanism of action is added to the first in treatment resistant patients. Augmentation options include the addition of another antidepressant,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , an atypical antipsychotic, thyroid hormone, or a stimulant drug (",
"    <a class=\"graphic graphic_table graphicRef51851 \" href=\"UTD.htm?19/12/19660\">",
"     table 1",
"    </a>",
"    ). In a study of VA patients (n = 250,000) treated for depression in 2002, 22 percent were treated with an augmentation medication for at least 60 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/25\">",
"     25",
"    </a>",
"    ]. The most commonly selected augmentation drugs were a second antidepressant (11 percent), an atypical antipsychotic (7 percent), and lithium (0.5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Another antidepressant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adding a second antidepressant, from a different class than the original medication, has been shown to be effective. A second step of the STAR*D trial randomly assigned 565 outpatients who did not achieve remission despite a mean of 12 weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    therapy to receive augmentation with either sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    (up to 400 mg per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    (up to 60 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/20\">",
"     20",
"    </a>",
"    ]. Remission was achieved in approximately 30 percent of patients in both groups; patients who received bupropion had a lower dropout rate due to intolerance, and achieved lower scores on a depression symptom rating scale.",
"   </p>",
"   <p>",
"    Tricyclic antidepressants, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    (which primarily increases noradrenaline) may also be added to an SSRI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. If a tricyclic antidepressant is added to an SSRI, it is important to carefully monitor side effects and tricyclic serum levels because the SSRI can increase these levels.",
"   </p>",
"   <p>",
"    S-adenosyl methionine (SAMe) is a naturally occurring molecule that appears to be an effective and well-tolerated treatment for depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/28\">",
"     28",
"    </a>",
"    ]. It is available in the United States as an oral dietary supplement. In a six-week randomized trial, 73 patients with unipolar major depression who failed adequate treatment with an SSRI received adjunctive SAMe (800 mg twice per day) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/29\">",
"     29",
"    </a>",
"    ]. Remission occurred in significantly more patients who received SAMe compared with placebo (36 versus 12 percent). In addition, discontinuation of treatment because of adverse side effects occurred in fewer patients who received SSRI plus SAMe (5 versus 9 percent). It is not known whether adjunctive SAMe is efficacious for treatment periods lasting longer than six weeks. Clinicians may consider SAMe augmentation for patients with treatment resistant depression who do not respond to augmentation with either lithium or a second-generation antipsychotic, based upon the more extensive evidence supporting the use of lithium or a second-generation antipsychotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Second-generation antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-generation antipsychotics are efficacious as augmentation for acute unipolar major depression that does not respond to initial treatment with an antidepressant.",
"   </p>",
"   <p>",
"    A meta-analysis of 16 randomized trials examined the efficacy of adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    in 3480 patients with nonpsychotic, unipolar major depression who failed at least one course of monotherapy with various antidepressants (usually a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/30\">",
"     30",
"    </a>",
"    ]. Remission occurred in significantly more patients who received an adjunctive antipsychotic compared with adjunctive placebo (31 versus 17 percent). Discontinuation because of adverse side effects was significantly higher in patients who received an adjunctive antipsychotic compared with adjunctive placebo (9 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/30\">",
"     30",
"    </a>",
"    ]. Use of second-generation antipsychotics as add-on therapy to treat unipolar, nonpsychotic major depression that is unresponsive to an antidepressant is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with second-generation antipsychotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    for augmentation of antidepressants has been studied more often than other augmentation strategies, and lithium is the only medication which has been shown to decrease the rate of suicide in major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/31\">",
"     31",
"    </a>",
"    ]. A meta-analysis examined 10 controlled trials of augmentation of antidepressants (primarily tricyclics) in 269 depressed patients (194 unipolar, 14 bipolar, and 61 polarity not reported) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/32\">",
"     32",
"    </a>",
"    ]. Significantly more patients responded to adjunctive lithium compared with placebo (41 versus 14 percent). However, the use of lithium for augmentation may be declining due to the need for serum levels, side effects on initiation (GI, tremor, polyuria), and availability of other drug options [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/25\">",
"     25",
"    </a>",
"    ]. The dose, duration, side effects, efficacy, and reduced risk of suicide associated with lithium are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=see_link&amp;anchor=H11208494#H11208494\">",
"     \"Unipolar depression in adults: Treatment with lithium\", section on 'Adjunctive treatment with lithium for acute depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=see_link&amp;anchor=H11208578#H11208578\">",
"     \"Unipolar depression in adults: Treatment with lithium\", section on 'Reduced risk of suicide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Triiodothyronine (T3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Augmentation with triiodothyronine (T3) may be effective and well tolerated in patients with major depression. In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study, an open-label, randomized trial compared adjunctive T3 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    in 73 patients and found that a comparable number remitted with either T3 or lithium (25 versus 16 percent), and that T3 was better tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/33\">",
"     33",
"    </a>",
"    ]. However, the lithium doses used in the comparison trial may have been lower than generally used, and serum lithium levels were not regularly confirmed for therapeutic levels. The use of T3 as add-on therapy to treat unipolar major depression, as well as the efficacy of adjunctive T3 compared with adjunctive lithium, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27175?source=see_link\">",
"     \"Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=see_link&amp;anchor=H2757334#H2757334\">",
"     \"Unipolar depression in adults: Treatment with lithium\", section on 'Triiodothyronine (T3)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Psychostimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials involving 411 patients with treatment resistant depression (and fatigue in most cases) compared augmentation of antidepressant treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. There was no significant difference in reducing depressive symptoms, indicating that modafinil augmentation is not efficacious in treatment resistant-depression.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    as adjunctive treatment was also not effective in reducing depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92878399\">",
"    <span class=\"h2\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delay in therapeutic effect of many available antidepressants may be due to their targeted action on the monoaminergic system, which is thought to be upstream from the ultimate central nervous system site responsible for response to pharmacotherapy. A potential, more immediate target is the glutamatergic system, particularly the N-methyl-D-aspartate (NMDA) receptor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is an NMDA receptor antagonist that is used as an anesthetic and may possibly be effective for unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/37\">",
"     37",
"    </a>",
"    ] (as well as bipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/38\">",
"     38",
"    </a>",
"    ]). Evidence for the efficacy of ketamine includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A crossover trial compared a single intravenous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      with a single infusion of saline, administered one week apart, in 18 patients with treatment resistant unipolar major depression; patients were randomly assigned to the order in which they received the two infusions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/39\">",
"       39",
"      </a>",
"      ]. Improvement of depression symptom rating scale scores was significantly greater with ketamine. In addition, response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in 71 percent of patients who received ketamine within one day of the infusion, and persisted for one week in 35 percent. Transient side effects that were more common with ketamine than saline included confusion, elevated blood pressure, euphoria, dizziness, and increased libido.",
"     </li>",
"     <li>",
"      An open label study that administered a single intravenous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      to 42 patients with treatment resistant unipolar major depression found that response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred within four hours in 62 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other open label studies of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    in treatment resistant depression have also found clinically moderate to large benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, the long-term beneficial and adverse effects of ketamine are not known, due to lack of follow-up in these studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Electroconvulsive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroconvulsive therapy (ECT) is more efficacious than any other treatment used for severe major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. An overview of ECT, the indications for treating unipolar major depression with ECT, its efficacy, and the technique for administering it are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=see_link\">",
"     \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Repetitive transcranial magnetic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive transcranial magnetic stimulation (rTMS) uses an electric coil to generate magnetic fields that stimulate the cerebral cortex. It is very well tolerated by patients and, in contrast to ECT, does not require the use of anesthesia and does not appear to cause cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized, controlled studies of rTMS compared to placebo sham procedures have produced conflicting results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review concluded that there is no strong evidence of benefit with rTMS in depressed patients, although the small sample sizes in most of the studies do not exclude the possibility of benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent randomized trial of rTMS in 60 patients with treatment resistant depression did show a significantly higher rate of response in two active treatment groups (high-frequency left-sided rTMS and low frequency stimulation to the right prefrontal cortex) compared with placebo; the absolute benefit, however, appeared to be relatively small [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment response (at least 50 percent improvement in Hamilton Rating Depression Scale [HAMD] score) was demonstrated in 31 percent of the active treatment group, compared with 6 percent of the sham treatment group, in another randomized trial of rTMS for treatment of resistant depression [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large multicenter international trial compared rTMS (20 to 30 sessions over 4 to 6 weeks) with sham procedure in 301 patients with treatment-resistant depression, who were off medication [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/51\">",
"       51",
"      </a>",
"      ]. The primary outcome (50 percent improvement in score on the Montgomery-Asberg Depression Rating Scale [MADRS] score at 4 weeks) occurred in 18 percent of patients who received rTMS compared to 11 percent of controls. Secondary outcomes (HAMD scores at 4 and 6 weeks; MADRS score at 6 weeks, and remission rates at six weeks) were also significantly higher for the treatment group, compared to control.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    rTMS has also been compared with ECT. In a randomized trial comparing a 15-day course of rTMS or a standard course of ECT, remission was achieved in 59 percent of the ECT group compared to 17 percent of patients receiving rTMS at the end of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/52\">",
"     52",
"    </a>",
"    ]. HAM-D scores did not differ at six months, although other mood scores were lower for the ECT group; cognitive measures were the same for both groups.",
"   </p>",
"   <p>",
"    In 2008, the US Food and Drug Administration cleared one device (NeuroStar TMS) for use in patients who have not benefited from prior antidepressant treatment. A treatment course usually consists of 6 weeks of 40 minute sessions (five days a week), and rTMS has caused seizures with some devices [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Deep brain stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency electrical deep brain stimulation (DBS) has been used for treatment of patients with Parkinson disease. The procedure involves stereotaxic placement of electrodes that are connected to a permanently implanted neurostimulator. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgical treatment of Parkinson disease\", section on 'Deep brain stimulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link&amp;anchor=H20#H20\">",
"     \"Surgical treatment of Parkinson disease\", section on 'Thalamotomy and pallidotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is preliminary evidence that some patients with treatment-resistant depression may benefit from DBS. The optimal site of electrode placement for treatment of major depression is unclear, with studies targeting either the ventral",
"    <span class=\"nowrap\">",
"     capsule/ventral",
"    </span>",
"    striatum",
"    <span class=\"nowrap\">",
"     (VC/VS)",
"    </span>",
"    or the subcallosal white matter. A case series of 20 patients with major depression unresponsive to more than 4 antidepressants and ECT (17 of the 20 patients) who underwent DBS with subcallosal electrode placement found response and remission rates to be 60 and 35 percent respectively at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/54\">",
"     54",
"    </a>",
"    ]. Adverse effects included infection (5), generalized seizure (1), and headache or pain at the implant site (4). Response and remission rates of 40 and 20 percent respectively at six months with",
"    <span class=\"nowrap\">",
"     VC/VS",
"    </span>",
"    electrode placement were reported in another group of 15 patients with refractory depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/55\">",
"     55",
"    </a>",
"    ]. Adverse events, affecting 6 patients, included pain at implant site, lead fracture, increased depression or suicidality, and syncope.",
"   </p>",
"   <p>",
"    DBS should be considered only in patients refractory to all other interventions, with fully informed consent, and supported by an interdisciplinary team (including neurosurgery and psychiatry) able to provide close patient monitoring over time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/56\">",
"     56",
"    </a>",
"    ]. Pending further evaluation related to patient selection, procedure specifics, and treatment outcomes, DBS is not recommended for refractory depression outside of the research setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Vagus nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagus nerve stimulation (VNS) has been used for the treatment of epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .) VNS has also been studied for the treatment of refractory depression. A 10-week randomized trial of VNS in 235 treatment-resistant depressed patients found no statistically significant difference in response, defined as a 50 percent reduction in the HAM-D assessment score, comparing treatment with sham stimulation (15 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend VNS for the treatment of depression, based on available data. Although the United States Food and Drug Administration (FDA) approved VNS in 2005 for adjunctive use in patients with depression who failed at least four adequate antidepressant trials, it remains unclear from the literature how effective this treatment modality is [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27609/abstract/60\">",
"     60",
"    </a>",
"    ]. Moreover, other somatic treatments, such as ECT, are likely more effective in this treatment-resistant population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       \"Patient information: Depression (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/18/11554?source=see_link\">",
"       \"Patient information: When you have depression and another health problem (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"       \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/50/37664?source=see_link\">",
"       \"Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are resistant to monotherapy for depression should be evaluated for adherence, social stressors, substance abuse, and bipolar disorder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes of treatment resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A combination of antidepressant medication and psychotherapy (cognitive behavioral analysis) was more effective than either treatment alone for patients with severe recurrent depression. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Psychotherapeutic strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who fail to respond to one SSRI may achieve remission when a second SSRI is substituted. After two negative SSRI trials, agents of a different class should be tried. Dual action medications (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ) may be more effective in patients with severe depression. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Switching medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Augmentation with a second antidepressant (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      added to an SSRI) or augmentation with an atypical antipsychotic medication, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      , are also effective strategies (",
"      <a class=\"graphic graphic_table graphicRef51851 \" href=\"UTD.htm?19/12/19660\">",
"       table 1",
"      </a>",
"      ). Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      is another option, but used less frequently with the availability of other agents. Augmentation regimens are more appropriately managed by a psychopharmacologist. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Augmentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ECT can be offered to patients with major depression who have a high degree of symptom severity and functional impairment, are at high risk for suicide, or when there are concomitant psychotic symptoms or catatonia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Electroconvulsive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repetitive transcranial magnetic stimulation, deep brain stimulation, and vagus nerve stimulation are not recommended for management of resistant major depression at this time. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonpharmacologic treatments'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Depression Guideline Panel. Depression in Primary Care: Treatment of Major Depression: Clinical Practice Guideline. US Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR publication 93-0551, Rockville, MD 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/2\">",
"      Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998; 55:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/3\">",
"      Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med 1998; 7:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/4\">",
"      Katon WJ, Fan MY, Lin EH, Un&uuml;tzer J. Depressive symptom deterioration in a large primary care-based elderly cohort. Am J Geriatr Psychiatry 2006; 14:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/5\">",
"      Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004; 66:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/6\">",
"      Zimmermann P, Br&uuml;ckl T, Nocon A, et al. Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry 2009; 66:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/7\">",
"      Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004; 161:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/8\">",
"      Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/9\">",
"      Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 2013; 381:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/10\">",
"      Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/11\">",
"      Thase ME, Friedman ES, Fasiczka AL, et al. Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. J Clin Psychiatry 2000; 61:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/12\">",
"      Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007; 164:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/13\">",
"      Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry 2007; 164:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/14\">",
"      Chiesa A, Serretti A. Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry Res 2011; 187:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/15\">",
"      Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 2008; 76:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/16\">",
"      Segal ZV, Bieling P, Young T, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry 2010; 67:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/17\">",
"      Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007; 164:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/18\">",
"      Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/19\">",
"      Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/20\">",
"      Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/21\">",
"      Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008; 63:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/22\">",
"      Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/23\">",
"      Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 1999; 175:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/24\">",
"      McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006; 163:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/25\">",
"      Valenstein M, McCarthy JF, Austin KL, et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006; 163:1219.",
"     </a>",
"    </li>",
"    <li>",
"     Nelson, JC, Mazure, C, Bowers, MD, et al. Synergistic effects of fluoxetine and desipramine: a prospective study. Presented at the 21st meeting of the Collegium Internationale Neuro-psychopharmacologicum Congress; July 12-16, 1998; Glasgow, Scotland.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/27\">",
"      Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989; 50:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/28\">",
"      Nelson JC. S-adenosyl methionine (SAMe) augmentation in major depressive disorder. Am J Psychiatry 2010; 167:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/29\">",
"      Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010; 167:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/30\">",
"      Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/31\">",
"      Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/32\">",
"      Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/33\">",
"      Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/34\">",
"      DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/35\">",
"      Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/36\">",
"      Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; :CD006722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/37\">",
"      Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/38\">",
"      Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/39\">",
"      Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/40\">",
"      Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012; 37:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/41\">",
"      Machado-Vieira R, Yuan P, Brutsche N, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 2009; 70:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/42\">",
"      Covvey JR, Crawford AN, Lowe DK. Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother 2012; 46:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/43\">",
"      Fink M, Taylor MA. Electroconvulsive therapy: evidence and challenges. JAMA 2007; 298:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/44\">",
"      Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med 2007; 357:1939.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Committee on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, 2nd ed. Washington, DC, American Psychiatric Association, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/46\">",
"      UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/47\">",
"      Martis B, Alam D, Dowd SM, et al. Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. Clin Neurophysiol 2003; 114:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/48\">",
"      Martin JL, Barbanoj MJ, Schlaepfer TE, et al. Transcranial magnetic stimulation for treating depression. Cochrane Database Syst Rev 2002; :CD003493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/49\">",
"      Fitzgerald PB, Brown TL, Marston NA, et al. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 2003; 60:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/50\">",
"      Avery DH, Holtzheimer PE 3rd, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006; 59:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/51\">",
"      O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007; 62:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/52\">",
"      Eranti S, Mogg A, Pluck G, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatry 2007; 164:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/53\">",
"      Repetitive transcranial magnetic stinulation (TMS) for medication-resistant depression. Med Lettr Drugs Ther 2009; 51:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/54\">",
"      Lozano AM, Mayberg HS, Giacobbe P, et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008; 64:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/55\">",
"      Malone DA Jr, Dougherty DD, Rezai AR, et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 2009; 65:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/56\">",
"      Kringelbach ML, Aziz TZ. Deep brain stimulation: avoiding the errors of psychosurgery. JAMA 2009; 301:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/57\">",
"      Schlaepfer TE, Lieb K. Deep brain stimulation for treatment of refractory depression. Lancet 2005; 366:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/58\">",
"      Vagus nerve stimulation for depression. Med Lett Drugs Ther 2005; 47:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/59\">",
"      Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27609/abstract/60\">",
"      Shuchman M. Approving the vagus-nerve stimulator for depression. N Engl J Med 2007; 356:1604.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1707 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27609=[""].join("\n");
var outline_f26_61_27609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF TREATMENT RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PSYCHOTHERAPEUTIC STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOLOGIC STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Switching medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Augmentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Another antidepressant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lithium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Triiodothyronine (T3)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Psychostimulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92878399\">",
"      Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NONPHARMACOLOGIC TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Repetitive transcranial magnetic stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Deep brain stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vagus nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1707\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1707|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/12/19660\" title=\"table 1\">",
"      Tx of resistant depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/43/25278\" title=\"table 2\">",
"      Pharmacology antidepressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8584?source=related_link\">",
"      Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/50/37664?source=related_link\">",
"      Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/18/11554?source=related_link\">",
"      Patient information: When you have depression and another health problem (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=related_link\">",
"      Surgical treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27175?source=related_link\">",
"      Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=related_link\">",
"      Unipolar depression in adults: Treatment with lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=related_link\">",
"      Unipolar depression in adults: Treatment with second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=related_link\">",
"      Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_61_27610="Clinical presentation and diagnosis of non-Hodgkin lymphoma";
var content_f26_61_27610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/61/27610/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/61/27610/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/61/27610/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/61/27610/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/61/27610/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/61/27610/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/61/27610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/61/27610/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/61/27610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Hodgkin lymphoma (NHL) consists of a diverse group of malignant neoplasms of the lymphoid tissues variously derived from B cell progenitors, T cell progenitors, mature B cells, or mature T cells.",
"   </p>",
"   <p>",
"    This topic will review the initial evaluation of a patient with suspected NHL. The classification, staging and prognosis of NHL, including specific details on the use of imaging modalities and the diagnosis of individual NHL variants, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of NHL varies tremendously depending upon the type of lymphoma and the areas of involvement. Some NHLs behave indolently with lymphadenopathy waxing and waning over years. Others are highly aggressive, resulting in death within weeks if left untreated. In typical cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive lymphomas commonly present acutely or subacutely with a rapidly growing mass, systemic B symptoms (ie, fever, night sweats, weight loss),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated levels of serum lactate dehydrogenase and uric acid. Examples of lymphomas with this aggressive or highly aggressive presentation include diffuse large B cell lymphoma, Burkitt lymphoma, adult T cell leukemia-lymphoma, and precursor B and T lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma.",
"      </span>",
"     </li>",
"     <li>",
"      Indolent lymphomas are often insidious, presenting only with slow growing lymphadenopathy, hepatomegaly, splenomegaly, or cytopenias. Examples of lymphomas with this indolent presentation include follicular lymphoma, chronic lymphocytic",
"      <span class=\"nowrap\">",
"       leukemia/small",
"      </span>",
"      lymphocytic lymphoma, and splenic marginal zone lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The natural history of these tumors shows significant patient-to-patient variability. Less common presentations, most frequently seen with T cell lymphomas, include skin rash, pruritus, generalized fatigue, malaise, fever of unknown origin, ascites, and effusions. Approximately 50 percent of patients will develop extranodal disease (secondary extranodal disease) while between 10 and 35 percent of patients will have primary extranodal lymphoma at initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/1\">",
"     1",
"    </a>",
"    ]. The initial presentation may reflect involvement of extranodal tissues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with primary gastrointestinal (GI) tract lymphoma may present with anorexia, weight loss, nausea and vomiting, chronic pain, abdominal fullness, early satiety, symptoms associated with visceral obstruction, or even acute perforation and GI hemorrhage (",
"      <a class=\"graphic graphic_table graphicRef68593 \" href=\"UTD.htm?30/61/31708\">",
"       table 1",
"      </a>",
"      ). Occasional patients will present with malabsorption syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with primary CNS lymphoma may present with headache, lethargy, focal neurologic symptoms, seizures, paralysis, spinal cord compression (0.1 to 6.5 percent of patients), or lymphomatous meningitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oncologic emergencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially emergent complications of NHL need to be considered during the initial workup and evaluation. Prompt recognition and therapy is critical for these situations, which may be life-threatening or may interfere with and delay treatment of the underlying NHL. These can include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spinal cord compression",
"     </li>",
"     <li>",
"      Pericardial tamponade",
"     </li>",
"     <li>",
"      Hypercalcemia (eg, adult T cell leukemia-lymphoma)",
"     </li>",
"     <li>",
"      Superior or inferior vena cava obstruction",
"     </li>",
"     <li>",
"      Hyperleukocytosis (eg, B or T cell lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma)",
"      </span>",
"     </li>",
"     <li>",
"      Acute airway obstruction (eg, mediastinal lymphoma)",
"     </li>",
"     <li>",
"      Lymphomatous meningitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CNS mass lesions",
"     </li>",
"     <li>",
"      Hyperuricemia and tumor lysis syndrome",
"     </li>",
"     <li>",
"      Hyperviscosity syndrome (eg, lymphoplasmacytic lymphoma with Waldenstrom macroglobulinemia)",
"     </li>",
"     <li>",
"      Intestinal obstruction, intussusception",
"     </li>",
"     <li>",
"      Ureteral obstruction, unilateral or bilateral hydronephrosis",
"     </li>",
"     <li>",
"      Severe hepatic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Venous thromboembolic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/3-7\">",
"       3-7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Severe autoimmune hemolytic anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia (eg, small lymphocytic lymphoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If patients with NHL develop angioedema, they may have an acquired form of C1 inhibitor deficiency that requires emergent treatment with infused C1 inhibitor concentrates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Abnormal laboratory results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common presentations of systemic NHL include abnormal laboratory results such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unexplained anemia, thrombocytopenia, or leukopenia due to extensive bone marrow infiltration or hypersplenism from splenic involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"       \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypercalcemia &mdash; Although 15 percent of patients with NHL develop hypercalcemia at some time during their overall clinical course, hypercalcemia is uncommon at diagnosis, except in HTLV-1 associated adult T cell leukemia-lymphoma and transformed follicular lymphoma. Symptoms include dehydration, lethargy, weakness, nausea, vomiting and constipation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"       \"Hypercalcemia of malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\", section on 'Hypercalcemia and lytic bone lesions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of relapsed or refractory follicular lymphoma\", section on 'Histologic transformation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperuricemia &mdash; Hyperuricemia causing symptoms of gout or nephrolithiasis are unusual at presentation, but more commonly present problems during initial treatment of rapidly proliferating NHLs. Spontaneous tumor lysis is seen with Burkitt lymphoma and uncommonly with some aggressive NHLs. Hyperuricemia and tumor lysis syndrome are more commonly seen in patients presenting with underlying renal failure, due to either independent pre-existing renal disease or coincident obstruction of the ureters secondary to NHL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"       \"Asymptomatic hyperuricemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"       \"Uric acid renal diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated level of serum lactate dehydrogenase (LDH) &mdash; LDH elevation associated with NHL may be due to high tumor burden, extensive infiltration of the liver, coincident hemolytic anemia secondary to immune-mediated red blood cell destruction or association with particular rapidly proliferative NHL such as Burkitt or lymphoblastic lymphoma. An elevated LDH, especially if greater than two to three times normal, is associated with a poorer prognosis.",
"     </li>",
"     <li>",
"      Serum protein electrophoresis &mdash; A monoclonal immunoglobulin (M-spike) may be detected by serum protein electrophoresis (SPEP). Relatively large M-spikes (&gt;0.5",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      are most commonly associated with lymphoplasmacytic lymphoma. Other B cell NHLs, particularly small lymphocytic",
"      <span class=\"nowrap\">",
"       lymphoma/chronic",
"      </span>",
"      lymphocytic leukemia and extranodal marginal zone lymphoma, may be associated with small M-spikes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Paraneoplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic syndromes including neurologic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], hematologic, renal, dermatologic, gastrointestinal, and rheumatologic manifestations are an unusual presentation of NHL. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link\">",
"     \"Cutaneous manifestations of internal malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link\">",
"     \"Malignancy and rheumatic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Insect stings and bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exaggerated (hypersensitivity) reactions to insect stings or bites, especially mosquito bites, may be noted in some patients with NHL, most commonly chronic lymphocytic leukemia and indolent B cell NHLs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Presence of this phenomenon may antedate the diagnosis of NHL",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    may suggest the presence of a previously undiagnosed lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATIENT HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient with suspected NHL starts with a complete history and physical examination. The following historical features are of particular importance:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Past history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of diseases, infectious agents, and drugs or toxins have been associated with the development of NHL (",
"    <a class=\"graphic graphic_table graphicRef77563 \" href=\"UTD.htm?41/44/42700\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/15-27\">",
"     15-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A personal or family history of lymphoma or other prior hematopoietic malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/28-32\">",
"       28-32",
"      </a>",
"      ], use of radiation therapy, immunosuppressive agents, chemotherapy, organ transplantation, and other underlying diseases should be obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exposure to certain agricultural pesticides, hair dyes, and dioxins (eg, Agent Orange) has also been associated with an increased risk of development of NHL [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/15,33-35\">",
"       15,33-35",
"      </a>",
"      ]. In contrast, the consumption of vegetables and fruit rich in antioxidants and regular routine residential ultraviolet exposure have been associated with a reduced likelihood of developing NHL [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/36-38\">",
"       36-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relevant infections include human immunodeficiency virus (HIV), human T lymphotropic virus type I (HTLV-I), Epstein-Barr virus (EBV), hepatitis C, Borrelia burgdorferi (B. afzelii species), Chlamydia psittaci, and hepatitis B virus (HBV) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29529?source=see_link\">",
"       \"Overview of the pathobiology of the non-Hodgkin lymphomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link&amp;anchor=H5#H5\">",
"       \"Extrahepatic manifestations of hepatitis C virus infection\", section on 'Lymphoma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"       \"Clinical manifestations of Lyme disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While epidemiologic studies have noted an increased incidence of NHL among patients who have received blood transfusions, there are insufficient data at this time to determine the cause and magnitude of this association [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Associated disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune diseases (eg, lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, Hashimoto's thyroiditis) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/42-44\">",
"       42-44",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link\">",
"       \"Malignancy and rheumatic disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link&amp;anchor=H31#H31\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\", section on 'Lymphoma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H35#H35\">",
"       \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Is cancer risk increased?'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Immunodeficiency disorders",
"     </li>",
"     <li>",
"      Mixed cryoglobulinemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link&amp;anchor=H46#H46\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\", section on 'Lymphoproliferative disorders'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Multicentric Castleman's disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link&amp;anchor=H16#H16\">",
"       \"Castleman's disease\", section on 'Non-Hodgkin lymphoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inflammatory gastrointestinal diseases (eg, Crohn's disease, gastrointestinal nodular lymphoid hyperplasia, helicobacter pylori-associated chronic gastritis, and celiac disease) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Predisposing conditions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link&amp;anchor=H16#H16\">",
"       \"Management of celiac disease in adults\", section on 'Ulcerative jejunitis and intestinal lymphoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Systemic complaints (B symptoms)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 40 percent of patients with NHL present with systemic complaints of fever, weight loss, or night sweats (ie, B symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/1\">",
"     1",
"    </a>",
"    ]. These complaints are of importance in determining prognosis, and have been formally defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever &mdash; temperature &gt;38&ordm;C (&gt;100.4&ordm;F)",
"     </li>",
"     <li>",
"      Weight loss &mdash; unexplained loss of &gt;10 percent of body weight over the past six months",
"     </li>",
"     <li>",
"      Sweats &mdash; the presence of drenching night sweats",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such systemic \"B\" symptoms are more common in patients with aggressive and highly aggressive histologies (47 percent), especially in those with hepatic and extranodal involvement (",
"    <a class=\"graphic graphic_table graphicRef64113 \" href=\"UTD.htm?34/39/35453\">",
"     table 3",
"    </a>",
"    ). In contrast, less than 25 percent of patients with indolent lymphomas have B symptoms. When present, systemic symptoms in patients with indolent lymphoma are usually associated with extensive advanced stage disease and with bulky masses more than 7.5 to 10 cm in greatest diameter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than two-thirds of patients with NHL present with peripheral lymphadenopathy that is generally painless. If present, the patient should be questioned concerning the duration, observed sites, and extent of lymphadenopathy. In particular, the patient should be asked about prior episodes of lymphadenopathy and waxing and waning of such nodes, which is commonly seen in patients with indolent lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As peripheral lymphocytosis and lymphadenopathy are commonly seen following infection, the initial evaluation of lymphadenopathy should be focused on the exclusion of infectious etiologies, including bacteria (eg, pertussis, tuberculosis), viruses (eg, infectious mononucleosis, cytomegalovirus and human immunodeficiency virus), and parasites (toxoplasmosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3274?source=see_link\">",
"     \"Approach to the patient with lymphocytosis or lymphocytopenia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Lymph node and tissue biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fever of unknown origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever of unknown origin (FUO) refers to a prolonged febrile illness without an established etiology despite intensive evaluation and diagnostic testing. Historically, the most common causes of FUO have been infection, connective tissue diseases, and malignancy. However, the number of FUO attributable to malignancy has declined (",
"    <a class=\"graphic graphic_figure graphicRef73878 \" href=\"UTD.htm?40/21/41310\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15431?source=see_link\">",
"     \"Etiologies of fever of unknown origin in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=see_link\">",
"     \"Approach to the adult with fever of unknown origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NHL, especially one of the aggressive or highly aggressive variants, is a common cause of FUO due to malignancy. In the absence of an obvious site to biopsy (eg, an enlarged peripheral lymph node), bone marrow",
"    <span class=\"nowrap\">",
"     aspiration/biopsy",
"    </span>",
"    may provide critical diagnostic information, as may the use of computed tomography (CT) or positron emission tomography (PET) scanning to detect sites of disease suitable for biopsy.",
"   </p>",
"   <p>",
"    The uncommon yet diagnostically challenging intravascular large B cell lymphoma commonly presents with fever, rash, or prominent and rapidly progressive neurologic signs and, unlike in other advanced lymphomas, does not usually involve the bone marrow, lymph nodes, peripheral blood, or cerebrospinal fluid. Biopsies of the skin, brain, liver, or lung may be required to make a diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=see_link\">",
"     \"Approach to the adult with fever of unknown origin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=see_link\">",
"     \"Intravascular large cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lymphoid survey",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination needs to be directed to all potentially involved lymphoid sites (",
"    <a class=\"graphic graphic_figure graphicRef63663 \" href=\"UTD.htm?21/28/21959\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/1,48\">",
"     1,48",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Waldeyer's ring (tonsils, base of the tongue, nasopharynx)",
"     </li>",
"     <li>",
"      Standard lymph node sites (eg, cervical, supraclavicular, axillary, inguinal, femoral)",
"     </li>",
"     <li>",
"      Liver and spleen",
"     </li>",
"     <li>",
"      Abdominal nodal sites (mesenteric, retroperitoneal)",
"     </li>",
"     <li>",
"      Less commonly involved nodal sites (eg, occipital, preauricular, epitrochlear, popliteal)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Head and neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodal and extranodal involvement of the head and neck, including Waldeyer's ring (tonsils, base of the tongue, nasopharynx) is suggested by enlargement of preauricular nodes and tonsillar asymmetry [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Involvement of the orbital structures (eg, eyelid, extraocular muscles, lacrimal apparatus, conjunctivae) is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/50\">",
"     50",
"    </a>",
"    ], but may be seen as a feature of marginal zone and mantle cell lymphoma. In addition, primary CNS lymphoma commonly involves the eye. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Extranodal (MALT) MZL'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Primary intraocular lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chest and lungs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of patients with NHL present with mediastinal adenopathy on clinical examination or chest radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76393 \" href=\"UTD.htm?2/58/2978\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65069 \" href=\"UTD.htm?42/28/43460\">",
"     image 2",
"    </a>",
"    ). Mediastinal involvement can be seen either as the sole site of disease (eg, primary mediastinal large B cell lymphoma) or as part of systemic disease. Patients with mediastinal involvement can present with persistent cough, chest discomfort, or without clinical symptomatology but with an abnormal chest x-ray. In 3 to 8 percent of patients with NHL, a superior vena cava syndrome is part of the clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other associated findings in the thorax include pleural and, less commonly, pericardial effusions. Chylothorax, alone or in combination with chylopericardium or chylous ascites, can be present if major obstruction (infiltration, compression) to lymphatic drainage has occurred, either in the chest (thoracic duct) or abdomen (cisterna chyli or one of its mesenteric tributaries). Pleural disease is seen in up to 10 percent of all patients with NHL at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5126?source=see_link\">",
"     \"Chylopericardium and cholesterol pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/168?source=see_link\">",
"     \"Chylous, bloody, and pancreatic ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Abdomen and pelvis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of retroperitoneal, mesenteric, and pelvic nodes is common in most histologic subtypes of NHL (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58932 \" href=\"UTD.htm?3/43/3764\">",
"     image 3",
"    </a>",
"    ). Unless massive or leading to obstruction, nodal enlargement in these sites usually does not produce symptoms.",
"   </p>",
"   <p>",
"    While diffuse hepatosplenomegaly (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71379 \" href=\"UTD.htm?38/59/39860\">",
"     image 4",
"    </a>",
"    ) is common in the indolent lymphomas, synthetic liver function is usually intact. In contrast, discrete hepatic masses are more commonly seen in the aggressive or highly aggressive subtypes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59628 \" href=\"UTD.htm?38/32/39427\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all focal liver lesions in a patient with NHL are due to lymphoma. As an example, in one study of 414 consecutive patients with NHL, only 39 percent of the detected focal liver lesions at disease onset were due to NHL; 58 percent were benign [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/54\">",
"     54",
"    </a>",
"    ]. Conversely, 74 percent of the liver lesions detected during follow-up were due to NHL, while 15 percent were due to a malignancy other than NHL (eg, hepatocellular carcinoma, metastatic lesions from a second malignancy).",
"   </p>",
"   <p>",
"    Ascites may be present and can be chylous in the setting of lymphatic obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/168?source=see_link\">",
"     \"Chylous, bloody, and pancreatic ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Extranodal sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of patients will develop extranodal disease (secondary extranodal disease) while between 10 and 35 percent of patients will have primary extranodal lymphoma at initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common site of primary extranodal disease is the GI tract (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72998 \" href=\"UTD.htm?8/6/8290\">",
"     image 6",
"    </a>",
"    ), followed by skin. Other sites involved with aggressive NHLs at presentation include the testis, bone, and kidney. Rare sites include the prostate, bladder, ovary, orbit, heart, breast, salivary glands, thyroid, and adrenal glands [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/50,55-63\">",
"     50,55-63",
"    </a>",
"    ]. Symptoms due to extralymphatic disease are usually associated with aggressive NHL, and are uncommon in the indolent lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=see_link\">",
"     \"Breast lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35974?source=see_link\">",
"     \"Thyroid lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The skin is the second most common extranodal site of disease and should be carefully examined; all suspicious areas should be biopsied.",
"     </li>",
"     <li>",
"      Testicular NHL, presenting as a mass, constitutes 1 percent of all NHLs and 2 percent of all extranodal lymphomas; it is the most common malignancy involving the testis in men over age 60 (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50490 \" href=\"UTD.htm?22/1/22544\">",
"       image 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/64\">",
"       64",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link&amp;anchor=H30#H30\">",
"       \"Anatomy and pathology of testicular tumors\", section on 'Testicular lymphoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NHL of bone is usually the manifestation of disseminated disease, but can present as a solitary lesion, usually with pain, mass, swelling, or pathologic fracture (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66388 \" href=\"UTD.htm?25/1/25631\">",
"       image 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32599?source=see_link\">",
"       \"Primary lymphoma of bone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical evidence of renal involvement occurs in 2 to 14 percent of patients with NHL, usually of the aggressive or highly aggressive subtypes, but rarely presents with symptoms of renal failure at diagnosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81101 \" href=\"UTD.htm?12/59/13233\">",
"       image 9",
"      </a>",
"      ). Ureteral obstruction due to retroperitoneal disease or tubular obstruction due to acute uric acid nephropathy are more likely causes of renal insufficiency at the time of diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4744?source=see_link\">",
"       \"Overview of renal disease associated with malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link&amp;anchor=H2#H2\">",
"       \"Uric acid renal diseases\", section on 'Acute uric acid nephropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NHL can involve the CNS either as the sole area of disease (primary CNS lymphoma) or as secondary spread of systemic disease. Primary CNS lymphoma constitutes only 1 percent of all NHLs. Direct lymphomatous involvement of peripheral nerves (neurolymphomatosis) is a rare event, often occurring in the presence of widespread systemic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=see_link\">",
"       \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thirty-five to 65 percent of poorly-differentiated neoplasms of unknown primary site may represent cases of NHL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=see_link\">",
"       \"Overview of the classification and management of cancers of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LYMPH NODE AND TISSUE BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A biopsy is required for the diagnosis and classification of NHL. This should be obtained urgently if an aggressive NHL is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lymph node selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to biopsy a lymph node is dependent upon the clinical situation, characteristics of the patient (age, gender), as well as the location of the involved node(s). Regardless of whether lymphadenopathy is localized, regional, or more generalized, if other diagnostic tests do not support another diagnosis, a lymph node should be considered for biopsy if one or more of the following lymph node characteristics is present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant enlargement (see below for definition)",
"     </li>",
"     <li>",
"      Persistence for more than four to six weeks",
"     </li>",
"     <li>",
"      Progressive increase in size",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, lymph nodes larger than 2.25 cm2 (ie, a node with biperpendicular diameters of 1.5 x 1.5 cm) or 2 cm in a single diameter have the best diagnostic yields, whereas lymph nodes less than 1 cm are unlikely to provide a specific diagnosis. The diagnostic yield from lymph nodes of an intermediate size is variable.",
"   </p>",
"   <p>",
"    Two series have investigated the impact of lymph node size on diagnostic yield. In patients ranging from 9 to 25 years of age, a maximum lymph node diameter &gt;2 cm was associated with a diagnosis necessitating treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Another series in adults found that a size of 2.25 cm2 (ie, a node with biperpendicular diameters of 1.5 x 1.5 cm) was the lower size limit for differentiating neoplastic or granulomatous (TB, sarcoid) adenopathy from other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enlarged peripheral lymph nodes are generally preferred to other lymph nodes for diagnostic biopsy because they are easily accessed and have a relatively high diagnostic yield. When enlarged peripheral lymph nodes are absent, computed tomography-guided core needle biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/70-72\">",
"     70-72",
"    </a>",
"    ] or laparoscopic biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/73\">",
"     73",
"    </a>",
"    ] can be used to obtain diagnostic material in a majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once a decision to biopsy an enlarged lymph node has been made, the percentage of lymph nodes that result in a diagnosis of malignancy varies according to the anatomic site of lymphadenopathy. In a retrospective study of 925 patients undergoing lymph node biopsy, 12 percent overall had lymphoma; lymphoma was found in 4 percent of abdominal biopsies, 1 percent of intrathoracic biopsies, and 15 percent of peripheral nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific yields of peripheral lymph nodes in patients who are subsequently proven to have NHL are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Supraclavicular nodes &mdash; 75 to 90 percent",
"     </li>",
"     <li>",
"      Cervical and axillary nodes &mdash; 60 to 70 percent",
"     </li>",
"     <li>",
"      Inguinal nodes &mdash; 30 to 40 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Context",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether an enlarged node is an isolated finding or is part of more generalized adenopathy also influences the diagnosis. In a study of 220 patients, a diagnosis of NHL was made in 6.4, 2.2, and 14 percent of those with localized, limited (2 or 3 anatomic areas), or generalized (&gt;3 areas) lymphadenopathy, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/68\">",
"     68",
"    </a>",
"    ]. While models have been developed to identify patients in whom a lymph node biopsy might lead to a diagnosis requiring treatment, these are not practical for regular use in the clinic. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A model used for younger patients (ages 9 to 25) included three variables: abnormal chest radiogram, lymph node size &gt;2 cm, and lack of recent ear, nose, and throat symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]. Using this model in 195 patients, 41.5 percent had a diagnosis requiring therapy. Of these, approximately 4 percent had a diagnosis of NHL and 55 percent had a diagnosis of Hodgkin lymphoma.",
"     </li>",
"     <li>",
"      Another model used a different set of parameters, including: age (&gt;40 or &lt;40); location (supraclavicular or not); size (&lt;1, 1-2.25, 2.25-4, &gt;4 cm2); texture (hard or not); and the presence of tenderness (none, tender, painful). This model permitted approximately 90 percent of patients to be correctly classified as to whether a biopsy was necessary or led to a diagnosis requiring therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Type of biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients presenting with enlarged lymph nodes have a benign form of reactive lymphadenopathy. As a result, many centers use fine needle aspiration (FNA) as an initial screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/78\">",
"     78",
"    </a>",
"    ]. When coupled with comprehensive immunophenotyping (typically flow cytometry), FNA is particularly useful at distinguishing reactive B cell hyperplasias from clonal mature B cell neoplasms. However, the general consensus is that accurate histopathologic evaluation of lymphomas requires a tissue biopsy, preferably an intact lymph node, and that FNAs suggesting the presence of a lymphoma should be followed up with a definitive tissue biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link&amp;anchor=H28#H28\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\", section on 'Lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only an excisional biopsy of an intact node consistently allows sufficient tissue for histologic, immunologic, molecular biologic assessment, and classification by experienced hematopathologists [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/82\">",
"     82",
"    </a>",
"    ], and an accurate diagnosis of lymphoma based on FNA is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/83\">",
"     83",
"    </a>",
"    ], particularly in certain subtypes such as extranodal marginal zone NHLs and T cell NHLs. In patients with disease in deep sites (eg, retroperitoneal nodes), image-guided core biopsies may provide sufficient tissue for diagnosis. The importance of complete evaluation of an adequate tissue sample for accurate diagnosis, which determines prognosis and treatment, cannot be overemphasized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/79,84-86\">",
"     79,84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When combined with comprehensive immunophenotyping, analysis of FNA of lymph nodes can provide accurate diagnosis of clonal lymphoproliferative disorders, but for certain subtypes of NHL the precise histologic diagnosis is difficult to make with an FNA evaluation alone. As an example, in cases of extranodal marginal zone NHLs or T cell NHLs, FNA is limited in accuracy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Studies on excised tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lymphoma is based upon the evaluation of histologic, immunophenotypic, and genetic studies interpreted in the context of the clinical scenario.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic evaluation of the tumor includes both an assessment of the morphology of the individual tumor cells that comprise the lymph node infiltrate and the pattern of lymph node involvement. Patterns of involvement that can best be appreciated through examination of an intact lymph node include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Nodular/follicular",
"      </span>",
"      pattern (",
"      <a class=\"graphic graphic_picture graphicRef69885 \" href=\"UTD.htm?20/20/20805\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diffuse pattern (",
"      <a class=\"graphic graphic_picture graphicRef81795 \" href=\"UTD.htm?42/1/43029\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Change from a nodular to a diffuse pattern in adjacent nodes (",
"      <a class=\"graphic graphic_picture graphicRef79473 \" href=\"UTD.htm?30/34/31268\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Change from a lower to a higher grade of involvement within a single node (",
"      <a class=\"graphic graphic_picture graphicRef53282 \" href=\"UTD.htm?11/54/12135\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunophenotype of lymphoma cells can be determined by flow cytometry conducted on fresh unfixed single cell suspensions or by immunohistochemistry on sections of fixed or fresh frozen tissues. With recent advances in immunohistochemistry, it is now possible to detect almost all diagnostically relevant lymphoid markers in formalin-fixed paraffin-embedded tissue sections, with the important exception that stains for surface immunoglobulin light chains, which are very helpful in determining the clonality of B cell proliferations, remain challenging and are often uninformative. Frozen sections allow for better detection of light chains of certain other antigens, but in general such antigens are best evaluated by flow cytometry. Fresh frozen tissue remains the best source of high quality DNA and RNA for molecular studies, but genetic assays of clonality can now be conducted reliably using DNA retrieved from formalin-fixed paraffin-embedded tissues (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Genetic studies'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Flow cytometry has certain advantages over immunohistochemistry, such as the ability to detect two or more markers simultaneously, rapid turnaround, greater quantitative capacity (eg, the ability to distinguish between high and more modest levels of expression of an antigen), and higher sensitivity for certain markers (eg, surface immunoglobulin light chains), but sometimes misses tumor cell populations due to sampling issues or poor tumor cell representation within cell suspensions (eg, in lymphomas associated with extensive fibrosis). It is a useful diagnostic tool when suspected lymphomas are sampled by fine needle aspirate, with the caveats cited above.",
"   </p>",
"   <p>",
"    Immunophenotyping plays a crucial role in the diagnosis and subclassification of most forms of NHL. In general, the lymphoid neoplasms are divided according to whether they are of B or T cell derivation. The expression of cell surface lymphoid differentiation antigens are used to distinguish between B and T cells at various developmental stages (",
"    <a class=\"graphic graphic_table graphicRef78061 \" href=\"UTD.htm?31/10/31915\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Genetic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fresh and in some cases fixed tissue can be studied for cytogenetic abnormalities, chromosomal translocations, and immunoglobulin or T cell receptor (TCR) gene rearrangements. These and other studies can be important adjunct tests when samples are obtained by FNA, where limited diagnostic material is available for conventional histologic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromosomal abnormalities may be detected using conventional karyotypic analysis, fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR) for abnormal gene products. A choice among these tests is made depending upon the clinical situation and the suspected diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"       \"Cytogenetic and molecular genetic diagnostic tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunoglobulin (Ig) gene rearrangement studies using PCR can determine clonality of B-lymphocytes since every normal B-lymphocyte carries a unique sequence of the immunoglobulin heavy gene [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/88\">",
"       88",
"      </a>",
"      ]. PCR with consensus IgH primers followed by sizing of products by capillary electrophoresis detects clonal rearrangements in about 85 percent of B cell lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/89\">",
"       89",
"      </a>",
"      ]. PCR testing is somewhat less sensitive than Southern blot analysis, but is more rapid, does not require radioactivity, and can be performed reliably on DNA retrieved from formalin-fixed paraffin-embedded tissues; for these reasons, it has largely supplanted Southern blot analysis. At present, Southern blot analysis is still used to determine the clonality of EBV genomes in suspected EBV positive NHL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"       \"Immunoglobulin genetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similarly, T cell receptor (TCR) gene rearrangement studies using PCR can determine if T-lymphocytes are clonal or nonclonal [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/88\">",
"       88",
"      </a>",
"      ]. The TCR is composed of several subunits, including heterodimers composed of the alpha",
"      <span class=\"nowrap\">",
"       (a)/beta",
"      </span>",
"      (b) and gamma",
"      <span class=\"nowrap\">",
"       (g)/delta",
"      </span>",
"      (d) chains in association with the CD3 complex. As with Ig rearrangements, PCR studies have largely replaced older Southern blot analysis. PCR is conducted with consensus primers designed to amplify rearranged TCR gamma genes. When coupled to precisely sizing of products by capillary electrophoresis, this test detects clonal rearrangements in about 90 percent of T cell lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/89\">",
"       89",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"       \"T cell receptor genetics\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bone marrow (BM) aspiration with an adequate-size biopsy should be performed for all patients. This may help to determine the diagnosis, but also helps with staging. BM biopsy and aspirate specimens are typically evaluated for their morphology and immunophenotype. Aspirated cells can be subjected to analysis of cell surface markers by flow cytometry as well as cytogenetic analysis, both of which may provide key diagnostic information. However, some forms of NHL are commonly associated with marrow fibrosis (eg, follicular lymphoma) and, as a result, often inaspirable. For this reason, the diagnostic yield of bone marrow biopsy is higher than bone marrow aspirate.",
"   </p>",
"   <p>",
"    Overall, BM involvement occurs in 30 to 50 percent of all patients with NHL, most commonly in the indolent histologies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. There are also situations where bone marrow is the only accessible site to make the diagnosis of NHL. Although rare, patients may have isolated bone marrow involvement with NHL, presenting clinically with pancytopenia and systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone marrow involvement with NHL is usually focal. Thus, BM aspirates alone have a low yield of being positive in the absence of a positive BM biopsy, and are very often negative even when the bone marrow is involved, due to the presence of fibrosis that makes the portion of the marrow that is involved by tumor inaspirable. BM involvement is seen in 18 to 36 percent of patients with aggressive and highly aggressive NHL and in 40 to 90 percent in patients with indolent NHLs, making the yield of marrow biopsy quite high in the latter setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/90,93,94\">",
"     90,93,94",
"    </a>",
"    ]. However, in patients with stage I and II disease (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 5",
"    </a>",
"    ), the yield is low for a positive BM biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The yield of bone marrow biopsy may be increased by performing multiple biopsies at different sites, for example bilateral posterior iliac crests; however, most instances of involvement can be established with one adequate biopsy. Most patients receive systemic treatment as part of their overall management, and a single biopsy is sufficient for treatment planning.",
"   </p>",
"   <p>",
"    Differences in morphology between the malignant cells in the bone marrow and a lymph node (eg, small cleaved cells in the BM and large cells in the lymph node), occur in 20 percent of follicular lymphomas and 40 percent of diffuse large B cell lymphoma, but not in small lymphocytic",
"    <span class=\"nowrap\">",
"     lymphoma/chronic",
"    </span>",
"    lymphocytic leukemia or Burkitt lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/61/27610/abstract/91,96\">",
"     91,96",
"    </a>",
"    ]. Such differences, when present, may herald the transformation of an indolent NHL into a more aggressive histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other studies, such as a lumbar puncture or endoscopy are reserved for patients with symptoms suggesting involvement of these sites or those with specific histologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     EVALUATION OF OTHER TISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph node biopsy is the preferred diagnostic test for most patients with NHL. However, there are less common subtypes of NHL that do not present with overt lymphadenopathy and require the pathologic evaluation of another tissue (ie, pleural fluid, spleen) for diagnosis. In addition, pathologic evaluation of these tissues may be necessary for the staging of patients with signs or symptoms worrisome for involvement of these sites or for patients with subtypes of NHL that have a high incidence of involvement of these tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture with analysis of the cerebrospinal fluid (CSF) is indicated for patients suspected of having leptomeningeal metastases (lymphomatous meningitis) or primary central nervous system lymphoma and for patients with subtypes of NHL that have a high incidence of central nervous system involvement (eg, Burkitt lymphoma). If involved, the CSF often reveals an elevated protein concentration and a lymphocytic predominant pleocytosis. Glucose concentration is usually normal, but may be low. The presence of malignant lymphoid cells may be confirmed by cytology, immunohistochemistry performed on cytospin preparations, or flow cytometry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Pleural fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a pleural effusion should undergo thoracentesis to evaluate for lymphoma involvement. Common findings include an elevated protein concentration, a lymphocytic predominant pleocytosis, and a normal or low glucose concentration. Reactive T cells may be more prominent than the neoplastic cells. The presence of malignant lymphoid cells may be confirmed by cytology, immunohistochemistry performed on cytospin preparations or cells blocks, or flow cytometry. The differential diagnosis for patients who present with an effusion that is subsequently found to contain lymphoma cells includes systemic lymphomas with secondary involvement of the body fluid (ie, secondary effusion), extranodal variants of various subtypes of lymphoma (eg, extranodal large cell lymphoma), and lymphomas that develop primarily within chronic pleural effusions (ie, pyothorax associated lymphoma and primary effusion lymphoma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link&amp;anchor=H13#H13\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Peritoneal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal fluid sampling is indicated if ascites is present in order to evaluate the possibility of lymphoma. Common findings include an elevated protein concentration, a lymphocytic predominant pleocytosis, and a normal or low glucose concentration. Reactive T cells may be more prominent than the neoplastic cells. The presence of malignant lymphoid cells may be confirmed by cytology, immunohistochemistry performed on cytospin preparations or cells blocks, or flow cytometry. Such involvement can develop in the context of a systemic nodal lymphoma or as a primary effusion lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy is rarely indicated in the diagnosis or staging of NHL, but infrequently, splenectomy is required for diagnosis. Subtypes of lymphoma that are more likely to involve the spleen and less likely to involve lymph nodes include splenic marginal zone lymphoma and hepatosplenic T cell lymphoma. Pathologic findings in such cases vary depending upon the histologic subtype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=see_link\">",
"       \"Patient information: Lymphoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical presentation of non-Hodgkin lymphoma (NHL) varies tremendously depending upon the type of lymphoma and the areas of involvement. Common presentations include lymphadenopathy, hepatosplenomegaly, fever, weight loss, and night sweats. Less common presentations include rash or side effects related to extranodal involvement (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Complications of NHL need to be considered during the initial workup. Prompt recognition and therapy is critical for these situations, which may be life-threatening, interfere with,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delay treatment of the underlying NHL (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Oncologic emergencies'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      An excisional biopsy of an intact node consistently allows sufficient tissue for histologic, immunologic, and molecular biologic assessment by experienced hematopathologists. Fine needle aspiration (FNA) of a lymph node without evaluation of the architecture is usually insufficient for definitive NHL diagnosis. The importance of this evaluation for appropriate diagnostic, prognostic, and treatment purposes cannot be overemphasized (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Lymph node and tissue biopsy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/1\">",
"      Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/2\">",
"      Ghobrial IM, Wolf RC, Pereira DL, et al. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc 2004; 79:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/3\">",
"      Ottinger H, Belka C, Kozole G, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995; 54:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/4\">",
"      Mohren M, Markmann I, Jentsch-Ullrich K, et al. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 2005; 92:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/5\">",
"      Caruso V, Di Castelnuovo A, Meschengieser S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood 2010; 115:5322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/6\">",
"      Zhou X, Teegala S, Huen A, et al. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 2010; 123:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/7\">",
"      Grigoropoulos NF, Shaw AS, Hampson FA, et al. Incidental pulmonary emboli in lymphoma patients are associated with aggressive disease and poor prognosis. J Thromb Haemost 2010; 8:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/8\">",
"      Kelly JJ, Karcher DS. Lymphoma and peripheral neuropathy: a clinical review. Muscle Nerve 2005; 31:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/9\">",
"      Viala K, B&eacute;hin A, Maisonobe T, et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry 2008; 79:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/10\">",
"      WEED RI. EXAGGERATED DELAYED HYPERSENSITIVITY TO MOSQUITO BITES IN CHRONIC LYMPHOCYTIC LEUKEMIA. Blood 1965; 26:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/11\">",
"      Wakimoto N, Niitsu N. Lymphoid neoplasms associated with mosquito bites. Intern Med 2005; 44:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/12\">",
"      Vassallo C, Passamonti F, Cananzi R, et al. Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases. Acta Derm Venereol 2005; 85:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/13\">",
"      Mascar&oacute; JM Jr. Cutaneous signs of hematologic malignancies: \"Doctor, is there something wrong with my blood?\". Arch Dermatol 2011; 147:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/14\">",
"      Dodiuk-Gad RP, Dann EJ, Bergman R. Insect bite-like reaction associated with mantle cell lymphoma: a report of two cases and review of the literature. Int J Dermatol 2004; 43:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/15\">",
"      Frumkin H. Agent Orange and cancer: an overview for clinicians. CA Cancer J Clin 2003; 53:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/16\">",
"      Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 2005; 162:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/17\">",
"      Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 2004; 110:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/18\">",
"      Negri E, Little D, Boiocchi M, et al. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004; 111:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/19\">",
"      Takkouche B, Etminan M, Montes-Mart&iacute;nez A. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA 2005; 293:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/20\">",
"      Altieri A, Bermejo JL, Hemminki K. Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood 2005; 106:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/21\">",
"      Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/22\">",
"      Brennan P, Sc&eacute;lo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005; 93:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/23\">",
"      Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/24\">",
"      Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006; 166:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/25\">",
"      Chiu BC, Dave BJ, Blair A, et al. Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. Blood 2006; 108:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/26\">",
"      Rafnsson V. Risk of non-Hodgkin's lymphoma and exposure to hexachlorocyclohexane, a nested case-control study. Eur J Cancer 2006; 42:2781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/27\">",
"      Ramos-Casals M, la Civita L, de Vita S, et al. Characterization of B cell lymphoma in patients with Sj&ouml;gren's syndrome and hepatitis C virus infection. Arthritis Rheum 2007; 57:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/28\">",
"      Chang ET, Smedby KE, Hjalgrim H, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst 2005; 97:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/29\">",
"      Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 109:3479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/30\">",
"      Lu Y, Sullivan-Halley J, Cozen W, et al. Family history of haematopoietic malignancies and non-Hodgkin's lymphoma risk in the California Teachers Study. Br J Cancer 2009; 100:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/31\">",
"      Goldin LR, Bj&ouml;rkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/32\">",
"      Herro E, Dicaudo DJ, Davis MD, et al. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol 2009; 61:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/33\">",
"      Zhang Y, Sanjose SD, Bracci PM, et al. Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma. Am J Epidemiol 2008; 167:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/34\">",
"      Eriksson M, Hardell L, Carlberg M, Akerman M. Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. Int J Cancer 2008; 123:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/35\">",
"      Agopian J, Navarro JM, Gac AC, et al. Agricultural pesticide exposure and the molecular connection to lymphomagenesis. J Exp Med 2009; 206:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/36\">",
"      Thompson CA, Habermann TM, Wang AH, et al. Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study. Int J Cancer 2010; 126:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/37\">",
"      Chang ET, Canchola AJ, Cockburn M, et al. Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study. Blood 2011; 118:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/38\">",
"      Ollberding NJ, Maskarinec G, Conroy SM, et al. Prediagnostic circulating carotenoid levels and the risk of non-Hodgkin lymphoma: the Multiethnic Cohort. Blood 2012; 119:5817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/39\">",
"      Ulcickas Yood M, Quesenberry CP Jr, Guo D, et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/40\">",
"      Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007; 109:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/41\">",
"      Castillo JJ, Dalia S, Pascual SK. Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies. Blood 2010; 116:2897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/42\">",
"      Ekstr&ouml;m Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111:4029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/43\">",
"      Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer 2009; 124:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/44\">",
"      Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009; 125:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/45\">",
"      Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 2010; 15:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/46\">",
"      Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies. Eur J Cancer 2011; 47:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/47\">",
"      Krikorian JG, Portlock CS, Cooney P, Rosenberg SA. Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases. Cancer 1980; 46:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/48\">",
"      Moormeier JA, Williams SF, Golomb HM. The staging of non-Hodgkin's lymphomas. Semin Oncol 1990; 17:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/49\">",
"      Urquhart A, Berg R. Hodgkin's and non-Hodgkin's lymphoma of the head and neck. Laryngoscope 2001; 111:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/50\">",
"      Bhatia S, Paulino AC, Buatti JM, et al. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 2002; 54:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/51\">",
"      Filly R, Bland N, Castellino RA. Radiographic distribution of intrathoracic disease in previously untreated patients with Hodgkin's disease and non-Hodgkin's lymphoma. Radiology 1976; 120:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/52\">",
"      Goffinet DR, Castellino RA, Kim H, et al. Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas. Cancer 1973; 32:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/53\">",
"      Risdall R, Hoppe RT, Warnke R. Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases. Cancer 1979; 44:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/54\">",
"      Civardi G, Vallisa D, Bert&egrave; R, et al. Focal liver lesions in non-Hodgkin's lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection. Eur J Cancer 2002; 38:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/55\">",
"      Aozasa K, Inoue A, Tajima K, et al. Malignant lymphomas of the thyroid gland. Analysis of 79 patients with emphasis on histologic prognostic factors. Cancer 1986; 58:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/56\">",
"      Gill PS, Chandraratna PA, Meyer PR, Levine AM. Malignant lymphoma: cardiac involvement at initial presentation. J Clin Oncol 1987; 5:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/57\">",
"      Gleeson MJ, Bennett MH, Cawson RA. Lymphomas of salivary glands. Cancer 1986; 58:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/58\">",
"      Harris GJ, Tio FO, Von Hoff DD. Primary adrenal lymphoma. Cancer 1989; 63:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/59\">",
"      Bostwick DG, Mann RB. Malignant lymphomas involving the prostate. A study of 13 cases. Cancer 1985; 56:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/60\">",
"      Doll DC, Weiss RB. Malignant lymphoma of the testis. Am J Med 1986; 81:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/61\">",
"      Paladugu RR, Bearman RM, Rappaport H. Malignant lymphoma with primary manifestation in the gonad: a clinicopathologic study of 38 patients. Cancer 1980; 45:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/62\">",
"      Woolley PV 3rd, Osborne CK, Levi JA, et al. Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer 1976; 38:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/63\">",
"      Wong WW, Schild SE, Halyard MY, Schomberg PJ. Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience. J Surg Oncol 2002; 80:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/64\">",
"      Seymour JF, Solomon B, Wolf MM, et al. Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2001; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/65\">",
"      Ghobrial IM, Buadi F, Spinner RJ, et al. High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis. Cancer 2004; 100:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/66\">",
"      Slap GB, Connor JL, Wigton RS, Schwartz JS. Validation of a model to identify young patients for lymph node biopsy. JAMA 1986; 255:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/67\">",
"      Slap GB, Brooks JS, Schwartz JS. When to perform biopsies of enlarged peripheral lymph nodes in young patients. JAMA 1984; 252:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/68\">",
"      Pangalis GA, Vassilakopoulos TP, Boussiotis VA, Fessas P. Clinical approach to lymphadenopathy. Semin Oncol 1993; 20:570.",
"     </a>",
"    </li>",
"    <li>",
"     Benign and Malignant Lymphadenopathies: Clinical and Laboratory Diagnosis, Pangalis G, Polliack A (Eds), Harwood Academic Publishers, Chur, Switzerland 1993. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/70\">",
"      Pappa VI, Hussain HK, Reznek RH, et al. Role of image-guided core-needle biopsy in the management of patients with lymphoma. J Clin Oncol 1996; 14:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/71\">",
"      Ben-Yehuda D, Polliack A, Okon E, et al. Image-guided core-needle biopsy in malignant lymphoma: experience with 100 patients that suggests the technique is reliable. J Clin Oncol 1996; 14:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/72\">",
"      Lachar WA, Shahab I, Saad AJ. Accuracy and cost-effectiveness of core needle biopsy in the evaluation of suspected lymphoma: a study of 101 cases. Arch Pathol Lab Med 2007; 131:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/73\">",
"      Asoglu O, Porter L, Donohue JH, Cha SS. Laparoscopy for the definitive diagnosis of intra-abdominal lymphoma. Mayo Clin Proc 2005; 80:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/74\">",
"      Lee Y, Terry R, Lukes RJ. Lymph node biopsy for diagnosis: a statistical study. J Surg Oncol 1980; 14:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/75\">",
"      Lee YT, Terry R, Lukes RJ. Biopsy of peripheral lymph nodes. Am Surg 1982; 48:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/76\">",
"      Sriwatanawongsa V, Cardoso R, Chang P. Incidence of malignancy in peripheral lymph node biopsy. Am Surg 1985; 51:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/77\">",
"      Doberneck RC. The diagnostic yield of lymph node biopsy. Arch Surg 1983; 118:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/78\">",
"      Steinfort DP, Conron M, Tsui A, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for the evaluation of suspected lymphoma. J Thorac Oncol 2010; 5:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/79\">",
"      Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004; 22:3046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/80\">",
"      Florentine BD, Staymates B, Rabadi M, et al. The reliability of fine-needle aspiration biopsy as the initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a community hospital-based outpatient aspiration biopsy clinic. Cancer 2006; 107:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/81\">",
"      Hunter S, Samir A, Eisner B, et al. Diagnosis of renal lymphoma by percutaneous image guided biopsy: experience with 11 cases. J Urol 2006; 176:1952.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/83\">",
"      Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/84\">",
"      Siebert JD, Harvey LA, Fishkin PA, et al. Comparison of lymphoid neoplasm classification. A blinded study between a community and an academic setting. Am J Clin Pathol 2001; 115:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/85\">",
"      Lester JF, Dojcinov SD, Attanoos RL, et al. The clinical impact of expert pathological review on lymphoma management: a regional experience. Br J Haematol 2003; 123:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/86\">",
"      Proctor IE, McNamara C, Rodriguez-Justo M, et al. Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network. J Clin Oncol 2011; 29:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/87\">",
"      Zeppa P, Marino G, Troncone G, et al. Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions. Cancer 2004; 102:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/88\">",
"      Langerak AW, Groenen PJ, Br&uuml;ggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012; 26:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/89\">",
"      van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007; 21:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/90\">",
"      Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990; 8:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/91\">",
"      Foucar K, McKenna RW, Frizzera G, Brunning RD. Bone marrow and blood involvement by lymphoma in relationship to the Lukes--Collins classification. Cancer 1982; 49:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/92\">",
"      Ponzoni M, Li CY. Isolated bone marrow non-Hodgkin's lymphoma: a clinicopathologic study. Mayo Clin Proc 1994; 69:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/93\">",
"      Bennett JM, Cain KC, Glick JH, et al. The significance of bone marrow involvement in non-Hodgkin's lymphoma: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1986; 4:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/94\">",
"      McKenna RW, Bloomfield CD, Brunning RD. Nodular lymphoma: bone marrow and blood manifestations. Cancer 1975; 36:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/95\">",
"      Stein RS, Ultmann JE, Byrne GE Jr, et al. Bone marrow involvement in non-Hodgkin's lymphoma: implications for staging and therapy. Cancer 1976; 37:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/61/27610/abstract/96\">",
"      Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011; 29:1452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4695 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27610=[""].join("\n");
var outline_f26_61_27610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oncologic emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Abnormal laboratory results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Paraneoplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Insect stings and bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATIENT HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Past history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Systemic complaints (B symptoms)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lymphoid survey",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chest and lungs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Abdomen and pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Extranodal sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LYMPH NODE AND TISSUE BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lymph node selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Context",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Type of biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Studies on excised tissue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Genetic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      EVALUATION OF OTHER TISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cerebrospinal fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Pleural fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Peritoneal fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Spleen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4695\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4695|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/58/2978\" title=\"diagnostic image 1\">",
"      Mediastinal lymphoma x ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/28/43460\" title=\"diagnostic image 2\">",
"      Mediastinal lymphoma Gallium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/43/3764\" title=\"diagnostic image 3\">",
"      Retroperitoneal nodes CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/59/39860\" title=\"diagnostic image 4\">",
"      Lymphoma liver spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/32/39427\" title=\"diagnostic image 5\">",
"      Lymphoma liver CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/6/8290\" title=\"diagnostic image 6\">",
"      Lymphoma colon CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/1/22544\" title=\"diagnostic image 7\">",
"      Lymphoma testis ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/1/25631\" title=\"diagnostic image 8\">",
"      Lymphoma bone MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/59/13233\" title=\"diagnostic image 9\">",
"      Lymphoma kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4695|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/21/41310\" title=\"figure 1\">",
"      Causes of FUO over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/28/21959\" title=\"figure 2\">",
"      Follic lymphoma nodal areas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4695|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/20/20805\" title=\"picture 1\">",
"      Reactive node vs FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/1/43029\" title=\"picture 2\">",
"      Reactive vs diffuse node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/34/31268\" title=\"picture 3\">",
"      Transformation FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/54/12135\" title=\"picture 4\">",
"      Richters transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4695|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/61/31708\" title=\"table 1\">",
"      Symptoms GI lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/44/42700\" title=\"table 2\">",
"      Conditions leading to lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/39/35453\" title=\"table 3\">",
"      Presenting features NHL types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/10/31915\" title=\"table 4\">",
"      Lymphocyte markers by cytometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 5\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=related_link\">",
"      AIDS-related lymphomas: Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26824?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25927?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=related_link\">",
"      Approach to the adult with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3274?source=related_link\">",
"      Approach to the patient with lymphocytosis or lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=related_link\">",
"      Breast lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5126?source=related_link\">",
"      Chylopericardium and cholesterol pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/168?source=related_link\">",
"      Chylous, bloody, and pancreatic ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38872?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15431?source=related_link\">",
"      Etiologies of fever of unknown origin in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=related_link\">",
"      Intravascular large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4744?source=related_link\">",
"      Overview of renal disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=related_link\">",
"      Overview of the classification and management of cancers of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29529?source=related_link\">",
"      Overview of the pathobiology of the non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=related_link\">",
"      Patient information: Lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32599?source=related_link\">",
"      Primary lymphoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35974?source=related_link\">",
"      Thyroid lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_61_27611="Somatostatin in variceal bleed";
var content_f26_61_27611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Somatostatin for active variceal hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial hemostasis*, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mortality*, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse effects*, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kravetz",
"       </td>",
"       <td>",
"        74 vs 87",
"       </td>",
"       <td>",
"        45 vs 47",
"       </td>",
"       <td>",
"        26 vs 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jenkins",
"       </td>",
"       <td>",
"        33 vs 100",
"       </td>",
"       <td>",
"        33 vs 20",
"       </td>",
"       <td>",
"        17 vs 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bagarini",
"       </td>",
"       <td>",
"        28 vs 68",
"       </td>",
"       <td>",
"        28 vs 4",
"       </td>",
"       <td>",
"        0 vs 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saari",
"       </td>",
"       <td>",
"        57 vs 84",
"       </td>",
"       <td>",
"        36 vs 34",
"       </td>",
"       <td>",
"        14 vs 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hwang",
"       </td>",
"       <td>",
"        54 vs 88",
"       </td>",
"       <td>",
"        50 vs 46",
"       </td>",
"       <td>",
"        0 vs 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Huang",
"       </td>",
"       <td>",
"        62 vs 75",
"       </td>",
"       <td>",
"        43 vs 25",
"       </td>",
"       <td>",
"        0 vs 0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Vasopressin versus somatostatin.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27611=[""].join("\n");
var outline_f26_61_27611=null;
var title_f26_61_27612="Diagnosis of Wiskott Aldrich";
var content_f26_61_27612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for Wiskott-Aldrich syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Definitive diagnosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Male patient with congenital thrombocytopenia (less than 70,000 platelets/mm",
"        <sup>",
"         3",
"        </sup>",
"        ), small platelets, and at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Mutation in the WAS gene.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Absent WAS mRNA on Northern blot analysis of lymphocytes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Absent WASp protein in lymphocytes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Maternal cousins, uncles, or nephews with small platelets and thrombocytopenia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Probable diagnosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Male patient with congenital thrombocytopenia (less than 70,000 platelets/mm",
"        <sup>",
"         3",
"        </sup>",
"        ), small platelets, and at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Eczema.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Abnormal antibody response to polysaccharide antigens.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Recurrent bacterial or viral infections.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Autoimmune diseases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Lymphoma, leukemia, or other malignancies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Possible diagnosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Male patient with thrombocytopenia (less than 70,000 platelets/mm",
"        <sup>",
"         3",
"        </sup>",
"        ) and small platelets, or male patient splenectomized for thrombocytopenia, who has at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Eczema.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Abnormal antibody response to polysaccharide antigens.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Recurrent bacterial or viral infections.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Autoimmune diseases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Lymphoma, leukemia, or other malignancies.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85 percent probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some but not all of the characteristic clinical or laboratory findings of a particular disorder.",
"    </div>",
"    <div class=\"reference\">",
"     From: Conley ME, Notarangelo LD, Etzioni A. Clin Immunol 1999; 93:190.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27612=[""].join("\n");
var outline_f26_61_27612=null;
var title_f26_61_27613="Methods to quantify gene expression";
var content_f26_61_27613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of methods to quantify gene expression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amount of starting RNA required",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity of test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Analytic requirements",
"       </td>",
"       <td class=\"subtitle1\">",
"        Information obtained from the test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of targets",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative cost",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Northern blot",
"       </td>",
"       <td rowspan=\"4\">",
"        High",
"       </td>",
"       <td rowspan=\"4\">",
"        Low",
"       </td>",
"       <td rowspan=\"4\">",
"        Low",
"       </td>",
"       <td rowspan=\"4\">",
"        Presence and size of RNA of interest",
"       </td>",
"       <td rowspan=\"4\">",
"        Few",
"       </td>",
"       <td rowspan=\"4\">",
"        Low",
"       </td>",
"       <td rowspan=\"4\">",
"        Straightforward",
"       </td>",
"       <td>",
"        Risk of RNA degradation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radioactivity use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Higher starting quantity of RNA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Ribonuclease protection assay",
"       </td>",
"       <td rowspan=\"2\">",
"        High",
"       </td>",
"       <td rowspan=\"2\">",
"        Moderate",
"       </td>",
"       <td rowspan=\"2\">",
"        Low",
"       </td>",
"       <td rowspan=\"2\">",
"        Presence and size of RNA of interest",
"       </td>",
"       <td rowspan=\"2\">",
"        Few",
"       </td>",
"       <td rowspan=\"2\">",
"        Low",
"       </td>",
"       <td>",
"        Higher specificity for the gene",
"       </td>",
"       <td>",
"        Complex protocol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Better sensitivity",
"       </td>",
"       <td>",
"        Radioactivity use",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        In-situ hybridization",
"       </td>",
"       <td rowspan=\"2\">",
"        High",
"       </td>",
"       <td rowspan=\"2\">",
"        Low to moderate",
"       </td>",
"       <td rowspan=\"2\">",
"        Low",
"       </td>",
"       <td rowspan=\"2\">",
"        Presence and spatial localization of RNA of interest",
"       </td>",
"       <td rowspan=\"2\">",
"        Few",
"       </td>",
"       <td rowspan=\"2\">",
"        Low",
"       </td>",
"       <td rowspan=\"2\">",
"        Spatial localization in a tissue section or cell",
"       </td>",
"       <td>",
"        Low sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Qualitative, not quantitative",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Spotted cDNA arrays",
"       </td>",
"       <td rowspan=\"2\">",
"        Moderate",
"       </td>",
"       <td rowspan=\"2\">",
"        Moderate to high",
"       </td>",
"       <td rowspan=\"2\">",
"        Moderate to high",
"       </td>",
"       <td rowspan=\"2\">",
"        Relative gene expression between two conditions",
"       </td>",
"       <td rowspan=\"2\">",
"        Several hundred",
"       </td>",
"       <td rowspan=\"2\">",
"        Moderate",
"       </td>",
"       <td>",
"        Simultaneous detection of hundreds of genes",
"       </td>",
"       <td rowspan=\"2\">",
"        Limited reproducibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Direct comparison of two samples",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Oligonucleotide arrays",
"       </td>",
"       <td rowspan=\"2\">",
"        Low to moderate",
"       </td>",
"       <td rowspan=\"2\">",
"        Moderate to high",
"       </td>",
"       <td rowspan=\"2\">",
"        Moderate to high",
"       </td>",
"       <td rowspan=\"2\">",
"        Relative gene expression",
"       </td>",
"       <td rowspan=\"2\">",
"        Thousands",
"       </td>",
"       <td rowspan=\"2\">",
"        Moderate",
"       </td>",
"       <td>",
"        Simultaneous detection of thousands of genes",
"       </td>",
"       <td>",
"        Analysis limited to known genes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Higher resolution than older methods",
"       </td>",
"       <td>",
"        Decreased sensitivity for lowly expressed transcripts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        RT-PCR",
"       </td>",
"       <td rowspan=\"2\">",
"        Low",
"       </td>",
"       <td rowspan=\"2\">",
"        High",
"       </td>",
"       <td rowspan=\"2\">",
"        Low to moderate",
"       </td>",
"       <td rowspan=\"2\">",
"        Relative gene expression",
"       </td>",
"       <td rowspan=\"2\">",
"        Few to several hundred",
"       </td>",
"       <td rowspan=\"2\">",
"        Low",
"       </td>",
"       <td>",
"        Straightforward protocol",
"       </td>",
"       <td rowspan=\"2\">",
"        Needs careful primer selection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Higher sensitivity",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Transcriptome sequencing",
"       </td>",
"       <td rowspan=\"4\">",
"        Low to moderate",
"       </td>",
"       <td rowspan=\"4\">",
"        High",
"       </td>",
"       <td rowspan=\"4\">",
"        Very high",
"       </td>",
"       <td rowspan=\"4\">",
"        Digital counts of each RNA molecule (as measure of gene expression) with excellent dynamic range",
"       </td>",
"       <td rowspan=\"4\">",
"        Unlimited",
"       </td>",
"       <td rowspan=\"4\">",
"        High",
"       </td>",
"       <td>",
"        Higher resolution than microarrays",
"       </td>",
"       <td>",
"        High cost",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large dynamic range, can detect low abundance transcripts",
"       </td>",
"       <td>",
"        Low throughput",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Detects novel transcripts",
"       </td>",
"       <td>",
"        Large storage space needed for data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can identify polymorphisms within a sequence",
"       </td>",
"       <td>",
"        Intensive computational analysis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27613=[""].join("\n");
var outline_f26_61_27613=null;
var title_f26_61_27614="Maternal outcome multiple gest";
var content_f26_61_27614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of maternal health outcomes among women with twin, triplet, and quadruplet and higher-order pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Twin (n, percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Triplet (n, percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Quadruplet or higher (n, percent)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Triplets vs twin",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Quadruplet vs twin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Crude odds ratio (95% CI)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Adjusted odds ratio (95% CI)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Crude odds ratio (95% CI)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Adjusted odds ratio (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Chroinc hypertension",
"       </td>",
"       <td>",
"        1429",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.96",
"       </td>",
"       <td>",
"        0.90",
"       </td>",
"       <td>",
"        1.27",
"       </td>",
"       <td>",
"        1.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (0.95)",
"       </td>",
"       <td>",
"        (0.92)",
"       </td>",
"       <td>",
"        (1.20)",
"       </td>",
"       <td>",
"        (0.71, 1.29)",
"       </td>",
"       <td>",
"        (0.68, 1.20)",
"       </td>",
"       <td>",
"        (0.46, 3.16)",
"       </td>",
"       <td>",
"        (0.53, 3.13)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Gestation hypertension",
"       </td>",
"       <td>",
"        11692",
"       </td>",
"       <td>",
"        567",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        1.38",
"       </td>",
"       <td>",
"        1.19",
"       </td>",
"       <td>",
"        1.57",
"       </td>",
"       <td>",
"        1.35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (7.68)",
"       </td>",
"       <td>",
"        (10.32)",
"       </td>",
"       <td>",
"        (11.57)",
"       </td>",
"       <td>",
"        (1.26, 1.52)",
"       </td>",
"       <td>",
"        (1.09, 1.31)",
"       </td>",
"       <td>",
"        (1.15, 2.15)",
"       </td>",
"       <td>",
"        (1.00, 1.83)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Eclampisa",
"       </td>",
"       <td>",
"        1522",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1.94",
"       </td>",
"       <td>",
"        1.70",
"       </td>",
"       <td>",
"        1.69",
"       </td>",
"       <td>",
"        1.46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (1.00)",
"       </td>",
"       <td>",
"        (1.93)",
"       </td>",
"       <td>",
"        (1.69)",
"       </td>",
"       <td>",
"        (1.58, 2.38)",
"       </td>",
"       <td>",
"        (1.38, 2.09)",
"       </td>",
"       <td>",
"        (0.24, 3.69)",
"       </td>",
"       <td>",
"        (0.69, 3.09)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Anemia",
"       </td>",
"       <td>",
"        4685",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        1.04",
"       </td>",
"       <td>",
"        1.26",
"       </td>",
"       <td>",
"        0.69",
"       </td>",
"       <td>",
"        0.87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (3.13)",
"       </td>",
"       <td>",
"        (3.24)",
"       </td>",
"       <td>",
"        (2.17)",
"       </td>",
"       <td>",
"        (0.88, 1.21)",
"       </td>",
"       <td>",
"        (1.08, 1.47)",
"       </td>",
"       <td>",
"        (0.33, 1.37)",
"       </td>",
"       <td>",
"        (0.45, 1.68)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Diabetes mellitus",
"       </td>",
"       <td>",
"        5085",
"       </td>",
"       <td>",
"        328",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        1.84",
"       </td>",
"       <td>",
"        1.56",
"       </td>",
"       <td>",
"        2.10",
"       </td>",
"       <td>",
"        1.81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (3.34)",
"       </td>",
"       <td>",
"        (5.97)",
"       </td>",
"       <td>",
"        (6.75)",
"       </td>",
"       <td>",
"        (1.63, 2.07)",
"       </td>",
"       <td>",
"        (1.39, 1.76)",
"       </td>",
"       <td>",
"        (1.40, 3.12)",
"       </td>",
"       <td>",
"        (1.23, 2.67)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cardiac disorder",
"       </td>",
"       <td>",
"        930",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1.48",
"       </td>",
"       <td>",
"        1.14",
"       </td>",
"       <td>",
"        1.56",
"       </td>",
"       <td>",
"        1.21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (0.62)",
"       </td>",
"       <td>",
"        (0.92)",
"       </td>",
"       <td>",
"        (0.96)",
"       </td>",
"       <td>",
"        (1.10, 1.99)",
"       </td>",
"       <td>",
"        (0.86, 1.53)",
"       </td>",
"       <td>",
"        (0.50, 4.32)",
"       </td>",
"       <td>",
"        (0.45, 3.26)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Placental abruption",
"       </td>",
"       <td>",
"        1842",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        1.30",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.61",
"       </td>",
"       <td>",
"        1.68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (1.21)",
"       </td>",
"       <td>",
"        (1.57)",
"       </td>",
"       <td>",
"        (1.94)",
"       </td>",
"       <td>",
"        (1.03, 1.63)",
"       </td>",
"       <td>",
"        (1.06, 1.66)",
"       </td>",
"       <td>",
"        (0.74, 3.34)",
"       </td>",
"       <td>",
"        (0.83, 3.38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Placenta previ",
"       </td>",
"       <td>",
"        700",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1.16",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"       <td>",
"        2.15",
"       </td>",
"       <td>",
"        1.90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (0.46)",
"       </td>",
"       <td>",
"        (0.53)",
"       </td>",
"       <td>",
"        (0.99)",
"       </td>",
"       <td>",
"        (0.77, 1.70)",
"       </td>",
"       <td>",
"        (0.66, 1.42)",
"       </td>",
"       <td>",
"        (0.68, 5.79)",
"       </td>",
"       <td>",
"        (0.71, 5.12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Premature rupture of membrane",
"       </td>",
"       <td>",
"        9985",
"       </td>",
"       <td>",
"        598",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        1.76",
"       </td>",
"       <td>",
"        1.68",
"       </td>",
"       <td>",
"        1.67",
"       </td>",
"       <td>",
"        1.63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (6.66)",
"       </td>",
"       <td>",
"        (11.17)",
"       </td>",
"       <td>",
"        (10.65)",
"       </td>",
"       <td>",
"        (1.61, 1.93)",
"       </td>",
"       <td>",
"        (1.54, 1.84)",
"       </td>",
"       <td>",
"        (1.21, 2.31)",
"       </td>",
"       <td>",
"        (1.19, 2.23)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cord prolapse",
"       </td>",
"       <td>",
"        856",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1.02",
"       </td>",
"       <td>",
"        1.06",
"       </td>",
"       <td>",
"        1.28",
"       </td>",
"       <td>",
"        1.36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (0.57)",
"       </td>",
"       <td>",
"        (0.58)",
"       </td>",
"       <td>",
"        (0.73)",
"       </td>",
"       <td>",
"        (0.70, 1.48)",
"       </td>",
"       <td>",
"        (0.74, 1.53)",
"       </td>",
"       <td>",
"        (0.33, 4.09)",
"       </td>",
"       <td>",
"        (0.44, 4.25)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cesarean delivery",
"       </td>",
"       <td>",
"        77966",
"       </td>",
"       <td>",
"        4765",
"       </td>",
"       <td>",
"        359",
"       </td>",
"       <td>",
"        3.25",
"       </td>",
"       <td>",
"        5.86",
"       </td>",
"       <td>",
"        5.34",
"       </td>",
"       <td>",
"        5.04",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (51.21)",
"       </td>",
"       <td>",
"        (86.78)",
"       </td>",
"       <td>",
"        (84.87)",
"       </td>",
"       <td>",
"        (5.77, 6.77)",
"       </td>",
"       <td>",
"        (5.42, 6.35)",
"       </td>",
"       <td>",
"        (4.06, 7.04)",
"       </td>",
"       <td>",
"        (3.86, 6.58)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Labor induction",
"       </td>",
"       <td>",
"        19176",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0.21",
"       </td>",
"       <td>",
"        0.18",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (12.75)",
"       </td>",
"       <td>",
"        (2.92)",
"       </td>",
"       <td>",
"        (3.13)",
"       </td>",
"       <td>",
"        (0.17, 0.24)",
"       </td>",
"       <td>",
"        (0.15, 0.21)",
"       </td>",
"       <td>",
"        (0.12, 0.39)",
"       </td>",
"       <td>",
"        (0.11, 0.32)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Vacuum/forceps",
"       </td>",
"       <td>",
"        9798",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"       <td>",
"        0.14",
"       </td>",
"       <td>",
"        0.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (6.44)",
"       </td>",
"       <td>",
"        (0.80)",
"       </td>",
"       <td>",
"        (9.45)",
"       </td>",
"       <td>",
"        (0.08, 0.16)",
"       </td>",
"       <td>",
"        (0.07, 0.14)",
"       </td>",
"       <td>",
"        (0.04, 0.38)",
"       </td>",
"       <td>",
"        (0.05, 0.69)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The risks of maternal  morbidity and obstetric complications tend to be higher for women with  triplet pregnancies and quadruplet and higher-order multiple  pregnancies than for women with twin pregnancies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wen, SW, Demissie, K, Yang, Q, Walker, MC. Maternal morbidity and obstetric complications in triplet pregnancies and quadruplet and higher-order multiple pregnancies. Am J Obstet Gynecol 2004; 191:254. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27614=[""].join("\n");
var outline_f26_61_27614=null;
var title_f26_61_27615="Peak pollen periods US";
var content_f26_61_27615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Peak pollen periods in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 508px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_61_27615=[""].join("\n");
var outline_f26_61_27615=null;
